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Abstract 
Developing strategies to cope with increase in the ageing population and age-related chronic 
diseases is one of the societies biggest challenges. The characteristics of the ageing process shows 
significant inter-individual variation. Building genomic signatures that could account for variation 
in health outcomes with age may facilitate early prognosis of individual age-correlated diseases 
(e.g. cancer, coronary artery diseases and dementia) and help in developing better targeted 
treatments provided years in advance of acquiring disabling symptoms for these diseases. The aim 
of this thesis was to explore methods for diagnosing molecular features of human ageing. In 
particular, we utilise multi-platform transcriptomics, independent clinical data and classification 
methods to evaluate which human tissues demonstrate a reproducible molecular signature for age 
and which clinical phenotypes correlated with these new RNA biomarkers.  
Using machine-learning approach (kNN), applied to RNA data derived from muscle tissues 
from healthy donors, we developed a novel and statistically robust neuro-muscular 150 probe-set 
RNA signature and demonstrated its potential as a health-status diagnostic. Validated using 
multiple independent human muscle cohorts and external validation methods, the RNA signature 
was effective at distinguishing between young and old human muscle, brain and skin. In muscle, 
the RNA signature was not correlated with lifestyle regulated phenotypes in muscle or life-style 
diseases in blood (coronary vascular disease and Type 2 diabetes). This 150 probe-set neuro-
muscular signature was related to cognitive status in two independent studies confirming that our 
‘ageing genes’ were consistently regulated in muscle, hippocampus and blood tissue in humans.  
To establish how unique this 150 probe-set neuro-muscular ageing was, we contrasted a 
“random” sampling approach with published genomic signatures of human ageing. This involved 
‘transferring’ DNA and DNA methylation signatures to their equivalent RNA signature, before 
considering their prognostic or diagnostic performance. It was observed that our 150 neuro-
muscular gene-set was the only one related to hippocampus ageing and cognitive health, while 
‘stress’ resistant (selected from DNA analysis) and ‘epidemiologically’ selected linear models 
(RNA derived) were related with vascular disease. We then attempted to develop an RNA vascular 
ageing gene-expression model to complement our neuromuscular ageing diagnostic. While 
statistically significant, the gene-set did not contribute to clinical variance in a sufficient manner 
over and above key clinical variables e.g. blood pressure and chronological age.  
In summary, vascular ageing appears to be distinct from neuro-muscular ageing, at least 
from the stand point of RNA gene-sets. Overall, this research has resulted in identifying a 
predictive diagnostic for human neuro-muscular ageing that could be potentially useful in assisting 
research aimed at finding treatments for and/or management of Alzheimer’s disease. 
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1.1 Introduction to thesis topic 
Advances in infection control, medical diagnosis, and treatment have led to an improved ‘health’ 
span as well as an increase in human longevity. The extended life span has presented new medical 
challenges such as greater number of people with cardiac disease, cancer, and in particular 
neurodegeneration. This consequently is placing huge demands on our medical services. Currently, 
treatment of these age-associated diseases is based on interventions aimed to yield clinical benefits 
in randomized clinical trials (Wiesweg et al. 2013). To revolutionize current approaches in health 
care it is essential to identify effective strategies to substantially improve ‘health span’ in humans.  
Personalized selection of treatment strategies, or health advice, has an increasing impact on the 
planning of modern medical practice (Goldberger & Buxton 2013).  
Personalized approaches to cancer diagnosis and treatment have been substantially 
influenced by molecular diagnostics (Abd El-Rehim et al. 2005; Shedden et al. 2008; Sebastiani et 
al. 2012). For human ageing, global RNA profiling based on linear correlative analysis have been 
utilised to search for consistent molecular events correlating with age across tissues (Willemijn M 
Passtoors et al. 2012; Gheorghe et al. 2014; Phillips et al. 2013; Glass et al. 2013; Peters et al. 
2015). But these attempts failed to find any common gene-sets that could characterise human 
ageing as most of them were based on cohorts that blended in ageing, disease and drug-treatment 
and thus had very low reproducibility. Therefore, there are numerous challenges to both the 
development of, and implementation of personalized strategies for most major age-related diseases 
(Patnaik et al. 2010) such as the time to measure a biological profile that can provide reliable long-
term prognostic information and the technological platform to utilize. Nonetheless, it would be 
interesting to explore if it is possible to find a common gene set for human tissue ageing and if this 
gene set signature has prognostic abilities to predict different types of age related diseases i.e. 
neurodegenerative, vascular etc., and health outcomes. This personalized molecular diagnostic 
approach could potentially not only estimate an individual’s true biological age but will also help in 
developing therapies that could positively impact ageing and postpone related diseases. 
1.2 Thesis Objectives 
Developing a diagnostic tool for healthy ageing and applying that knowledge to precision 
medicine can lead to better therapeutics at an individual level targeted specifically to the genotype. 
To develop such a tool, a very strict set of methodologies and benchmarks, distinguishing them 
from descriptive studies of differential RNA expression should be applied. Therefore, the aim of 
this thesis was to: 
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• Identify ‘healthy ageing genes’ (RNA, gene expression) that could distinguish ‘healthy’ old 
muscle tissue from young sedentary muscle with high accuracy. 
• Use the very same RNA signature to distinguish hundreds of old from young tissue across 
independent cohorts and tissue-types which has never been achieved before. 
• Evaluate whether the validated RNA signature would relate to different human diseases 
thought to be ‘caused’ by ageing such as neurological, vascular etc. 
• To compare if neuromuscular ageing is similar or different from vascular ageing. 
To achieve these objectives, we would implement machine-learning methods on transcriptomics 
data from carefully phenotyped clinical samples to develop the first accurate molecular diagnostic 
that could discriminate between healthy young and healthy older humans. To this end, we 
hypothesized that production of an accurate and sensitive diagnostic, built using muscle tissue from 
young subjects contrasted with humans reaching their older age in good health, would provide the 
platform to produce a prognostic molecular ‘signature’ that could be applied to longitudinal studies 
for the purpose of forecasting health outcomes. To delve into the uniqueness of the discovered gene 
set we would further conduct a comparative analysis of some of existing signatures of human 
ageing. This should potentially provide a well-rounded perspective about relevance of different 
signatures of human ageing and their limitations, if any.  
1.3 Outline 
The research work consists of six chapters. The first chapter is the introduction and review of the 
research that establishes the concept of understanding the importance of biomarkers in ageing and 
describes all the important aspect that is necessary for completing the research. The second chapter 
begins with general methods to process and understand microarray data and discusses method 
development part of research through which the results will be conducted.  
The third chapter is the results section that explains the reader the result and discoveries of the 
research topic. It is dedicated to the validation and application of the transcriptomic signature 
obtained from second chapter and thus provides the outcome of the research. Here, we investigate 
ageing with reference to neurocognitive health with particular emphasis on Alzheimer and 
Dementia. Further to fulfil the research goal and provide a comprehensive evaluation, we compare 
different genomic and transcriptomic signatures of human ageing and longevity in fourth chapter of 
this thesis. This chapter explores the uniqueness of our 150 gene set signature for neuro-muscular 
ageing with respect to the other published genomic signatures of human aging.  In the next chapter 
of this research work we develop a linear model for vascular ageing to explore if vascular ageing is 
distinct from neuro-muscular ageing, from the stand point of RNA gene-sets. The results drawn 
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from this work will highlight the importance of clinical (practical) significance of an effect and the 
pitfalls of formulating inferences solely based on statistical weight. The last chapter is based on 
discussion, and explains in detail the most important factors in the findings. The discussion section 
translates the outcomes in this area and point out any additional findings. The conclusion segment 
in the discussion relates the study discoveries and clarifies and derives the overall outcome of the 
research with recommendations and implications.  
1.4 A review of human ageing  
Ageing is described as the process that influences the human physiological system and its 
performance and increases the chances of death and chronic diseases. It is a genetically complex 
multi-causal biological process that is certain and leads to a decline in adaptive capacities (K. 
Christensen et al. 2009). It unavoidably leads to death as it is accompanied by the development of 
age-related pathologies (Zaidi 2008). The general perception of human ageing includes the reduced 
ability of surviving chronic diseases as well as mobility loss, decline in cognitive or sensory 
functions and increase in health costs.  
Visual examinations, biochemical analyses, physiological, psychological, and functional 
tests are used to examine age-related changes through the methods of conventional evaluation. The 
phenotype of ageing is considered as a complicated interaction of stochastic factors along with the 
genetic, environment and epigenetic variables (Rattan 2006). These variables favour molecular 
fidelity loss and intensify the random damages in the tissues, cells or in the human being as a 
whole. Along with these, the chances of death and disorder also increase (Candore et al. 2006).  
However, it is observed that the processes that influence biological ageing are not apparent. 
This insight can be provided by identifying biomarkers as it can explain the heterogenetic aspect of 
the functional decline related to ageing (Niccoli & Partridge 2012). Thus, biomarkers are in need of 
urgent evaluation for the assessment of health conditions of elderly individuals, which could aid in 
developing therapeutic interventions. 
1.4.1 Population ageing  
The term ‘Population ageing’ is used to define the shift in the distribution of age of a nation 
towards older individuals. It is a concept that challenges gaining lives with longevity and is an 
outcome of decreased fertility and increased expectancy of life (Dobriansky et al. 2007). Older 
individuals and ageing population are considered as the most important demographic and global 
trend of the 21st century. As per UNFPA, every ninth individual in the world is above 60 years 
(UNFPA and HelpAge 2012). Greying of the population is inevitably going to occur in the next 
decades and this transition in demographics is unprecedented in human history, which will have 
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major implications on all aspect of life. It will be a real threat to retirement systems and social 
security systems. Nevertheless, the extent to which it will occur is uncertain and will particularly 
depend on future trends in mortality.  
Population ageing is considered as the rapidly progressing problem worldwide. The 
countries that faced decline in fertility and mortality in the beginning are now facing increased 
proportion of elderly people (Lutz et al. 2008). The global share of older people (aged 60 years or 
over) has swollen from 9.2 in 1990 to 11.7 per cent in 2013 and is projected to reach 21.1 per cent 
by 2050. The demographics of UK and Europe are also dynamically changing. The demographic 
analysis conducted recently predicts that Europe’s average age in 2020 will be 42.2 years in 
comparison to 39.8 years in 2010. Life expectancy rate has also been predicted to increase in 2020 
to 77.84 years compared to 2005-2010 that was 75.34 years (United Nations, Department of 
Economic and Social Affairs 2013). As shown in Figure 1.1 the global median age has moved from 
24 years in 1950 to 29 years in 2010, and will continue to increase to 36 years in 2050. 
Furthermore, within the older population itself the proportion of those aged 80 years or over has 
doubled from 7 per cent in 1950 to 14 per cent in 2013. This rise is occurring at a faster pace in the 
less developed regions than in the more developed regions (United Nations, Department of 
Economic and Social Affairs 2013; UNFPA and HelpAge 2012).    
Thus, world is going through a demographic shift which is a direct consequence of health 
transition occurring globally at different speeds. People around the world are living longer, but 
many are also living sick-lives for long. This transitional period is impacted by different 
interconnected influences which includes the change from high to low fertility rates, a steady rise in 
life expectancy at birth and at advanced ages and a move from mainly infectious diseases to non-
transmitted diseases and chronic conditions (International Conference of Social Security Actuaries 
and Statisticians 2009).  
1.4.2 Social and Economic Effects of Ageing 
The major factor that is connected with the addition of older ageing population is the severe 
challenges it poses on the traditional state of social welfare and economy of a nation (Turner et al. 
1998). In many developed countries, it is observed that ageing increases pressure on social security 
programs. It is now considered that the policies are in need to be addressed in order to maintain and 
manage the retirement programs (Lefebvre & Goomar 2005). The ageing population is now a 
global concept for definite reasons. It not only poses a challenge to the society’s security system, 
but is a great struggle for the health care systems as well. As humans age, the incidence of illness, 
disabilities and likelihood of age-associated diseases such as alzheimer, dementia, or diabetes 
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increases noticeably (Niccoli & Partridge 2012). In addition to this a substantial increase in health 
care expenses occurs, not only because of higher proportion of elderly people in the population, but 
also as a result of increasing costs per person, among others due to new and more expensive 
medical technology. Furthermore, increasing trends in physical and mental functioning may lead to 
an increased demand for formal and informal care, while at the same time sources of support 
decline (Rechel et al. 2013). One approach of addressing this health and social care challenge is by 
maintaining health and reducing disability among the elderly and more importantly ensuring to 
extend the period that older people remain healthy, independent and contributing to society (Figure 
1.2) (Gavrilov & Heuveline 2003). 
       
Figure 1.1 The median age of the population for the world and developed and developing nations. The 
data by Department of Economic and Social Affairs Population Division, United nations across years shows 
that median age of the population is rising across the world in developed as well as developing nations thus 
establishing that population ageing is rapidly progressing problem. 
	
Economically, ageing has an impact on the labour market directly because of the influence 
of life expectancy and health on the way an individual behaves and make the decision of either 
working longer or retiring. The ages of 14-64 years old are considered to positively affect the 
economy and makes productive approaches, however ages 65 and above are considered dependent. 
Thus, in this regard population ageing can prove to be a challenge for the world economy 
(International Conference of Social Security Actuaries and Statisticians 2009). The problem due to 
ageing influences negatively in the growth of economy and in the participation rate of the labour 
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market which forces the researchers to analyse the changing directions through the trends of early 
retirements. In UK, the ratio of working individuals as compared to the ratio of people that are 
above 65 fell from 3.7 to 1 in the year 1999 and could fall from 2.1 to 1 in 2040 (Office for national 
statistics 2012). This estimation suggests that dependency ratio is about to be increased, which 
means more candidates of pension claiming individuals with less working individuals. This is a 
matter of concern for the government as the number of taxpayers will be reduced and dependency 
on government’s funds will rise. The chances are that due to augmented dependency ratio, diseases, 
and human ageing, government will have to increase spending on pensions and healthcare as well. 
This will result in higher tax rates and less people paying it (World of Work 67 2009).  Therefore, it 
is crucial to invest in discovering more successful ways of preventing or treating the major causes 
of illness and disability.  
                
Figure 1.2: Different phases in lifespan of an individual. An individual starts from an initial phase of 
development, followed by a peak in vitality of physical and physiological capacity, followed by a period of 
steady decline ending in morbidity. Instead of simply aspiring to extend the maximum lifespan it is important 
to have interventions that could possibly reduce the morbidity phase and move the curve towards right 
(Larrick & Mendelsohn 2010).  
1.5 Biological and molecular hallmarks of ageing  
A progressive loss in the functional decline of an individual is considered as ageing, which leads to 
functional impairment and susceptibility to death. Throughout the history of humankind, the field 
of ageing has attracted a number of researchers (Zaidi 2008) as it is a basic risk-factor for many 
physiological and psychological human diseases such as diabetes, dementia, etc. (Niccoli & 
Partridge 2012). Many researchers have given their effort in the identification and categorisation of 
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cellular and molecular hallmarks of ageing. Here we discuss nine hallmarks of ageing, which have 
proved their contribution in ageing process, and mutually determine the phenotype of ageing 
(López-Otín et al. 2013).  
1.5.1 Cellular Senescence  
In 1961, Hayflick and Moorehead first described cellular senescence as a process that limited the 
proliferation of somatic human cells in culture. They suggested that this interruption of cell growth 
in culture reflects ageing in-vivo and also limits the lifespan of an organism (Hayflick & Moorhead 
1961). It is understood that senescence is brought about by a variety of inherent and extrinsic 
stimuli including DNA damage, physiological stress, telomere shortening and stimulation of 
cancer-causing genes (Cech 2004). Senescent cells normally experience vivid structural and 
functional changes and are characterised by extremely distinguishable gene and protein expression 
profile. For example, increased adhesion to the extracellular framework and a levelled and highly 
augmented phenotype with a vacuolated morphology (Collado et al. 2007; Narita et al. 2003). 
Progression of ageing with senescence occurs in two ways that is by loss of the beneficial, 
replicative capacity of certain cell types and through the creation of proinflammatory cytokines 
which constitute the senescence-associated secretory phenotype (SASP) (Tchkonia et al. 2013).  
This implies that aggregation of senescent cells with ageing is also associated with the 
production of proinflammatory factors. Chronic inflammation due to progressive accumulation of 
senescent cells is a defining characteristic of mammalian ageing, which promotes several age-
related phenotypes, including neurodegenerative pathologies, such as loss of brain function, as well 
as proliferative diseases such as cancer (Newgard et al. 2013).    
1.5.2 Telomere Attrition  
Age-related DNA damage accumulation results in affecting the genome near-to-random, but some 
chromosomal region such as the telomeres are more prone to age-related deterioration (Blackburn 
et al. 2006). As cells divide repeatedly, small portion of telomeric DNA is lost with each cell 
division because of limitations of the DNA polymerases in completing the replication of the ends of 
the linear molecules, leading to telomere shortening with every replication. When telomere length 
reaches a critical limit, the cell undergoes senescence and/or cellular death. This restricted 
proliferative capacity due to telomere exhaustion is termed as Hayflick limit or replicative 
senescence (Blasco 2007). Thus, telomere length can serve as a sign of a cell's replicative activity                  
Chapter-1                                                     Introduction: Development of molecular diagnostics of healthy ageing
  	
	 15	
                       
Figure 1.3:  Proposed causes of cellular senescence.	Cellular senescence can be caused by a number of 
cellular stresses including oxidative stress, telomere dysfunction etc. Senescence prevents proliferation of 
potentially damaged cells and is initiated by inherent and extrinsic stimuli. 
 
rather than chronological age. Shorter telomeres have additionally been connected with the genomic 
instability and oncogenesis. Rate of telomere shortening has therefore been considered critical to an 
individual’s health and pace of ageing (although more recently it has been accepted that telomere 
assays have proven insufficient to be prognostic for disease in the clinic). It has likewise been 
embroiled in pulmonary fibrosis, aplastic anemia and congenital dyskeratosis and all other  
premature developmental diseases that include the loss of regenerative capacity in varying tissues 
(Walne et al. 2008; Savage et al. 2008) 
1.5.3 Genomic Instability 
Genomic Instability affects a range of diseases and has been considered as one of the major causes 
behind ageing. Somatic cells are exposed to numerous sources of DNA damage such as 
environmental mutagens, UV radiation and exposure to reactive oxygen species(Nicholson et al. 
2011). An intricate network of genome maintenance system acts to cope with millions of such 
attack on cell genome and restore the genomic base pair sequence that needs to be correct for 
normal functioning. Generally, the reason for epimutations and mutation is the flaw in this self-
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repair phenomenon. However, occasional failures in correct replication of genome during the times 
of cell division is also a contributing factor (Boyette & Tuan 2014).  
Genomic stability is an essential element in all eukaryotes’ ageing but how it is related still 
remains unclear. The free radical theory of ageing hypothesizes that the oxidative damage to DNA 
and other cellular components is the key determinant of ageing (Harman 1955). Most exploratory 
proof for the free radical hypothesis of ageing originates from invertebrate models such as 
transgenic fruit flies. Recent alterations of this hypothesis states mitochondria as being responsible 
for oxygen species generation and oxidative damage (Vijg & Suh 2013). 
1.5.4 Mitochondrial Dysfunction 
Mitochondria are central regulators of various important cellular processes (Tait & Green 2012). 
The decrease in mitochondrial capacity compromises cellular integrity and has been proposed as 
one of the reasons for ageing (Sohal & Weindruch 1996). Mitochondrial DNA (mtDNA) mutations, 
dysfunction of the electron transport chain, oxidative stress, disparity in mitochondrial turnover, 
impaired trafficking and disruption of the fusion/ fission machinery are broadly involved in disease 
pathology and ageing (Wallace 2005).  
Aged cells in post mitotic tissues, such as brain, heart and skeletal muscles, often have poor 
respiratory capacity because of mitochondrial dysfunction. Incidentally, these cells are regularly 
connected with aggregation of mtDNA mutations, surpassing the limit important for supporting 
mitochondrial capacity (Park & Larsson 2011). In spite of the fact that mtDNA just involve around 
1% of the total DNA present in the cell, lots of evidence suggests that its role in cell physiology 
may well be far important than projected by its sum or size (Bratic et al. 2013). Because of the 
oxidative microenvironment of mitochondria and the absence of protecting histones, mtDNA 
becomes responsible for age-related mutations of somatic cells. Comprehending how mtDNA 
mutations proliferate and clonally expand in cells is critical in explaining the development of 
mitochondrial diseases along with the ageing process (Singh 2004). 
1.5.5 Stem Cells Exhaustion 
Adult stem cells dwell in most mammalian tissues, yet the degree to which they add to homeostasis 
and repair varies broadly (Wagers & Weissman 2004). These rare and specialised cells with the 
ability of self-renewal are required for tissue substitution all through the human lifespan. Tissues 
regenerative potential diminishes with age, hence a question emerges whether the attributes of an 
ageing tissue can be understood via declining utility of the adult stem cells that reside in it (Singh 
2004). There are numerous reasons for stem and progenitors cell exhaustion with ageing, one of 
which is genomic instability as discussed before caused due to DNA damage which comes from a 
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variety of sources including the free radicals originating from normal metabolic respiration and 
failures amid DNA replication. Lack of an appropriate preventive response to DNA damage could 
lead to cancer initiation and progression and in order to avoid this regenerative potential is 
decreased. Thus, tumor suppressive response to DNA damage to prevent uncontrolled cell 
proliferation, could cause loss of stem cell function (Ruzankina & Brown 2007). Additionally 
researchers have also connected epigenetic modifications such as changes in DNA methylation, to 
the loss of regenerative capacity of stem cells with age (Vas et al. 2012).	
1.5.6 Dynamic Alterations in gene expression and transcription 
Among the three principle groups of biological macromolecules particularly connected with 
exchange and expression of genetic data i.e. DNA, RNA and proteins, the RNA stage is the least 
studied for conceivable age-related changes. Ageing process is connected with an increment in 
transcriptional noise, and an atypical generation and development of numerous mRNAs. A gradual 
loss of fine-tuning of gene regulatory pathways would presumably lead to a dysregulation of gene 
expression, which could have deleterious effects (Rivas et al. 2014). Some studies have tested the 
effects of ageing on gene expression using microarrays in model organisms and found variation in 
gene expression in some tissues of ageing mice (Weindruch et al. 2001). Microarray-based 
examinations of young and old tissues from a few animal types have recognised age-related 
transcriptional changes which are regulated by a small set of GATA transcription factors. The 
authors hypothesised that this network of GATA factors has evolved to regulate gene expression 
during development but may become unbalanced in old animals, thereby effecting the changes in 
gene expression observed with age (Budovskaya et al. 2008). Another study observed a shared gene 
expression signature for ageing in human, mouse and rat by comparing expression changes in seven 
microarray datasets from these organisms (Wennmalm et al. 2005). Further global RNA profiling 
using differential expression and regression models have been utilised to search for consistent 
molecular events correlating with age (Willemijn M Passtoors et al. 2012; Gheorghe et al. 2014; 
Phillips et al. 2013; Glass et al. 2013; Peters et al. 2015). 
1.5.7 Proteostasis Dysfunction and Loss  
All cells exploit a variety of mechanisms to safeguard the utility of their proteomes e.g. autophagy. 
Proteostasis includes systems for the adjustment of effectively collapsed proteins and proteotoxic 
stress, most distinctly the transcription factors including the heat shock group of proteins, forkhead 
factors and molecular chaperones (Taylor & Dillin 2011). Every one of these frameworks work in a 
facilitated manner to restore the structure of misfolded polypeptides or to evacuate and destroy 
them completely, consequently keeping the aggregation of harmed segments in control and 
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guaranteeing the consistent replenishment of intracellular proteins. Numerous studies have shown 
that this state of proteostasis is modified with ageing (Balch et al. 2008).  In ageing cells over time, 
there is a functional decline in proteostasis machinery, resulting in continuous accumulation of 
damaged and mis-folded proteins, leading to reduced cellular viability and advancement of some 
age-related pathologies, for example, Alzheimer's disease, Parkinson's  etc., (Rodier & Campisi 
2011). 
1.5.8 Altered Intercellular Communication  
Intercellular communication is critical for coordination of physiology in multicellular organisms.	
Along with cellular level modifications, ageing also includes changes at the level of intercellular 
correspondence, impacting on endocrine and hormonal regulation (Downing & Miyan 2000). The 
functions of endocrine organs are linked in a such a way that reduced function in one alters the 
regulation of others. Another distinctive age-related change in intercellular communication relates 
to inflammation, which may come about because of numerous reasons such as aggregation of 
damage in pro-inflammatory tissue, decline in resistance framework’s ability to successfully clear 
pathogens and the affinity of senescent cells towards pro-inflammatory cytokines. These 
modifications bring about an improved actuation of the NLRP3 inflammasome and other pro-
inflammatory pathways which play a direct role in the pathogeneses of atherosclerosis, Type 2 
diabetes and artery disease in the elderly (Baroja-Mazo et al. 2014). Overall, changes in metabolism 
and production of various hormones with age results in alterations in body composition 
characterized by decrease in lean body mass and bone mass and increase in fat mass. Furthermore, 
there is decline in functional status as well, such as reduced immune function, reduced capacity of 
the cardiovascular system, anaemia, insulin resistance and this leads to fatigue, depression and poor 
libido (Chahal & Drake 2007).  
1.5.9 Immunosenescence or loss of immune function 
As stated before, age correlated diseases such as rheumatoid arthritis (autoimmunity), cancer (e.g., 
prostate and lung), Type 2 diabetes(T2DM) and cardiovascular diseases (CVD) are major concerns 
for the elderly. The link between few of these diseases such as T2DM and CVD is immunity. With 
age, there is loss of immune functions known as immunosenescence which may explain the age-
associated incidence of such diseases. Immunosenescence has been associated with an increased 
predisposition to diseases, malignancy, infections,poor response to treatments and impaired wound 
healing (Pawelec 2007).  
The changes affecting the immune system often leads to global dysfunctions in both adaptive and 
innate immune system (Makinodan et al. 1991). An important contributor being impaired B and T 
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cells production in bone marrow and thymus and diminished function of mature lymphocytes 
because of which the elderly individuals do not respond to immune challenge as robustly as their 
younger counterparts (Montecino-Rodriguez et al. 2013). Immunosenescence also causes increased 
CD8+ cytotoxic/suppressor cell numbers, and decreased CD4+ T-cell and CD19+ B-cell numbers  
which has been associated with increased morbidity and mortality (Ferguson et al. 1995). Further, 
in ‘frail individuals’ immunosenescence is often characterised by increased serum IL-6 and TNF-α 
levels causing chronic systemic inflammation, referred to as inflammaging (Franceschi et al. 2007; 
Franceschi & Campisi 2014)(Franceschi & Campisi 2014). 
1.6 Age-Associated Diseases  
Age associated diseases are conditions that generally manifest at advanced age causing disability or 
premature death (Partridge 2010). Physical and psychological disorders such as cancer, 
osteoporosis, cataract, arthritis, dementia, cardiovascular disease, diabetes, Alzheimer's disease, and 
hypertension are few examples of age-associated diseases (Boots et al. 2013; Wu et al. 2014; 
Barzilai et al. 2012). All these diseases and their incidence and severity increases with increase in 
age (World Health Organization 2011). Accumulation of damage and lack of repair mechanism at 
cellular, and molecular levels leading to the gradual decline of body function is considered as a 
starting point of several diseases and their pathogenesis.  Some of these diseases result in change in 
hearing, muscular strength, vision, bone strength, nerve function and immunity (Niccoli & 
Partridge 2012). Ocular problems such as Glaucoma and cataract are also associated with ageing 
(Salvi et al. 2006). Ageing makes an individual more vulnerable to weaknesses and infections 
(Herbig et al. 2006). To comprehend this vulnerability of aged towards these diseases, it is crucial 
to understand the process of ageing and the underlying mechanism of these diseases.  
1.6.1 Cardiovascular disease  
Cardiovascular system pumps and supplies oxygenated blood to all parts of the body and is 
responsible for the health of every single tissue within an organism. Ageing being an inevitable part 
of life significantly affects the heart and arterial system and is the major risk factor for 
cardiovascular disease (CVD) including stroke, atherosclerosis (Coronary artery disease or CAD), 
myocardial infarction, and hypertension which are some of the leading causes of morbidity and 
death in the elderly population (North & Sinclair 2012). Various animal and human models have 
shown mechanisms such as oxidative stress and inflammation to play a central role in age-related 
cardiovascular dysfunction (Lakatta 2000; Judge et al. 2005). Ageing of the vasculature results in 
increased thickening and stiffness of the large blood vessels and also results in impaired endothelial 
function in the smaller blood vessels. Because changes in collagens are reported with ageing (Jani 
& Rajkumar 2006) and because large blood vessels contain high levels of collagens that determine 
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stiffness, it is possible large vessel status can be a biomarker for vascular ageing. Pulse wave 
velocity (PWV) is a widely used clinical measure of arterial stiffness. Alterations in the heart with 
age includes fibrosis, hypertrophy (increase in volume) and calcification. These physiological 
changes lead to increased systolic blood pressure, which increases the vulnerability for developing 
CVD and advances the risk of heart attacks.  
               In addition to non-modifiable risk factors such as gender and age, there are other risk 
factors for CVD, such as smoking, cholesterol, obesity, high blood pressure, lack of physical 
activity and diabetes (Anderson et al. 1991; Ambrose & Barua 2004; Sowers 2013) and these risk 
factors are thought to impact on small and large vessels to different extents. Different scoring 
systems have been developed to assess the risk of suffering from CVD, which work by allocating 
certain scores for each of the individual risk factors and then calculating a cumulative score, with 
higher score associated with higher risk profile. Amongst these, Framingham scoring system is the 
most popular approach that has been successfully applied to a wider population (Benjamin et al. 
1994; Bhopal et al. 2005).  
In terms of genomic knowledge of CVDs and stroke, enormous strides have been made over 
the past century, ranging from understanding cardiovascular physiology to molecular and cellular 
studies exploring the underlying risk factors (Feero et al. 2011). Methods such as whole genome 
sequencing and genome-wide association studies (GWASs) have recognized about twenty five loci 
associated with myocardial infarction and CAD by analyzing a large set of genetic variants by 
comparing case and control subjects from a population to determine which variants are associated 
with the disease in question (Anderson et al. 2010; Yasuno et al. 2010). Further, meta-analysis of 
these different GWAS based studies involving around ~90,000 CAD and control participants in 
addition to confirming the earlier observations have also identified 13 new loci associated with 
CAD (Smith et al. 2010; Feero et al. 2011; Schunkert et al. 2011). While this is a progressive step 
forward, it is important to know that CVD is a complex disease that occurs due to the sum of 
multiple polymorphisms, with each variant having a relatively small effect (<10%) on gene 
expression and disease. Transcriptomic signatures based on differential gene expression have been 
related to prognosis of CVD in humans and has indicated that quantitative differences in gene 
expression have the potential to define a person’s phenotype (Heidecker et al. 2008). Thus 
combining genome-wide gene expression together with genetic variation could yield a far more 
promising approach that could disclose the link between transcriptional regulation and CVD (Dixon 
et al. 2007; Schnabel et al. 2012). Further age-related stiffening of large elastic arteries such as the 
aorta has also been an important predictor of future cardiovascular events. In chapter -5 we explore 
the possibility of building a vascular ageing signature using a skin gene expression data for subjects 
for whom clinical measure of arterial stiffness (Pulse wave velocity measure) were available. We 
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hypothesized that skin gene expression could potentially serve as a surrogate measure of elasticity 
and since with ageing there is a changes in collagen and loss of elastin, a model based on the 
transcriptome and clinical covariates could potentially provide an insight into a person’s vascular 
(or extracellular matrix) ageing.  
1.6.2 Sarcopenia 
Sarcopenia is the progressive loss of skeletal muscle mass and function with age. It is often a result 
of or leads to decrease in physical activity which leads to functional impairment or disability and 
increases vulnerability towards other chronic ailments such as CVD and insulin resistance 
(Roubenoff & Hughes 2000). With age, there is a decline in mitochondrial biogenesis as well as 
reduction in the ability to promote muscle protein synthesis, which has substantial impact on the 
age-associated loss of muscle mass and strength. Both of which are the two most recognized risk 
phenotypes associated with sarcopenia. Previous work has reported enormous inter-individual 
variability in these phenotypes arising due to interaction of genetic and environmental factors 
(Cesari et al. 2006; Janssen 2006). Linkage and association studies have shown IGF1 (positive) and 
IL-6 (negative) group of genes to be statistically correlated with skeletal muscle strength and/or 
mass (Tan et al. 2012). Other factors that have been linked to the cause of sarcopenia include 
oxidative stress, poor nutrition and impaired regulation of growth hormones and sex steroids 
(McArdle et al. 2002; Rudman et al. 1990; Hickson 2006). 
            There is currently no fully accepted criteria or standardised technique that can diagnose and 
track sarcopenia related muscle decline. In clinical studies, it is commonly diagnosed using the 
appendicular lean mass calculation derived from the dual-energy X-ray absorptiometry (DXA) 
estimate. Though widely used, DXA tends to overestimate skeletal muscle mass as it is unable to 
discriminate muscle from water retention and muscle fat infiltration, thereby under estimating the 
extent of sarcopenia in an individual (Kim et al. 2002). This lack of an accurate and well 
established diagnostic criteria to identify patients with sarcopenia hinders the potential prevention 
and management options. Examining factors that determine skeletal muscle mass can possibly help 
in understanding and treating the age linked sarcopenia. Studies have indicated that resistance 
exercise training can stabilize the progress of sarcopenia as resistance training enhances muscle 
protein synthesis and improves muscle protein quality (Melov et al. 2007; Phillips et al. 2013). 
1.6.3 Dementia and Alzheimer 
Dementia is a loss of cognitive abilities in multiple domains that results in impairment in normal 
activities of daily living and loss of independence. Alzheimer’s disease (AD) is a progressive 
neurodegenerative disease and is the most common form of dementia that accounts for 60–80% of 
all dementia cases (Jessen et al. 2011). The primary risk factor for AD is age. Around 7% of the 
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population above 65 years of age have dementia (at least 65% of these have AD), and with the shift 
in population demographics in the coming decades >150 million Europeans will be aged above 65 
years (>1.2 billion, world-wide) (Harper 2014). 
It is believed that the cellular and molecular alterations causing brain circuitry dysfunction 
in AD have a slow onset and full blown disease may take many years to develop. Alzheimer’s 
disease is characterized by the accumulation of β-amyloid peptide (Aβ) within the brain and hyper-
phosphorylated and cleaved forms of the microtubule-associated protein tau in elderly people 
(Kolarova et al. 2012).	Also, unlike many other disorders and illnesses that can be associated to 
their fundamental cause, AD has been identified to be a result of combination of biological and 
environmental factors. These include mutations in the apo-lipoprotein, presenilin-1 and presenilin-2 
genes, prior head injury, or having the ε4 allele of apo-lipoprotein (Hardy 1997; Kensinger & 
Corkin 2009; Mormino et al. 2014). 
The early symptoms of AD are loss of episodic and working memory, which are due to 
network disconnections caused by oligomeric Aβ (Donohue et al. 2014). Alzheimer’s disease 
causes severe suffering for patients and emotional distress to the family. The gradual disease 
progression is accompanied by cognitive decline related to memory impairment as well as decline 
in motor functions, attention, higher-order functions, personality as a whole and recognition of 
objects (DE Toledo-Morrell et al. 2000). Risk of AD is linked to ageing but also lifestyle diseases, 
such as T2DM and hence also related to physical activity. There has been preliminary evidence 
suggesting that physical activity such as walking and exercise may reduce some of the negative 
characteristics associated with cognitive impairment and reduce the risk of dementia (Ahlskog et al. 
2011) 
1.6.3.1 Diagnostics for Alzheimer’s Disease  
 It is important to understand the early and asymptomatic states of the disease with the aim of 
proposing preventive therapeutic strategies. Around £26 billion is spent on health and social care 
activities for the 850,000 dementia patients in the UK alone and 250,000 new cases are expected 
each year (Dementia UK 2014). There is an urgent need to validate an AD diagnostic for primary 
physicians for a variety of social, medical and economic reasons – including a perceived under-
diagnosis (e.g. Dementia Action Alliance report).  Ultimately a treatment that will prevent or 
dramatically slow the progression of AD will be useful but this will not be possible without 
advances in population screening and robust diagnostics. MMSE scores (Folstein et al. 1983) is  
widely used to characterise cognitive decline in the elderly with scores below 24 commonly used to 
indicate a cognitive deficit. It serves as a neuropathological criterion for the diagnosis of AD. 
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However, the score is known to be affected by age and education and has a potential for 
misclassification or wrong diagnosis if not carefully reviewed by a trained clinician (Crum et al. 
1993; Wind et al. 1997). 
There are currently no drug-treatments for AD that halt or cure the disease (Salloway et al. 
2014). Clinical view is that only the earliest possible intervention is likely to significantly impact on 
the structural features of neurodegeneration (e.g. such as anti-beta-amyloid compounds). However, 
currently available diagnostic techniques are neither scalable for mass population screening nor 
sufficiently cost-effective to be practical (Biasutti et al. 2012). For example, magnetic resonance 
imaging (MRI) combined with contrast agents has less than 5% utility in a ‘screen and medicate’ 
cost-effectiveness analysis. To date advances have been made in medical imaging and bioassays to 
confirm evidence of already extensive neurodegeneration (e.g. cerebral atrophy on MRI or CSF 
levels of beta-amyloid species) but these are expensive, invasive techniques requiring specialist 
medical centers and are technically restricted to specialists. 
1.7 Human brain, ageing and cognition 
Empirical studies of healthy ageing have indicated that older adults while still being mentally fit, 
become slower and gradually start developing cognitive problems evidenced by reduced 
performance on different kinds of memory tests (Folstein et al. 1983; Glisky 2007). The age-related 
decline in memory and performance is believed to be a result of failure to control the cluttering of 
irrelevant information. This loss of functional specialization could be a result of reduced neuronal 
integrity. It is believed that the cognitive functions that are functionally separated in young adults 
show reduced differentiation in older adults (Reuter-Lorenz 2002). Thus, cognitive impairment is 
one of the key determinants of advancing age and a major challenge for healthy ageing (Hanninen 
et al. 1996).  
Cognitive processes are dependent upon the integrity of the brain, with age-related cognitive 
decline being widely associated with changes in the brain structure and function including 
neurochemical changes (Perry et al. 1982; Strong 1998), cerebral atrophy (Raz et al. 2005), 
reduction in brain volume (Walhovd, Fjell, Reinvang, Lundervold, et al. 2005) and reduced blood 
flow (Newberg et al. 2005). Research to understand the complexities of brain anatomy and its 
structure and function has been pursued for long and is still an on-going process. Though each of 
the brain regions have individual processes attributed to it such as cognition, problem solving 
ability, memory and response to sensory, spatial and visual stimuli (Goodale & Milner 1992; West 
1996; Coutlee & Huettel 2012) brain functions as a single unit by interaction between the different 
sections (Spreng & Mar 2012). In spite of the functional interconnectivity, the advent of ageing 
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occurs at different rates and in different manners between these regions.  These differences 
primarily can be observed in neurogenesis restricted to specific brain regions and the distinct 
deterioration in size with age (Raz et al. 2005). Biological changes associated with ageing 
eventually leads to dedifferentiation between cognitive and perceptual functions. Numerous genetic 
and environmental factors impact cognitive abilities (Winocur 1998; Mormino et al. 2014). To 
understand age-related decrease in cognitive functioning, it becomes imperative to study the 
changes in brain morphology and functioning. Deterioration in the brain regions was earlier 
considered to be the result of neuronal loss (Kemper 1994). However, with the advent of techniques 
such as positron emission tomography (PET) and MRI, researchers have found that neuronal loss is 
trivial, and atrophy could possibly be the result of reduced synaptic density, cell shrinkage and 
dendritic regression (Morrison & Hof 1997). Previous studies appear to present conflicting 
findings, especially when the brain is examined as a whole so as to assess the specific effects of 
ageing within each area it is important that each region of the brain is studied independently 
(Scahill et al. 2003).  
1.7.1 Ageing and structural variability among the brain regions  
Impact of the age-related effects are region dependent. Various cross-sectional studies have 
ascertained neuroanatomical age-related volume differences with different age trajectories for 
different brain regions. Some regions degenerate in a linear manner from early in life, whereas for 
some regions age-related volumetric changes are curvilinear where they continue to increase in 
volume, then stay constant (a plateau phase) and eventually begin to deteriorate (Walhovd, Fjell, 
Reinvang & Lundervold 2005). The greatest age-related change occurs in the striatum and frontal 
lobes with decrease in gray matter volume and an increase in white matter lesions. Volume losses 
within this region may contribute to age-related cognitive decline (Meguro et al. 2001; Abe et al. 
2008). Deterioration within the gray matter structures has not been able to predict decline in 
cognitive functions. Presence of lesions in the white matter tracts that interconnects cortical to 
subcortical regions disrupts the neural transmission and might result in cognitive dysfunction (De 
Groot et al. 2000). Ageing is also accompanied with accelerated degeneration of the hippocampus 
and putamen (Jack et al. 1999; Laakso et al. 2000; Walhovd, Fjell, Reinvang & Lundervold 2005).  
1.7.2 Ageing and brain transcriptome  
Brain tissue has a high level of gene expression, with approximately ~45% known protein-coding 
genes expressed across all the different brain regions (Colantuoni et al. 2000; Myers et al. 2007). 
Ageing of the brain is characterized by varied complex events, and studies have shown existence of 
a robust relationship between gene expression levels and brain ageing (Berchtold et al 2008, Kumar 
et al 2013, Kang et al 2011), but only few of these age-related expression changes have been 
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consistently found across datasets. A comparison of global expression patterns across different 
human tissues have shown a distinct gene expression profile for brain than the rest (Saito-
Hisaminato et al. 2002; Roth et al. 2006). Further, studies utilizing microarray and RNA-
sequencing technology have shown higher expression and intricacy in the transcriptome of the 
human brain than other tissues (De La Grange et al. 2010; Ramskold et al. 2009), which could be 
because of extensive changes in the physiology and function of the human brain throughout the 
lifespan (Oldham et al. 2008). Thus, transcriptional profile of brain is always evolving with a brief 
duration of 10-15 years at ~30 to 45 years of age where it stays constant. Thereafter, with the 
advent of old age (>60 years) numerous changes in gene expression are evident impacting its 
mental and cognitive ability and brain plasticity (Somel et al. 2009; Colantuoni et al. 2011). 
The enrichment of the brain transcriptome is accomplished by high level of alternative 
splicing events that enables the brain to express different isoforms of a gene (Wang et al. 2008; De 
La Grange et al. 2010). Aberrant splicing not only occurs in case of neurodegenerative disorders 
(Perez-Tur et al. 1995; Shehadeh et al. 2010), but also happens during normal ageing of the brain. 
Gene expression across brain regions also shows high variability due to anatomical and functional 
differences across regions (Roth et al. 2006). Over all cerebellum has the most distinct profile 
(Khaitovich et al. 2004) and this low concordance of gene expression is also observed within 
different cortical regions and neocortex (Strand et al. 2007). Therefore, it is safe to conclude that 
different brain regions exhibit changes with age, however with different rates and manifestations. 
Thus, to study the impact of ageing it is vital that every area of the brain is reviewed autonomously. 
1.8 Biomarkers of ageing  
It is critical to investigate healthy biomarkers of ageing to develop interventions that not only 
improves the healthy aspects of elderly but also stipulates approaches that monitor aspects of early 
or subclinical disease. It is also important to mention that our primary interest is in identifying 
biomarkers for ‘better’ or ‘worse’ ageing rather than a diagnostic of a disease. Diagnostics for 
diseases, such as Alzheimer’s are very challenging because of the low prevalence in the at risk 
population (e.g. 50-60yr old prevalence <5%) and the imprecise clinical criteria for defining 
Alzheimer’s disease in living individuals (e.g. ~90% correct). These combine, statistically, to make 
a high true-positive rate extremely challenging. Instead, if we could better define ageing, given it's 
the largest risk factor for Alzheimer’s, then we can identify an older population that has a much 
increased risk of Alzheimer’s disease in the future. In 1982, Reff and Schneider published a 
detailed set of criteria for the determination and measurement of a biomarker of ageing as follows 
(Reff & Schneider 1982): 
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a) Highly reproducible in general and in cross-species comparison 
b) Exhibits significant alterations over a relatively short time period 
c) Critical for successful maintenance of health and disease prevention 
d) Reveals a detectable parameter that can be predicted at a later age 
e) Reflects some basic biological process of ageing and metabolism  
 
However, studies investigating into ageing biomarkers are restricted by several challenges. 
Several researchers study ageing with respect to morbidity and disease. However, age and disease 
are not biologically synonymous (Thompson & Voss 2009). These biomarker studies focus on age-
related decline, which is not essentially a descriptor of healthy ageing. Inter-species differences in 
ageing also make this search for biomarkers more challenging. Living organisms are characterized 
by different lifespans, which implies that not all organisms age at the same rate (Piper et al. 2008). 
Genetic variation amongst different organisms have marked inter-species differences in the genes 
and proteins involved in the ageing processes thus implying that these processes are implemented 
and regulated differentially between organisms (Fontana et al. 2010). This restricted cross-species 
reproducibility becomes a greater challenge as most of the ageing studies are on model organisms. 
Many of the molecular mechanisms which extend the lifespan of laboratory animals have been 
reported to also positively impact on disease-free lifespan (Kenyon (2010) Nature 464: 504–512). 
Nevertheless, it has been difficult to establish if any of these are reliably modulated during human 
ageing (Phillips et al. 2013; Bell et al. 2012; Glass et al. 2013). Even if ageing-related molecular 
mechanisms are conserved across species, such molecules still may not represent reliable clinical 
biomarkers. 
Validity of any biomarker with regard to ageing can be assessed by a well-accepted definition 
published by Baker and Sprott in 1988: “a biological parameter of an organism that either alone or 
in some multivariate composite way, in the absence of disease, better predict functional capacity at 
some later age than chronological age” (Baker & Sprott 1988). The molecules that naturally change 
with age are the only potential candidates for the signature of healthy ageing and in this sense a true 
biomarker of healthy ageing is unlike standard biomarkers that help in detecting or examining a 
disease. No single marker can give sufficiently high segregation of cases from controls as a 
diagnostic test for clinical applications. Thus, utilizing numerous markers consolidated in some 
kind of algorithm will be necessary to deliver requisite level of predictive ability. Figure 1.4 
summarizes the characteristics of an ideal biomarker.	
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Figure 1.4 Characteristics of an ideal biomarker. In addition to being an accurate reproducible diagnostic, 
a biomarker should have clinical abilities as well. Further, it should be quick, consistent, economical, and 
quantifiable in an accessible biological fluid or clinical sample. 
 
1.8.1 Approaches for Identifying Biomarkers  
Different approaches are being explored to understand the distinctive physiological and 
pathophysiological processes that drive human ageing and longevity. These approaches can be 
broadly divided into genetic, epigenetic, transcriptomic and proteomic research (Deelen et al. 
2013). In the past, genome-wide association (GWAS) methods, linear models of epigenetic 
regulation and differential gene expression have identified traits associated with ageing and 
exceptional longevity in humans and have attempted to explain factors driving age-associated 
disease risk (Sebastiani et al. 2012; Hannum et al. 2013; Horvath 2013).     
1.8.1.1 Genomic (DNA) Approach  
Identification of genetic variants associated with exceptional longevity in humans, using genome-
wide association (GWAS) methods, is one approach that has been attempted to shed light on factors 
driving disease risk. For example, GWAS have reproducibly identified the APOE/APOC1 gene 
locus (Deelen et al. 2011; Sebastiani et al. 2012; Beekman et al. 2013), a locus associated with a 
rapid-ageing phenotype, Werner's syndrome (Yu et al. 1996) and a number of additional candidate 
Figure	1.4
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regions (Beekman et al. 2013). The largest study identified 281 single nucleotide polymorphisms 
(SNPs) that may explain up to 17% of exceptional longevity in humans (Sebastiani et al. 2012). 
However, long-lived humans share the common risk-alleles for coronary artery and other age-
related diseases (Beekman et al. 2010) with people who have an average life-span, suggesting that 
long-lived humans have beneficial mutations that can compensate for these risk factors. The 
relationship between DNA variation and ageing has been proposed to involve many small-effect 
size variants (Yashin et al. 2010). This means that production of sensitive diagnostics from DNA 
samples alone, for the purpose of personalized medicine, may prove challenging. Indeed, 
establishment of a strong statistical association between a genomic variant does not establish if such 
a measure can be used to accurately diagnose risk, as the information available is unable to 
distinguish between two similar medical conditions with divergent treatment strategies. 
1.8.1.2 Epigenomic Approach  
Research examining animal models and twins has elucidated that individuals or organisms having 
highly similar genetic background can age at varying rates (Fraga et al. 2005). DNA undergoes 
several alterations as we age, some of these modifications occur without changing the genetic 
sequence or code (Holliday 1987). These modifications to DNA are epigenetic in nature and 
constitute DNA methylation, histone modifications and non-coding RNAs. Epigenetic changes at 
the key genomic regions such as transcription start site, promoter regions , etc., can switch on or off 
specific genes. Thus by controlling which genes are active in a particular cell, epigenome governs 
which proteins are transcribed locally within a cell type. The importance of epigenetic changes and 
its influence on longevity has already been established in model organisms such as yeast, worms, 
etc., (Greer et al. 2011; De Lencastre et al. 2010) as well as in humans (Fraga 2009). Epigenome is 
a primary location of gene-environment interactions and exposure to certain environmental stimuli 
can readily alter it (Aguilera et al. 2010). An age-related methylation drift has been observed and 
established, which is not uniform across the genome, and is quite variable between individuals of 
the same age (Rakyan et al. 2010; Hernandez et al. 2011). Thus this epigenetic landscape has been 
hypothesized as a 'biological marker' that reflects cell’s identity, health and age.  
Availability of affordable high-throughput techniques such as sequencing platforms and 
other genome wide technologies has helped to provide better insights of the epigenetic landscape 
specifically DNA methylation. Using an epigenome wide association approach scientists have 
investigated human longevity with methylation data on 172 females between an age-range of 32 y 
to 80 y (Bell et al. 2012). They noticed that the majority of age-related changes in DNA 
methylation were not related with phenotypic measures of healthy ageing such as telomere length, 
systolic blood pressure, etc., However, for small subset of genes they found that DNA methylation 
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mediated environmental and genetic effects on the age-related phenotypes. This implied that either 
DNA methylation has very small individual effect on measures of biological ageing or it may be 
associated with yet unknown ageing phenotypes or pathways.  
Studies have examined the changes in DNA methylation as a potential marker for 
chronological age as well as biological age across species and cell types. These predictors of 
chronological age have been constructed across different tissues (Sinsheimer et al. 2011; Horvath et 
al. 2012; Hannum et al. 2013; Weidner et al. 2014). Hannum et al. built a multi-tissue linear model 
of DNA methylation in which age-related changes with DNA methylation state was closely related 
to chronological age but it could not distinguish between age and age-related disease. Horvath’s 
epigenetic clock examined the relationship between DNA methylation and ageing by using ~8000 
samples from brain, breast, skin, colon, kidney, liver, etc., with age range from newborns to 101 
years. They developed a quasi-linear regression model of chronological age (~ 353 CpG sites) and 
transformed age in a unique manner for ages less than and greater than 20 y (log and linear 
transformation respectively). The divergence from chronological age (±3years only) was explained 
as the biological age of the sample. However, instead of being an actual disparity in ageing rates 
this slight deviation could imply a possible over-fitting of the specific model. Also, for most of the 
tissues the divergence from chronological age was minimal which raises the question on its utility 
to identify healthy ageing because a successful diagnostic of this type should show higher 
variability within a similarly aged population (chronological age).  
For any epigenome-based markers it will be imperative to determine the effect of 
age-related changes in cell composition within tissues since methylation measures for these 
predictive markers are mostly taken on entire tissues (Zou et al. 2014). Even though there are many 
published epigenetic papers that have discovered markers of age and diseases such as cancer but 
very few of these relate the same markers in similar clinical specimens based on same assay 
technology. The consequence of employing diverse assays and varied markers discovered from 
them is that their real performance becomes incomparable. Further, these epigenetic assays are very 
poorly validated and need to be standardized if it have to be used as a diagnostic in clinical 
environment (Laird 2010).  
1.8.1.3 Transcriptomic (RNA) Approach  
Studies in model organisms and across different species have shown that ageing is characterised by 
molecular and physiological changes at cellular and tissue level. Identifying individual factors 
driving this multifaceted process is challenging as it is influenced not only by the genetic but also 
by the environmental factors such as diet, exercise, lifestyle, etc. Transcriptome has the ability to 
provide a better insight into age-related changes as the expression of RNA is under genetic 
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(Schwanhäusser et al. 2011; Westra & Franke 2014), epigenetic (Horvath et al. 2012) and 
environmental control (Keller et al. 2011; Larrouy et al. 2008). Transcriptomic study in skeletal 
muscle has successfully shown heterogeneity in gene expression profile for individuals from the 
age of 30 years, which implies that individuals have different ageing rate as they go through middle 
age and thus have diverse morbidity and mortality rates (Lu et al. 2004). The advent of global 
transcriptomic techniques such as next-generation sequencing and microarrays has helped 
researchers to unravel and understand the expression of whole transcriptome (Rodwell et al. 2004; 
Zahn et al. 2006).  The potential of using RNA based classification approach for another major 
human phenotype i.e. adaptability of the aerobic capacity system in young and middle-aged adults 
has been previously established by our research group (Timmons et al. 2010). Machine learning 
methods applied to global transcriptomic profiles has already yielded sensitive and specific 
diagnostic and prognostic tools for cancer, using sets of gene-expression values of limited size 
(Shedden et al. 2008; Menden et al. 2013).  However, in cancer studies gene expression changes are 
often of higher magnitude, to what can be expected from a study designed to identify healthy 
ageing, meaning it is unclear what size of gene-set would be required. 
Ageing studies are usually carried out on cross-sectional datasets that cover individuals over a 
broad age-range. Several such transcriptomic studies have been designed and investigated across 
different tissue types such as skeletal muscle (Welle et al. 2004), kidney (Rodwell et al. 2004) , 
blood (Peters et al. 2015), brain (Erraji-Benchekroun et al. 2005) , etc. Even though there has been 
similarity in age affected pathways across these studies (partly reflecting inappropriate use of gene 
ontology analysis) but in terms of transcriptional changes with age there has been very limited 
overlap. This might imply that in each tissue different individual genes change their expression with 
age. However, a comparative analysis of transcriptomic data from different studies and different 
tissues such as muscle, kidney and brain found that along with tissue specific changes with age 
there is a possibility to find an underlying common ageing signature across tissues that might reflect 
the true biological age of the organism (Zahn et al. 2006). The Zahn study was limited by the fact 
that the old tissue samples originated largely from a very different type of muscle tissue than the 
young samples and was not possible to replicate in our more recent studies (Phillips et al 2013 PLos 
Genetics). A meta-analysis study performed on cross-sectional RNA data from healthy non-treated 
samples from adult mice, rat and human found that by integrating gene expression profiles from 
several studies it is possible to identify set of genes that are consistently regulated i.e., under or over 
expressed with age (De Magalhães et al. 2009) but without carrying out a formal robust tests as to 
the reliability of these genes to classify unknown samples. 
 
Most of these earlier attempts of modelling the ageing phenotype have involved correlative 
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linear models that adjust for different age related covariates such as gender, blood pressure etc. This 
can be problematic as linear correlative approaches do not dissociate ‘age’ from age-related disease 
or drug treatment (unless the investigators strictly use healthy old subjects) specially when applied 
across a wide age range. For instance, a subject aged 40y can have the same measurement for an 
age related clinical covariate (blood pressure/ cholesterol) as a subject aged 60y. However, for latter 
the measurement could be an effect of a medication then an actual transcription profile reflective of 
its ageing. Therefore, both from a statistical and a clinical perspective linear correlative models for 
ageing are fraught with limitations without properly taking into account chronological age-range, 
concurrent drug-treatments etc. For this research work we have spent significant effort to build a 
good study design that could capture the trends of healthy ageing by taking into consideration strict 
set of benchmarks and established practices and have utilized classification statistical methods to 
evaluate which human tissues demonstrate a reproducible molecular signature for age (discussed in 
chapter-2 of the thesis). Thus, human ageing is characterised by focused changes in gene 
expression. If supported with good study designs and analysis, identifying such gene expression has 
the potential to yield robust biological ageing signature/biomarker. 
1.8.1.4 Proteomics Approach  
Proteome is defined as set of all expressed proteins that characterizes information flow within the cell or an 
organism and is considered as a dynamic reflection of both genes and environment. It is believed to hold a 
promise for biomarker discovery because proteins are ubiquitously affected in disease and disease response 
(Jain & Jain 2010). This is reflected in many protein disease biomarkers already available eg: CA-125 and 
alpha-fetoprotein (Bast Jr et al. 1997; Brock & Sutcliffe 1972). Thus, this approach is actively involved in 
the recognition of human physiology and its complexities. The techniques and procedures involved include 
mass spectrometry, western blot etc. While we gain much information from proteomic investigation it is 
complicated because of its domain size (>100000 proteins) and inability of the current technologies to detect 
low abundance proteins. Further, the quantity of data that is acquired with new techniques places new 
challenges on data processing and analysis (Chandramouli & Qian 2009). 
Probing into the transcriptional range of a particular genome tells us more about the expression 
rather than its protein library (Hegde et al. 2003). This is because of the fact, that in eukaryotes there 
happens to be many regulatory RNAs which do not actively translated into proteins. Further there are long 
non-coding RNA which is mostly an enigma, till now (Kung et al. 2013; Cesana et al. 2011). Although they 
do not seem to be carrying anything out in particular, the sheer numbers by which they are transcribed 
indicate that they serve some purposes.  Protein abundance regulation is much more convoluted then 
transcription regulation(Vogel & Marcotte 2012). In view of all this we believe that gene expression based 
biomarkers can potentially serve as a better proxy for biological activity associated with healthy ageing since 
transcriptomics are much cheaper and easier to do than proteomics.  
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1.9 Summary  
Yielding strategies to cope with increase in the ageing population and age-related chronic diseases 
is important. Since the ageing process demonstrates large inter-individual variation, a sensitive 
diagnostic able to predict these characteristics would be useful. Personalized treatment strategies 
have high impact on modern medical practice and such strategies are essential if we are to achieve a 
greater degree of certainty that a particular treatment will benefit the individual patient. The 
challenge is to identify sets of molecular ‘biomarkers’ that provide sensitive and specific 
information, enabling long-term guidance for personalized treatment. However, there are numerous 
challenges to both the development of, and the implementation of personalized strategies for most 
major age-related diseases including economic constraints. Large experimental groups as well as a 
good study designs are required to enable reproducible conclusions to be made from studies of gene 
expression and ageing. Most studies for biomarkers of human ageing have been based on 
epidemiological cohorts that blend in ageing, disease and drug-treatment. However, a good study 
design and strategy to find candidate biomarkers for human ageing is to compare molecular traits in 
normative and healthy ageing in groups within the human population with no metabolic or chronic 
diseases. Further, there are multiple competing technological platforms that can yield plentiful data, 
but progress in integrating divergent data formats to yield robust and sensitive diagnostics for 
clinical decision making remains slow. Possibly, a pragmatic strategy will be to utilize a single 
technology platform with proven technical features that captures sufficient clinical variance, that it 
can provide a stand-alone and robust diagnostic for healthy human ageing. 
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2.1 Overview of the chapter 
This chapter will describe the machine learning approaches used to develop an RNA expression 
signature of ‘healthy ageing’. We begin by examining the strengths and limitations of technologies 
that provide insight into the human transcriptome including RNA-sequencing and microarrays, 
followed by a discussion of approaches we used to handle microarray data in order to generate the 
most robust signal possible.  Following an overview of general methods relevant to this work, we 
describe in greater detail the development of our molecular diagnostic that was able to discriminate 
between healthy young and healthy older humans using a very strict set of methodologies and 
benchmarks. Thus, the principle goal of this chapter is to explain: 
• Motivation for using the RNA classifier approach to produce the signature. 
• Handling of the microarray data and extracting relevant information. 
• Building the age-diagnostic. 
2.2 Gene expression profiling 
Nearly all individual cells within a multicellular organism contains of the same genome. However, 
within each cell, different genes are transcriptionally active, resulting in cells and tissue displaying 
different gene expression patterns. This results in a myriad of structural, biochemical, functional 
and phenotypic variations amongst cells and tissues that might play a role in the differences 
observed between health and morbidity.  This complete set of transcribed genes expressed as 
mRNA within an individual is known as the transcriptome (Su et al. 2002). Gene expression 
profiles not only have the potential to explain cellular functions, regulation and biochemical 
pathways but when contrasted between cases and controls (e.g. normal vs healthy), the 
transcriptome may reveal insight into disease pathology and identify new therapeutic points of 
intervention, enhancing diagnosis and improving prognosis (Van’t Veer et al. 2002; Xiong et al. 
2013).  
Transcriptomic changes are an important biological aspect of ageing (López-Otín et al. 
2013; Glass et al. 2013). Indeed, variation in the regulation of gene expression, more-so than 
sequence variation, has been long postulated to be a more sensitive approach to studying ageing 
(King & Wilson 1975). The manifestation of profiling technologies and machine learning methods 
applied to global RNA profiles have already proven to yield sensitive and specific diagnostic and 
prognostic tools for cancer using sets of gene expression values of limited size (Patnaik et al. 2010; 
Shedden et al. 2008; Menden et al. 2013). While it is intuitive that a RNA profile obtained from a 
tumor demonstrates prognostic ability, the idea that a global RNA profile obtained from a non-
diseased tissue sample can also produce an accurate and sensitive diagnostic that informs about 
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future disease has not been demonstrated.  
2.2.1 Next-Generation sequencing and Microarrays 
The development of transcriptome profiling technologies has allowed us unprecedented access to 
the world of RNA, with an ever-growing number of studies changing our view of its extent and 
complexity. Advances in molecular biology have brought utilization of microarrays and next-
generation sequencing (NGS) technologies to the forefront of transcriptomics. Each of these 
technologies possesses a set of distinct features suitable for different applications and research 
goals. Current sequencing methods depend on the reconstruction of transcripts from sequenced 
fragments that generally do not exceed a few hundred nucleotides. These methods inevitably result 
in uneven coverage across the transcript (due to technical biases in the fragmentation and 
sequencing technologies), with the 5’ and 3’ ends often being the most problematic areas. With 
microarrays, RNA expression is measured through the amount of cDNA that hybridizes to pre-
designed short DNA fragments, known as probes, immobilized on a chip. This limits the 
quantification of expression to areas in the genome that are matched by the probes. In addition to 
the need for having the correct type of probes, the distribution of probes must also be uniform (to an 
appropriate extent) across the transcripts’ untranslated regions. Thus, arrays have a fundamental 
design bias i.e., one can only explore and analyze the transcriptomic regions for which probes have 
been designed. Also, arrays are highly dependent on reference databases from which they are 
designed. On the contrary, with NGS, reads are generated without any a priori knowledge of 
transcriptome, thus permitting analysis of novel transcripts, splice junctions and noncoding RNAs 
and defined based on current genome knowledge. Due to this potential for NGS technologies to 
provide a more detailed look at the transcriptome, researchers have been keen to use it for gene 
expression studies (Mutz et al. 2013). 
Despite the methodological benefits of RNA-Seq, microarrays have several potential 
advantages over sequencing, particularly for detecting lower abundance transcripts. Hybridization 
in microarray typically uses higher concentrations of cDNA than RNA-seq assays, but the detection 
of each unique cDNA (or cRNA) is independent thereby avoiding the competitive detection 
scenario encountered with NGS data.  With sequencing, the inability to detect a large proportion of 
lower abundant transcripts is caused by a few highly abundant RNA transcripts accounting for a 
very large proportion of a cDNA library (Lei et al. 2015). This inability to robustly detect low 
abundance transcripts leads to high variability in the quantitative measurement of transcript 
expression. Microarrays, on the other hand, provide coherent and accurate gene expression 
quantitation irrespective of transcript abundance. Use of microarrays for research remains 
prevalent, as the technology has been proven successful in consistently providing genomics insight 
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for the past two decades (Harrington et al. 2000; Trevino et al. 2006; Yan & Gu 2009). Also, 
microarrays are generally considered easier to use as protocols for sample labeling, array handling 
and data analysis are less intensive. Moreover, general agreement has emerged on the major 
methods for processing the data and a wealth of good tools exist to analyze them, while the same 
cannot be said yet for RNA-seq. Further, despite NGS advancements and a recent drop in the cost 
associated with NGS, expression arrays are still economical and easier when processing large 
numbers of samples (e.g., hundreds to thousands) and yield higher throughput. 
There are pragmatic reasons for using microarray technology in a study such as ours as well. 
The primary research objective within this thesis was to find a biomarker or a diagnostic tool for 
healthy ageing that had prognostic abilities for a clinical outcome. There are many pre-existing 
datasets profiling a variety of tissues in young and old available on a variety of microarray 
platforms. Therefore, from a validation perspective microarray was a sensible choice (Figure 2.1). 
The different datasets used in our study were profiled on various microarray platforms including 
Affymetrix HGU133Plus2, Affymetrix HuEx-1.0 ST, HTA-2.0, Illumina HT-12 V3 beadchip and 
Illumina HT-12 V4 beadchip (for detail of the datasets see Appendix 1). 
2.3 Handling microarray data by updating probe definition and annotation files 
The most popular platform for genome-wide expression profiling is the Affymetrix GeneChip. 
However, the selection of probes to represent the totality of the transcriptome relies on genome and 
transcriptome annotation information available when a particular GeneChip was designed. Over 
time changes in the annotation of genome, leads to inaccuracies in the design time probe definition 
and this can affect the biological interpretation of the derived data (Sandberg & Larsson 2007). In 
this work, we tackled these critical concerns and implemented a solution for these design related 
drawbacks. A similar approach has been successfully implemented and employed in gene 
expression studies in the past (Dai et al. 2005; Greco et al. 2008). 
A Chip Definition File (CDF) is an annotation file for Affymetrix chips that defines probes 
(cells in Affymetrix terminology) mapping to the genomic unit of interest. For instance, a CDF for 
gene expression will specify a sets of probes that maps to the same gene. Thus, different CDFs can 
be utilized to examine different genomic units (i.e. genes, transcripts, exons). Affymetrix provides 
CDFs based on design time annotations, collapsing a group of probes into an Affymetrix defined 
probeset. However, researchers have also developed ‘custom CDFs’ that are optimized for various 
genomic features. Custom CDFs reorganize the oligonucleotide probes on gene chip platforms 
based on the latest genome and transcriptome information allowing one to use the most updated 
annotation when analyzing the data (Dai et al. 2005). Custom CDFs can also be used define the 
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probes in alternative genomic contexts e.g. one could generate a custom CDF specifically targeting 
5’ and 3’UTR regions, noncoding regions etc. In addition, one can also resolve the polymorphism 
problem in the designed probes by removing the probes with SNPs’ or indels (insertion/deletion of 
a nucleotide). Basically comprehensive polymorphism data are used to identify probes which cover 
regions with SNPs since polymorphism could affect signal integrity. These probes can then be 
removed from the CDF (Ramasamy et al. 2013). This can be useful as a genotype filter in case of 
unpaired analysis (see section 2.3.2).  
                
Figure 2.1: Comparison of gene expression profiling technologies. Advantages of RNA-seq and 
Microarrays technology compared to each other. From personalized medicine and clinical perspective 
microarrays outweigh NGS. 
2.3.1 Generating custom CDF files 
To generate these CDFs we start by aligning the probe sequences available in FASTA format (from 
the Affymetrix website) to the reference genome of interest using the bowtie alignment tool 
(Langmead & Salzberg 2012). We then extract the uniquely mapped probes from the alignment 
files i.e., probes that map only once to the reference genome, thus removing cross 
hybridising/multiple genomic loci probes. From the bowtie alignment file we create an annotation 
for each uniquely mapped probe comprising of the chromosome, strand, X and Y coordinate for the 
probe on the gene chip and also the probe start and stop position on reference genome. We 
additionally create a genome boundary file that defines the genomic region of interest for the CDF, 
which can range from a gene, transcript or an exon to 5’ or 3’ UTR. To create this file we first 
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download genome level data defining boundaries for different genomic units (genes, transcripts, 
exons) in General Transfer Format (GTF) from Ensembl. We extract the ensembl ID, chromosome, 
strand and start and stop position from the GTF file (Cunningham et al. 2015). It is important to 
note that we include only the exonic regions of a gene/transcript avoiding the regions spanning the 
introns, as these are unexpressed sections of a gene. So, for a gene level CDF, probes mapping to 
all exons from all transcripts are included in a single unit (gene in this case). Lastly using an in-
house R script, we map the probe annotation file to the genome boundary file to produce a single 
tab-delimited file of all probes and their corresponding assignments to a genomic unit, with each 
row corresponding to a probe to be included in the custom CDF. The tab delimited file is converted 
into a custom CDF using a user defined function in R (Figure 2.2).  
2.3.2 Resolving polymorphism in-probe problem 
Microarray probes are typically designed to match one reference sequence only, based on reference 
genomes present in public databases at the design time. Sequences that depart from this reference, 
either due to the presence of SNPs’ or due to the presence or absence of nucleotides (i.e. indels), 
often show a weaker binding affinity for the probe in question. Ramasamy et al  proposes a solution 
to this problem which we adapted to generate custom CDFs by removing the probes with 
SNPs’/indels’ (Ramasamy et al. 2013). These custom CDFs without SNPs will work as a genotype 
filter in case of unpaired analysis where we cross compare two samples from different subjects. The 
process comprises of three main steps as follows: 
a) Extracting the variant information by identifying and downloading the latest and most 
comprehensive polymorphism set. There are different genetic variation databases 
available for reference in the public domain such as HapMap (The International HapMap 
Consortium 2010), exome variant server, 1000 genomes project (1000 Genomes Project 
Consortium 2010), differing in their completeness as well as diversity of the population 
profiled. For example: if our dataset comprises of subjects of European descent then the 
indels and SNPs information could be extracted from the European panel (n = 381) of 1000 
genomes project. From this we would take into consideration only those SNPs and indels 
which have minor allele frequency (MAF) above a chosen threshold (> 1%) for 
polymorphism identification (threshold of 1% MAF in this case implies that the minor allele 
should exist in ~4 or more people out of the 381 profiled). We avoid being too stringent 
with the threshold because it can result in removing valid probes signals. 
b) Preparing the Probe file for the specific platform with genomic coordinates of each 
probe. Unlike Ramaswamy et al. who used the design time annotations provided by the 
manufacturer to get the genomic coordinates of the probes on the reference genome 
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(GrCh37) we used the latest mappings, by aligning the probe sequences (in FASTA format) 
to reference genome GrCh37 using bowtie alignment tool.  
c) Comparing genomic coordinates of SNPs’ and Indels’ with probe coordinates. Finally 
we used BedTools (Quinlan & Hall 2010) and files from step 1) and 2) to get the list 
of probes that contain these SNPs and Indels. Using the intersectBed functionality from 
BedTools we compare the probe coordinates and SNPs/indel coordinates and identify 
probes that overlap polymorphic sequence. We then remove these probes (as shown in 
Figure 2.2) before generating custom the CDF which collapses probes into gene, transcript 
or exon. 
This ensures that our custom CDF’s overcome the polymorphism problem in probes. One limitation 
of this approach is that it relies on variant databases for SNP/Indel information (currently 
completed for GrCh37 genome assembly) which are not updated along with reference genome 
(current version GrCh38) due to which one is unable to use the most updated genome information. 
2.4 Feature selection from gene expression data 
The goal of classification is to identify the features that can be used to predict class membership for 
new samples. Low reproducibility and the limited biological interpretability of candidate biomarker 
signatures identified from high-throughput data (microarrays, NGS etc.) is one of the key issues 
which impedes the use of discovered biomarker signatures into clinical applications. Under the 
circumstances, gene set analysis that investigates groups of genes instead of individual genes is 
becoming a trend in interpreting gene expression data.  
2.4.1 Criticism of differential expression approach for biomarker discovery 
With microarrays differential expression analysis of genes is key to classify features that relate to a 
phenotype and also helps in recognizing significant biological pathways. This feature selection 
based on differential expression analysis of gene expression data has been a widely used approach 
for identification of biomarkers. The differences in biological characteristics, e.g. genes, expressed 
across different species or conditions are generally investigated and those genes significantly 
changed are considered as differentially expressed. If a differentially expressed gene generally 
correlates very well with the phenotype of interest, then it is considered as a potential biomarker for 
that phenotype e.g.  blood pressure, body mass index etc. The accumulation of wealth of the 
publically available gene expression data in databases such as Gene Expression Omnibus (GEO) 
has further helped in detecting genome-wide genes that are significantly differentially expressed 
between case and control samples or between different disease stages (Lewohl et al. 2000; De la 
Fuente 2010). Earlier approaches based on differential expression identified gene biomarkers by 
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setting arbitrary threshold/cut-offs for fold change and p values (Hibbs et al. 2004; Ginos et al. 
2004). However, the technical noise inherited in the gene expression data and experimental 
variation in measured gene expression levels makes it challenging to detect significant gene 
expression differences that reproduce consistently across studies and contributes to false positive 
results. Indeed different threshold choices for differential expression can result in entirely different 
biological conclusions (Pan et al. 2005). Furthermore, there could potentially be many biologically 
important genes which are not considered because they are not significantly differentially expressed 
but are indeed related to the phenotype under consideration (Ben-Shaul et al. 2005; Goeman & 
Bühlmann 2007). Thus, a standard differential expression approach is unable to give a ‘common’ 
multi-tissue set of discriminatory RNA molecules that could function as a biomarker or a diagnostic 
(Glass et al. 2013) and can thus be inaccurate when used as a classifying tool.  In this respect, 
machine learning approaches could alternatively provide a more useful and robust understanding of 
the large genomic datasets.  
2.4.2 Machine learning approaches in genomics 
Machine learning is a term used to describe a broad range of automated algorithms that learns from 
data. By and large machine learning strategies have two applications i.e. prediction or interpretation 
(Libbrecht & Noble 2015). In genomics, specifically, machine learning has been utilized to predict 
the location and function of genes and regulatory elements, to identify non-coding RNA and to 
model and decipher gene expression data etc. (Aerts et al. 2004; Segal et al. 2003; Carter et al. 
2001).  
Supervised machine learning techniques are frequently used for classification purposes. 
These techniques train an algorithm to recognise features in the data which discriminate classes. 
The classification labels are ‘seen’ by the algorithm in the initial training hence the term supervised 
learning. After training the same algorithm is tested on unlabelled samples but using only the 
features of the data which were most useful for prediction in the initial training phase. From a 
genomics classifier or a diagnostic perspective, this machine learning approach distinguishes which 
features of the data are likely to be relevant on the basis of gene expression estimations. Thus 
supervised learning can be a method to deal with the task of feature selection (Baldi & Brunak 
2001; Ding & Peng 2005) in classification problems.  
Selecting an ensemble of features that can provide high discriminatory power between 
different biological groups or conditions has been successfully achieved before by using algorithms 
like support vector machines (SVM) (Guyon et al. 2002), k nearest neighbours (kNN) and the 
random forest approach (RF) (Diaz-Uriarte & De Andres 2006). A recent in depth review of 
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different supervised classifiers used for microarrays datasets (Statnikov et al. 2005; Saeys et al. 
2007; Boulesteix et al. 2008) identified SVM and kNN as the most effective approaches for 
microarray data classification (Slonim 2002).  The Microarray Quality Control Consortium in the 
second phase (MAQC-II) set out to evaluate different methods used for developing and validating 
microarray-based predictive models and reach consensus on the “best practices” for the use of these 
models in personalized medicine. After assessing the classifiers developed by thirty-six teams for 
thirteen different endpoints (breast cancer, liver toxicity etc.), they concluded that simple data 
analysis methods often perform as well as and sometimes even better then more complicated 
approaches (Shi et al. 2010). Further, the MAQC-II ranked kNN as one of the best performing 
supervised learning algorithms for microarray based predictive models. Briefly, kNN is a non-
parametric method which assigns a label/class to an unknown sample on the basis of class 
membership of its k nearest neighbours, as determined by a Euclidean distance function. It is the 
simplest of all algorithms and has the power to perform well on non-linearly separable datasets, 
often giving better performance than more complex methods in many applications and is thus the 
approach we chose for our project. Therefore, for this research work we adopted the 
computationally inexpensive, relatively simple yet efficient kNN classifier for feature selection and 
classification.  
The number of features(dimensionality) in a feature selection process can range from tens to 
thousands. Certain machine learning algorithms may perform poorly in high-dimensional data and 
this is referred as the curse of dimensionality (Donoho & others 2000; Van Der Laan & Bryan 
2001).  It's hard to know what true distance means when you have so many dimensions and the 
difficulty of searching through the space gets a lot harder. An easier, yet often exceptionally 
powerful, method for managing high-dimensional information is to diminish the feature space by 
eliminating some coordinates that seem irrelevant. With microarrays, this can often be done 
efficiently and simply, by excluding from consideration all those genes whose expression value 
doesn't vary across hybridization experiments (Hu et al. 2012). For our gene expression based 
classifier work we evaded this issue of dimensionality (~54K features) by reducing the feature 
space based on a modified t- statistic (from limma) and using a subset of top 200 features based on 
this statistic (Smyth 2004).  
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Figure 2.2: Workflow for generating the custom CDF file. The figure shows the workflow for updating the 
custom definition file for microarrays. This allows one to get the latest information from microarray probes 
in the biological context of interest (gene, transcript or exon   level) using ENSEMBL annotation data. 
2.5 Building healthy ageing diagnostic 
We took a hypothesis driven approach to study healthy muscle ageing. For this we utilized the kNN 
classification method, embedded within a nested loop for feature selection and classification to 
capture data-features that share non-linear interactions and have robust performance using methods 
consistent with the MAQC-II. We decided against taking the approach of building a simple linear 
model for ageing (Rodwell et al. 2004; Horvath et al. 2012; Hannum et al. 2013) as the validity of 
the linear approach to build a diagnostic of ageing status when applied to the entire adulthood 
chronological age-range is limited. Extensive molecular work has shown that abrupt changes in 
metabolism (i.e. a non-linear event) can occur in the ‘early middle ages’ of model organisms 
(López-Otín et al. 2013). Therefore, our focus was primarily on a binary predictor that could 
discriminate between healthy old and healthy young muscle. 
2.5.1 Training Dataset  
Our goal was to generate a valid molecular classifier of human age using tissue samples from 
healthy individuals, obtained across the decades during which chronic disease begins to emerge, i.e. 
the 3rd to 6th decades. Identification of a molecular pattern would then presumably reflect some 
form of adaptive program in healthy older subjects, since they were free from chronic diseases. 
Most ageing biomarkers or signatures are built on epidemiological cohorts that blend in ageing, 
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disease and drug-treatment and do not primarily reflect ageing. Our healthy-age prototype 
diagnostic was built using 15 young (19-28y, chronological age, VO2max=2.52 L/min) and 15 older 
(59-77y chronological age, VO2max=2.65 L/min)  Scandinavian subjects free from metabolic and 
cardiovascular disease (Timmons et al. 2010; Keller et al. 2011). In humans, aerobic fitness has 
been found to be a powerful biomarker of all-cause mortality (Church et al. 2005; Wei et al. 1999; 
Blair et al. 1989; Myers et al. 2002), reflecting genetics (Timmons et al. 2010), and co-morbidities. 
Since the present aim was to develop a RNA diagnostic that when applied to any RNA tissue 
expression profile, would yield an accurate prediction of healthy physiological age and forecast 
long-term health, the younger and older samples, used in the prototype development, were matched 
for aerobic fitness to minimise the confounding effect of this aerobic fitness. We also constrained 
the gender effect in the study by including only the male subjects (Roth et al. 2002; Berchtold et al. 
2008). The muscle biopsies from the samples were profiled on the Affymetrix HGU133Plus2 
platform (GSE59880). Note that this dataset was solely used for feature selection and was discarded 
thereafter in the downstream steps to avoid over-fitting or bias. 
 
Figure 2.3: Building healthy ageing classifier. A nested loop strategy along with kNN method was used to 
select features that could together discriminate between healthy young and healthy old samples. 
 
2.5.2 Array processing and classifier strategy 
The probeset level intensities of the arrays were normalized using the Robust Multi-array Analysis 
method (RMA) (Irizarry et al. 2003) implemented within the R statistical software environment 
using the ‘affy’ package (Bioconductor project (Gentleman et al. 2004; Gautier et al. 2004)). The 
candidate probeset lists were created via a nested-loop, holding out two arrays at any one time to 
estimate two parameters from the data (Figure 2.3).  
	
1	Unknown	sample
Loop A Loop B Loop C
1	Held-out	sample
54,000	p-values	in	rank	order
Select	top	200	per	loop
Ensembl of	~800	selected	
Assess	1+1,	1+2…	ps
~180,000	calls
Rank	ps performance
Assess	the	predictive	
performance	of	top	
150ps	in	LOOCV	
operation
Chapter-2                                                                                                General Methods and signature development 
	
	 43	
a. The first parameter was the conventional test set result i.e. is the array correctly 
classified Yes/No. We used this to derive classification success ratios of each of 
the top 200 probeset to classify each sample. 
b. To calculate the second parameter (maximum appearance ratio), we first ranked 
the probesets based on number of times they correctly classified the array. We 
then estimated the maximum appearance ratio as the number of times a probeset 
appears in the top ranked list.  
 
Two-hundred probesets were selected during each of the inner-most computational loops by 
ranking gene expression differences using an empirical Bayesian statistic (implemented as eBayes 
in the ‘limma’ package) (Smyth 2004). Following iterative assessment of all probesets on the gene-
chip, involving ~180,000 permutations during which each one of the 30 samples was held-out of 
the ranking procedure, the best performing ~800 probesets were selected (based on the total number 
of correct sample classifications during the 180,00 iterations). We removed probesets that targeted 
multiple genomic loci (as discussed in section 2.3.1) and selected the top ranked 150 probesets 
(involved in >90% correct decisions) for further study. This reduced list was validated using 
multiple independent data sets using a kNN (n=3) classifier, implemented using the R ‘class’ 
package. To implement independent blind validation, we used both independent training and 
independent test muscle and brain data sets (chapter-3). The R code is included in Appendix 3 of 
the thesis. 
2.6 Summary 
Following a strict set of benchmarks we identified 150 RNA markers of muscle ageing using the 
following gene-chip profiles (GSE59880) from 15 young (19-28y) and 15 older subjects free from 
metabolic and cardiovascular disease (59-77y) (Keller et al. 2011; Gallagher et al. 2010). The RNA 
markers were selected using a nested-loop, holding out two arrays at any one time to estimate two 
parameters from the data. Following iterative assessment of all probesets and all samples, involving 
~180,000 permutations, ~800 probesets were identified as having good performance (>70% correct 
classifications). After removing the probesets that targeted multiple genomic loci the top ranked 
150 probesets for classification of healthy ageing were selected for further work. In the next chapter 
we test and validate the performance of this healthy ageing signature in independent datasets across 
different tissues and platforms and also explore its prognostic abilities (Figure 2.4). 
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Figure 2.4: Molecular diagnostic for healthy ageing. The figure summarizes the steps undertaken in this 
research work to build and validate the healthy ageing RNA signature.  Firstly, we did feature selection 
using a machine learning kNN based approach. The signature was then independently validated to ensure it 
is not biased/over-fitted and its prognostic abilities were tested (explained in chapter-3). 
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3.1 Overview of the chapter 
The previous chapter described the transcriptomic approach used to build the RNA expression 
signature of ‘healthy older tissue’, by gene-chip profiling sedentary normal subjects who reached 
65y in good health. The next step was to demonstrate its reproducibility and test the hypothesis that 
this gene expression pattern may provide reliable genomic predictors for healthy ageing and risk of 
age-related disease.  Thus, the key objectives of this chapter are to: 
• Perform independent validation of the healthy ageing signature on independent cohorts of 
human muscle, skin and brain tissue (n=594) to establish whether it is robust and 
reproducible. 
• Examine the relationship between RNA classifier and confounding life-style factors and 
chronological age. 
• Ascertain its clinical utility by examining its prognostic potential on a longitudinal study 
with 20y-follow up period. 
• Explore the hypothesis that this gene expression pattern may provide reliable genomic 
predictors for risk of age-related disease.  
• Investigate the biological narrative that governs this molecular signature for healthy ageing. 
3.2 External validation across different tissues and technology platforms 
Use of fully independent training and validation data sets allows for genuine external validation 
(EV) to be demonstrated. We implemented fully independent external validation (EV) of the 150-
probeset healthy ageing classifier, a process that requires both independent ‘known samples’ and 
independent test gene-chips (Shao et al. 2013). When combined with LOOCV methods, this 
represents a ‘gold standard’ approach for validation of a classification model. 
3.2.1 Independent validation cohorts and implementation 
A new set of young and old muscle profiles (Selected from data-set ‘Campbell’, n=66 chips 
GSE9419) (Thalacker-Mercer et al. 2010) was used to represent the new ‘expression space’ of 
known samples. We then carried out evaluation of sets of independent gene-chip profiles from 
young and old human muscle (all Affymetrix U133+2) normalised using fRMA (McCall et al. 
2010). The various fully independent samples were obtained from GEO or produced from our own 
clinical samples (Slentz et al. 2011). In each dataset the samples were selected to belong to either 
young (~25y) or old grouping (~65y) from a larger collection of samples. The sets of young and 
older samples were selected from ‘Trappe’ GSE28422(Raue et al. 2012) (n=48), ‘Hoffman’ 
GSE38718(Liu et al. 2013) (n=22), ‘Derby’ GSE47881 (Phillips et al. 2013) (n=26) and ‘Kraus’ 
GSE47969,[n=33). For all datasets, arrays were examined using hierarchical clustering and 
Chapter-3                                                                              Ageing	diagnostic:	Independent	Validation	and	prognosis	
	
	 46	
Normalized Unscaled Standard Error (NUSE). In case we identified a small number of gene-chips 
(~2-3) that had evidence of technical defects and these were removed prior to any analysis. To 
assess if human brain and skin also demonstrated the same 150 age-related gene expression 
signature as healthy older muscle, we used young and old samples brain-bank array source (n=120, 
GSE11882) and the MuTHER cohort skin dataset (n=279, which includes subset of 3 replicates 
(n=131, n=124 and n=24)). The skin data was produced using the Illumina Human HT-12 V3 Bead 
chip (Arrayexpress: E-TABM-1140) and log-2 transformed signals were normalised using quantile 
normalisation. The 150 Affymetrix probesets were mapped to the Illumina platform (giving 129 
probes). Due to differences in gene-chip technology, a leave-one-out cross validation (LOOCV) 
approach was used to classify age of each skin sample, using only the probes selected above. For 
skin, individuals aged < or = 45y were defined as young, and those > or = 70y as old to ensure 
balanced numbers of young and old samples existed to fairly assess the classifier performance. The 
R code for ‘independent validation’ is included in Appendix 3 of the thesis. The information about 
all the datasets used in this chapter is available in Appendix 1. 
3.2.2 Reproducible RNA signature for age of human muscle, brain and skin  
Using the ‘Campbell’ muscle data set (GSE9419) (Thalacker-Mercer et al. 2010) as the samples of 
known identity, we demonstrated that additional young and old muscle samples selected from 4 
additional muscle data sets (‘Trappe’ GSE28422 (Raue et al. 2012), ‘Hoffman’ GSE38718(Liu et 
al. 2013) ‘Kraus’ GSE47969 and ‘Derby’ GSE47881 (Phillips et al. 2013)) could be classified with 
an average ~93% accuracy (70-100%) using only the 150 probesets selected at the start of the 
project. Substitution of Campbell with the other muscle data sets worked equally as well. These 
data shared a common microarray platform (Affymetrix HGU133Plus2) but as we demonstrate 
below, the classifier remains robust in the face of alternative platforms. Receiver operator curves 
(ROC) for kNN=5 demonstrating classifier performance for a number of tissue types are presented 
in Figure 3.1.  
Using data from the HGU133Plus2 microarray platform for old and young samples of 
ectodermal origin (brain, n=120) (Gould et al. 1999) we confirmed that the 150 RNA ‘healthy age’ 
genes selected in muscle, could also distinguish the age of human brain one sample at a time, with a 
classification success rate up to 91% (Figure 3.1). Four brain regions were evaluated (Postcentral 
Gyrus, Entorhinal Cortex, Hippocampus and Superior Frontal Gyrus), GSE11882 and while they 
were confirmed disease-free by histopathology in the original study (Berchtold et al. 2008), unlike 
our muscle cohorts, their true functional status remains unknown. The Postcentral Gyrus samples 
were classified with 86% sensitivity and 89% specificity. Older hippocampal regions were often 
misclassified using the 150-genes (33% sensitivity) as ‘young’. This higher misclassification rate 
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may relate to the substantial neurogenesis known to take place in the adult hippocampus or delays 
in tissue processing. 
      
Table 3.1: Accuracy, sensitivity and specificity of the muscle-derived healthy age classifier when applied 
to multiple independent data sets. The sensitivity and specificity of the top 150-probe-sets from the 672 
probe-set derived from the STOCKHOLM U133+2 Affymetrix gene-chip data, was calculated for the human 
muscle data sets CAMPBELL, DERBY, HOFFMAN, TRAPPE AND KRAUS and the four brain regions 
derived from the Berchtold et al. study (Berchtold et al. 2008) and skin from the MuTHER cohort (Glass et 
al. 2013). The majority of data sets demonstrated both high sensitivity and high specificity using this un-
optimised list. A young sample misclassified as ‘old’ (e.g. in HOFFMAN) is noted as a reduced sensitivity. If 
an old sample was misclassified as being young and healthy, as was the case for some of the Hippocampus 
regions, then this is defined as a reduction in specificity where young is a true-positive in this model. The 
likely contributing factors to these misclassifications include lack of standardisation of a single laboratory 
gene-chip protocol and variation in RNA quality and in some cases examples of older donors that have not 
induced the ‘healthy ageing’ signature to any measurable extent.  
	
Lastly, we evaluated whether the 150 genes could accurately classify tissue age of 
mesodermal origin (skin) using gene expression data in a total of 279 human skin samples of which 
there were up to three technical replicates per clinical sample (Glass et al. 2013). Notably these data 
originated from a different technology platform (Illumina Human HT-12 V3, Arrayexpress: E-
TABM-1140) thus adding variability above that derived from a distinct tissue and potentially 
limiting the classification process. One hundred and twenty-nine genes were common to both gene-
chip technologies, and we observed excellent classification of age of human skin (n=131, 
Table 1 
     
Tissue Sample Size Accuracy % Sensitivity Specificity 
 
Muscle (Campbell) 
 
66 
 
96 
 
0.94 
 
0.97 
Muscle (Derby) 26 100 1.00 1.00 
Muscle (Trappe) 48 96 0.96 0.96 
Muscle (Hoffman) 22 91 0.93 0.88 
Muscle (Kraus) 33 70 1.00 0.60 
Brain (SFG) 33 91 0.71 0.96 
Brain (PCG) 31 88 0.86 0.89 
Brain (Hippocampus) 31 85 0.33 1.00 
Brain (EC) 25 72      0.43 0.94 
Skin (MuTHER Cohort) 279 78 0.59 0.90 
Table 3.1: Accuracy, sensitivity and specificity of the muscle-derived healthy age classifier when applied to multiple independent data 
sets. The sensitivity and sp cificity of the top 150-probe-sets from the 672 probe-set derived from th  STOCKHOLM U133+2 Affymetrix gene-
chip data, was calculated for the human muscle data sets CAMPBELL, DERBY, HOFFMAN, TRAPPE AND KRAUS and the four brain 
regions derived from the Berchtold et al. study [30] and skin from the MuTHER cohort [16]. The majority of data sets demonstrated both high 
sensitivity and high specificity using this un-optimised list. A young sample misclassified as ‘old’ (e.g. in HOFFMAN) is noted as a reduced 
sensitivity. If an old sample was misclassified as being young and healthy, as was the case for some of the Hippocampus regions, then this is 
defined as a reduction in specificity where young is a true-positive in this model. The likely contributing factors to these misclassifications 
include lack of standardisation of a single laboratory gene-chip protocol and variation in RNA quality and in some cases examples of older 
donors that have not induced the ‘ althy ageing’ signature to any m asurable extent.  
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AUC=0.85, Figure 3.1). The classification success was similar for all three replicates (71-78 raw 
classification success). Thus the technical performance of the 150-gene multi-tissue age classifier 
was excellent and robust, providing accurate classification despite inter-laboratory technical 
variation, different gene-chip platforms and ante-mortem tissues. We were therefore able to 
conclude that we have identified a reliable multi-tissue RNA signature of healthy tissue ageing in 
humans, something that has not been previously demonstrated (Glass et al. 2013; Phillips et al. 
2013).  
 
Figure 3.1. ROC curve showing predictive performance for tissue age classification using ‘healthy age’ 
biomarkers based on leave-one-out cross-validation (kNN=5) for muscle, brain and skin. Using only the 
150 probesets identified in the first stage of the project, this ‘healthy age classifier’ was able to correctly 
classify young and old samples across independent datasets with an accuracy of ~96%, 91%, 85% and 78%. 
We present two examples of independent muscle data (Raue et al. 2012) [50] and one example each for 
human brain (Berchtold et al. 2008) and skin datasets(Horvath 2013) with AUC of 0.99, 0.94, 0.78 and 0.85 
respectively reflecting excellent separation of the age groups and hence accurate multi-tissue performance. 
	
3.3 Prognostic abilities of healthy ageing signature and relation with life-style related risk-
factors 
Ideally, a true diagnostic of ‘healthy ageing’ should not correlate with age associated phenotypes or 
risk factors for chronic disease (Baker & Sprott 1988). The specificity for ‘healthy ageing’ in our 
RNA signature was examined by assessing the relationship between the signature genes, 
chronological age and markers of life-style associated disease in a twenty-year longitudinal cohort 
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(ULSAM, Uppsala Longitudinal Study of Adult Men cohort). To achieve this, the RNA signature 
was transformed into a ranking metric by collapsing the expression pattern of each gene in our 
signature into a single score termed as ‘healthy ageing score’ which was then related to risk factors 
and health outcomes in the ULSAM study. 
3.3.1 ULSAM longitudinal study and gene score calculation 
We used a set of tissue samples from a birth cohort of men, such that the same chronological age 
(~70y) could be contrasted with the variation in ‘healthy age gene score’. The ULSAM (Uppsala 
Longitudinal Study of Adult Men) is a cohort of men born in 1920-24 and living in Uppsala, 
Sweden to compare a constant chronological age (and similar environment) with the healthy muscle 
age gene score for each individual (Dunder et al. 2004). Dual-energy X-ray absorptiometry (DXA) 
scan measurements were performed during the last decade of the study and muscle mass status 
varied between -15% to +10% between age 70y to 88y and was unrelated to physical activity scores 
(recorded at 82y and 88y of age, with 80% being recorded as being moderately active). We had 
access to 129 skeletal muscle biopsies that were taken at age 70y (in 1992) and were processed in 
2012 with the majority having excellent NUSE plot profiles. Total RNA was extracted from frozen 
muscle biopsy samples (vastas lateralis) using TRIzol reagent as previously described (Timmons et 
al. 2005). A total of 113 samples provided sufficient RNA and 50ng total RNA was amplified using 
Ambion’s WT expression kit to produce cDNA. The cDNA was fragmented and labelled with 
GeneChip WT Terminal labelling kit (Affymetrix, Inc.). Unincorporated nucleotides from the IVT 
reaction were removed using the RNeasy column (QIAGEN Inc, USA). Hybridization, washing, 
staining and scanning of the arrays were performed according to the manufacturer’s instructions 
(Affymetrix, Inc., USA).  
     One hundred and eight samples passed gene-chip quality control procedures. A cumulative 
gene-ranking based score was calculated using each of the 150 gene expression values for each of 
the 108 male subjects and the final score was compared in a linear fashion with a number of clinical 
parameters. For an RNA down regulated in the original training classification dataset (i.e. down 
regulated between 25y to 65y) the ULSAM subject with the highest expression was assigned a 
score of 1 and the subject with the lowest expression 108. For genes up regulated in the original age 
classification model, the opposite strategy was used. Thus both feature selection (genes) and 
direction of regulation were taken from the original model. The median sum of these rank scores 
(for all 150 genes) was calculated and that represented the ‘healthy age gene score’ for each 70y 
individual. Median rank ensured each gene provided equal weighting and regression analysis was 
used to study the variation in gene score in these men all of who had approximately the same 
chronological age. The R code for ‘Gene score ranking’ is included in Appendix 3 of the thesis. 
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3.3.2 Healthy ageing gene score is distinct from chronological age and is unrelated to life-style 
factors  
The distribution of scores was examined for 70y old males and the scores were also correlated with 
markers of life-style associated disease (Figure 3.2). We ranked each subject for each of the 150 
genes, taking the direction of gene expression change from the original classifier model into 
account (85% down-regulated). We then converted the individual gene scores into a summed 
median gene-score for each subject. We demonstrated that despite all subjects being ~70y of age at 
the time of the RNA sample, there was a very wide distribution in gene score (Figure 3.2A). Thus 
the ‘healthy age gene-score’ in muscle was very distinct from chronological age.  
The ‘healthy age gene-score’ was regressed against a variety of continuous clinical variables 
(variables listed in Table A3.1 in Appendix 2). The gene-score at chronological age 70y was 
unrelated to conventional life-style regulated biomarkers at baseline e.g. renal function (estimated 
from cystatin-c, r2<0.001), systolic blood pressure (mmHg, r2=0.0013), 2hr glucose concentration 
following a standard oral glucose tolerance test (mmol, r2=0.015) or total cholesterol (mmol, 
r2=0.002). Gene score was also unrelated to resting heart rate or physical activity questionnaire. 
Infact the ‘healthy-ageing’ gene score was not correlated with any conventional risk factors (Figure 
3.2B). This confirmed that the 150 gene expression markers were not reflecting a variety of life-
style factors and diseases (e.g. exercise, diabetes). 
3.3.3 Healthy ageing gene signature as prognostic of long-term health status in the ULSAM 
study 
Our primary hypothesis was that a validated diagnostic of healthy physiological age could be used 
to predict health outcomes in a longitudinal study, where subjects were all the same chronological 
(calendar) age at the point of assessment. The relationship between the gene score at age 70y for 
subjects in ULSAM study and a number of clinical features was carried out using multi-factor 
models. At 70y three subjects had Cystatin C > 1.5 mg/l, while by 82y 36 of the subject studied in 
the present analysis had Cystatin C > 1.5 mg/l Cystatin C. A 1.5 mg/l Cystatin C corresponds to an 
estimated GFR of ~45 ml/min which is borderline for a moderately (30-45 ml/min) elevated risk for 
all-cause mortality. We estimated renal function using Cystatin C to calculate glomerular filtration 
rate (eGFR) as it is a robust marker for early renal impairment (Coll et al. 2000; Laterza et al. 2002) 
and demonstrated that the baseline healthy-age diagnostic ranking score was related to renal 
function 12 years later (age 82, p=0.009). While renal function is not sufficiently powerful to 
predict mortality in disease-free older subjects from the ULSAM cohort (Zethelius et al. 2008), we 
found that the healthy age diagnostic was able to strongly predict 20y survival in a cox-regression 
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model. Over the observation period mortality rate was 18% (19 events) and the relationship 
between mortality and gene-score was analysed as a continuous variable.  
Remarkably, the ‘healthy age gene-score’ in muscle at 70y was independently related to 20-
year survival (p=0.0295, Figure 3.3A) in a logistic regression model. While this observation should 
be interpreted cautiously, to illustrate the temporal relationship between the ‘healthy age gene-
score’ and death, we divided gene-score into quartiles and applied a Cox-regression model (Figure 
3.3B) and found a significant difference between the first versus the fourth quartile (p=0.04). In 
contrast to the ‘healthy age gene-score’, a median gene rank score based on inflammatory gene 
(GO:0006954) or mitochondrial gene (GO:0005739) expression in muscle demonstrated no 
relationship with health or mortality (Appendix 2 Figure A3.1, p=0.173 and p=0.337 respectively). 
For the cox-model we used the latest ‘survival package’ whereas the logistic regression model was 
estimated using the glm (generalized linear model) function and ‘logit’ model which models the log 
odds of the outcome as a linear combination of the predictor variables.  For the Kaplan-Meier plots, 
gene-score was divided into quartiles and the plot was produced using the ‘plot-survfit’ function in 
the survival package. All three approaches yielded consistent results.   
Thus, despite the limited sample size of the ULSAM cohort (n=108), we were able to 
establish that subjects with the highest muscle ‘healthy ageing gene score’ at age 70y had 
significantly better renal function 12 years later (at age 82 years) and a better survival rate 20 years 
later. The prediction of mortality in the ULSAM 20y follow-up study is of course preliminary, 
given the size of this part of our study, but it provides further support that induction of the age 
signature, by the 6th decade of life, represents a positive event since the directional shift in gene-
expression and better ‘health’ was consistent for the renal and mortality analysis i.e. largest gene 
score in the ranking system was associated with better health in ULSAM. 
3.4 Relation between ‘healthy ageing gene signature’ and cognitive health 
Neurocognitive pathology (e.g. Alzheimer’s disease – AD) becomes more pronounced with age and 
is often apparent in individuals who are otherwise healthy. Our analysis of the relationship between 
life-style factors and the ‘healthy age gene score’ in the ULSAM cohort suggested that the gene 
score was robust to confounding effects of life-style disease. We next examined whether the 
‘healthy ageing gene score’ [median rank sum of the 150 RNA markers] was selectively useful in 
relation to identifying neurocognitive disease over life-style disease. To support this analysis, we 
utilised a large publically available gene-chip data-set derived from healthy human brain samples of 
various ages (Ramasamy et al. 2014). The BrainEac.org gene-chip resource (Ramasamy et al. 
2014)(GSE60862) comprises 10 post-mortem brain samples from 134 subjects representing 1,231 
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Figure 3.2. Distribution of healthy age gene score in ULSAM samples and its relation with clinical 
parameters. At the date of assessment (1992), when the muscle biopsy was taken for subsequent gene-chip 
profiling, all subjects would be considered in reasonable health for their age and remained physically 
active. A) Distribution of Gene score based on the median rank for each of the 150 age genes. B) Clinical 
variables were determined as previously reported for ULSAM samples (chronological age=69-70y) (Huang 
et al. 2013)(Zethelius et al. 2008). Linear regression was used to examine the relationship between the 
healthy-ageing gene-score at ~70y and a variety of clinical parameters at age ~70y. No relationship 
between gene score and renal function (estimated from cystatin-c, r2<0.001), systolic blood pressure 
(mmHg, r2=0.0013), 2hr glucose concentration following a standard oral glucose tolerance test (mmol, 
r2=0.015) or total cholesterol (mmol, r2=0.002) was observed. Gene score was also unrelated to resting 
heart rate or physical activity questionnaire.  
60#
65#
70#
75#
80#
30# 40# 50# 60# 70# 80# 90#
Ch
ro
no
lo
gi
ca
l#a
ge
#(y
ea
rs
)#
Healthy#age#RNA#score#
DistribuAon#of##healthy#age#gene#score#in#human#muscle#
(ULSAM#cohort)#
0.2#
0.8#
1.4#
2#
30# 50# 70# 90#
U
ni
ts
#(m
g/
l)#
#
EsAmated#Renal#FuncAon#
70#
120#
170#
220#
30# 50# 70# 90#
#U
ni
ts
#(m
m
Hg
)#
Systolic#Blood#Pressure#
1#
4#
7#
10#
30# 50# 70# 90#
U
ni
ts
#(m
m
ol
/l
)##
Total#cholesterol#
0#
6#
12#
18#
30# 50# 70# 90#
U
ni
ts
#(m
m
ol
/l
)##
#
2hr#Plasma#Glucose#OGTT#
A#
B#
Healthy#age#RNA#score#
Chapter-3                                                                              Ageing	diagnostic:	Independent	Validation	and	prognosis	
	
	 53	
 
Figure 3.3 A cumulative ranking metric of the healthy ageing metric was prognostic for mortality over a 
20-year follow-up period. One-hundred and eight subjects provided a healthy tissue biopsy in 1992 that was 
suitable for RNA profiling and the fully annotated mortality data, covering 2009–2011, was retrieved from 
the Swedish national health registry. A) The rank score for healthy ageing gene expression was calculated 
from the top 150 genes of the healthy ageing prototype classifier (n = 108, male subjects all ~70 years of 
age). Logistic regression analysis performed using the cumulative ranking metric of the top 150 genes from 
original prototype was prognostic for mortality. It showed that those subjects with the lowest median healthy 
ageing gene score had a much higher probability of death during the 20-year follow-up period (p = 0.0295). 
B) The rank score for healthy ageing gene expression was calculated from the top 150 genes of the healthy 
ageing prototype classifier (n = 108, male subjects all ~70 years of age) and Kaplan–Meier plots were used 
to illustrate the temporal pattern of survival. Gene score was divided into quartiles and the plot was 
produced using the plot-survfit function in the R survival package. The plot allows us to compare overall 
survival rates between the four quartiles for gene score. The third and fourth quartiles differed from the first 
quartile (p < 0.04).  
samples. Using the same ranking approach as applied to the ULSAM cohort, the median sum of the 
rank score was calculated for each anatomical brain region (Figure 3.4). As before, in healthy older 
individuals the ‘age’ signature was ‘switched on’ (yielding a greater ranking score). Regulation of 
the healthy age gene score increased across individual healthy brain regions with chronological age, 
especially in the hippocampus (p=	2 ×10-8), as well as other regions such as putamen, thalamus, 
substantia nigra and the occipital, frontal and temporal cortex regions (all at least p<0.002 by Holm 
adjusted Mann-Whitney test). From this it was ascertained that the healthy ageing gene score was 
clearly evident in neuromuscular tissue, which suggested that it might relate to cognitive health. 
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. 
Figure 3.4 The ‘healthy ageing’ RNA signature was studied across diverse anatomical human brain 
regions in healthy individuals using BrainEac.org gene-chip resource. The healthy Ten brain regions from 
134 subjects representing 1231 samples were individually ranked and the median sum of the ranked scores 
calculated. Regulation of the healthy ageing genes differed across brain regions with age, as determined by 
a Kruskal Wallis Test (hippocampus p = 2 ×10-8, putamen p =4 ×10-7, thalamus p =4 ×10-5, temporal cortex 
p = 0.0001, substantia nigra p = 0.0002, frontal cortex p = 0.001, occipital cortex p = 0.001, white matter p 
= 0.01, medulla p = 0.06 and cerebellar cortex p = 0.51). Post hoc Mann–Whitney test, with correction for 
multiple comparisons (Holm), confirmed a striking ‘increase’ of the healthy ageing score in the healthy 
older samples (hippocampus, putamen, thalamus, substantia nigra, and the occipital, frontal, and temporal 
cortex regions; at least p < 0.002) 
 
3.4.1 Translating healthy ageing gene signature in Alzheimer/MCI cohorts 
Based on the above observation our primary hypothesis was that, compared with control subjects of 
similar chronological age and gender, patients with AD would have a lower median healthy ageing 
gene score but the score would not distinguish diabetes or vascular disease patients from matched 
controls. To test this hypothesis, we used blood RNA profiles from subjects from the 
AddNeuroMed consortium, a large Cross-European AD biomarker study and a follow-on Dementia 
Case Register (DCR) cohort in London. Patient selection, design and clinical data have been 
reported previously (Lovestone et al. 2009; Lunnon et al. 2012). We used two independently 
produced gene-chip datasets from the consortia, one produced in a UK gene-chip facility and 
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another produced in the USA which have been deposited on GEO under GSE63060 and 
GSE63061. A summary of the cohort characteristics can be found in Table 3.2 
Gender & Age matched cohorts Age Gender (F/M) MMSE 
Batch 1    
ControlMCI (n=67) 69.6 (±4.2) 41/26 (61%F) 29.1 (±1.2) 
MCI (n=39)  70.0 (±3.3) 24/15 (62%F) 27.5 (±1.6) 
ControlAD (n=64) 70.2 (±3.7) 41/23(64%F) 29.1(±1.2) 
AD (n=49) 69.8 (±4.4) 34/15 (69%F) 21.8 (±4.5) 
Batch 2    
ControlMCI (n=71) 70.8 (±2.9) 44/27 (62%F) 28.9 (±1.9) 
MCI (n=31)  69.5 (±4.5) 23/8  (74%F) 27.6 (±1.9) 
ControlAD (n=71) 70.8 (±2.9) 44/27(62%F) 28.9(±1.9) 
AD (n=40) 69.9 (±4.3) 23/17 (58%F) 21.0 (±5.6) 
 
Table 3.2: Clinical characteristics of batch 1 and batch 2 AD cohorts. Case-control subjects that 
contributed to the blood gene chip profiles analysed and presented in Figure 3.5 and Figure 3.6 
 
Briefly, subjects were excluded from the study if they had neurological or psychiatric illness other 
than AD, unstable systematic illness or organ failure, or a geriatric depression rating scale score ≥ 
4/5. AD was diagnosed using the National Institute of Neurological and Communicative Disease 
and Stroke and Alzheimer’s disease (NINCDS-ADRDA) and Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV) criteria for possible or probable AD. All MCI subjects reported 
problems with memory, corroborated by an informant, but had normal activities of daily living as 
specified in the Petersen’s criteria for amnestic MCI (Lovestone et al. 2009; Lunnon et al. 2012). 
All subjects underwent a structured interview and a battery of neuropsychological assessments 
including the Mini Mental State Examination (MMSE).  Control and MCI subjects were further 
assessed using the CERAD battery and detailed information on subject recruitment and assessments 
can be found in other published studies describing the AddNeuroMed consortium (Lovestone et al. 
2009; Snyder et al. 2014). RNA was obtained from whole venous blood and it was collected from 
the subjects who had fasted 2 hours prior to collection into a PAXgene™ Blood RNA tube (Becton 
& Dickenson, Qiagene Inc., Valencia, CA). The tubes were frozen at -20◦C overnight prior to long-
term storage at -80◦C. RNA was extracted using PAXgene™ Blood RNA Kit (Qiagen) according to 
the manufacturer’s instructions. Whole genome expression was produced using Illumina Human 
HT-12 v3 Expression BeadChips for the first case-control study (USA, ‘Batch 1’) and Illumina 
Human HT-12 v4 Expression BeadChips for the second case–control study (UK, ‘Batch 2’). cDNA 
was synthesized from 200ng total RNA using TotalPrep™ RNA Amplification Kit (Ambion) which 
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was followed by amplification and biotinylation of cRNA and hybridization. The expression data 
was first transformed using variance-stabilization and then quantile normalized using the LUMI 
package in R.  
For our primary analysis, control subjects were matched in a manner that created the largest 
possible group with the same chronological age and gender-balance as the AD or MCI groups. Thus 
our analysis was carried out on a sub-set of subjects deposited at GEO, with each case-control 
group having a similar median chronological age as the ULSAM cohort. A total number of 297 
samples were utilised (Batch 1 CTR=67, MCI=39, AD=49 and Batch 2 CTR=72, MCI=30, 
AD=40). Retrospective inclusion of the entire cohort (n=717) did not alter the outcome of our 
analysis. The 150 Probesets were mapped from the Affymetrix platform to the Illumina platform 
yielding 128 genes from the original 150-gene list. For each case-control comparison the ranking 
metric was computed in the exact same manner as for the ULSAM subjects (see section 3.3.1). 
From Batch 1, 113 subjects were ranked for gene score, while 111 subjects were ranked in Batch 2 
(Table 3.1). Wilcoxon rank sum test from the R stats package was used to test if the median gene 
score ranks between groups were significantly different or not. For data presentation, ranking scores 
were scaled to the total number of samples being ranked to ensure each data plot was on the same 
scale.  The relative median rank score for AD patients was significantly lower that the age and 
gender matched controls (p=0.004, Figure 3.5), based on Wilcoxon rank sum test. Blood RNA from 
the second AD case-control cohort was profiled on the Illumina HT-12 V4 platform and in this case 
122 genes were common to the 150-gene healthy ageing gene score.  
As before, the median rank healthy ageing gene-score for AD patients in Batch 2 was significantly 
lower than in the control group (p=0.009, Figure 3.5). Furthermore, for both Batch 1 and Batch 2, 
the age-matched controls had a higher median gene score than subjects diagnosed with mild 
cognitive impairment (MCI, Figure 3.5 p=0.00005 and Figure 3.5 p=0.003).  
It is important to note that the control samples used for comparison with MCI overlapped 
with those used for comparison with AD and that the MCI analysis cannot therefore be considered a 
fully independent observation. We also checked for overlap between the 150 healthy ageing gene 
markers and previous genomic and genetic disease markers of AD. Only three genes were in 
common (SPN, NPEPL1 and PDLIM7) and none were from previously validated AD diagnostics. 
Their inclusion or exclusion did not impact our analysis.  
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Figure 3.5 A cumulative ranking metric of the healthy-age metric could distinguish between control 
subjects with Alzheimer (AD) or Mild Cognitive impairment (MCI). The healthy ageing RNA signature was 
studied in blood samples from two independently processed case–control studies of AD. In cohort 1 the 
control median gene score was greater (p = 0.004) than AD samples and greater (p = 0.00005) than that of 
the MCI samples (Wilcoxon rank sum test). In cohort 2 the median gene score of control samples was 
greater than that of AD samples (p = 0.009) and that of MCI samples (p = 0.003). Data are median gene 
score and standard error. 
	
3.4.2 Healthy ageing signature as AD diagnostic 
We also formally evaluated whether the healthy ageing signature could act as a diagnostic for AD 
case-control cohorts using ROC analysis and found that it had robust independent performance on 
both cohorts that were used in the previous section (AUC=0.66-0.73, Figure 3.6). Our research 
group previously published a whole blood RNA based prototype AD diagnostic, consisting of 48 
genes which was also identified using machine learning methods applied to Cohort 1 samples 
(Lunnon et al. 2013). We demonstrated that this prototype ‘RNA disease signature’ was 
independently validated in Cohort 2 using LOOCV.    
Further, when we combined these two independently produced and validated gene expression 
classifiers (RNA age signature and RNA disease signature) we yielded an improved AD diagnostic 
(AUC=0.73-0.86, Figure 3.6), one which matches best in class (Snyder et al. 2014) for those blood-
based AD diagnostics validated using independent data, but using a technology platform more 
suited to reproducible high-throughput diagnostics.   
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Figure 3.6 Validation of novel blood RNA classifiers as a diagnostic for Alzheimer’s disease. We used the 
independent batch 2 AD data set to test the predictive performance of our healthy ageing classifier and our 
previously published AD prototype diagnostic. The performance of each was evaluated using ROC curves. 
The healthy ageing gene classifier generated independent AUCs of 0.73 and 0.66 for AD in cohorts 1 and 2, 
respectively. For the combined ‘healthy ageing’ plus ‘AD disease’ RNA classifier (150 + 48 probesets) we 
obtained AUCs of 0.86 and 0.73 for AD without any attempt at optimization. The AD disease RNA classifier 
probesets were selected using cohort 1. 
 
3.4.3 Relationship between the healthy age gene score and chronic life-style diseases 
Lastly, we utilised two additional large gene-chip clinical studies; one comparing blood RNA in 
Type II diabetes with control (Tabassum et al. 2014) and the other from our laboratory, comparing 
blood RNA in people with and without coronary artery disease (Sinnaeve et al. 2009).  The main 
purpose of this analysis was to further establish that the 150 gene expression markers were not 
reflecting a variety of lifestyle-regulated diseases.  
The diabetes data was profiled on Illumina Human HT.12.V4 arrays and comprised of 94 
controls versus 50 cases (group mean age = 66 y) and the vascular disease data had 112 controls 
and 110 cases (group age = 53.3 y) on Affymetrix HG-U133A arrays.  The case control analysis 
was done in same manner as for AD cohorts (section 3.3.1). Applying a Wilcoxon rank sum test, 
neither diabetes nor vascular disease (p=0.588 and p=0.430 respectively) was related to the healthy 
ageing gene score (Figure 3.7). This is consistent with our original hypothesis, and methods, that 
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the healthy ageing gene score is not related to lifestyle factors and it is also consistent with the 
results observed in the ULSAM cohort (Figure 3.2B). 
 
 
Figure 3.7 The healthy ageing signature activation was studied in blood samples from two independent 
large case–control studies of diabetes and vascular disease. Applying a Wilcoxon rank sum test, neither 
diabetes nor vascular disease was related to the healthy ageing gene score. This is consistent with our 
original hypothesis, and methods, that the healthy ageing gene score is not related to lifestyle factors and it 
is also consistent with the results observed in the ULSAM cohort (Figure 3.2B). A) The diabetes data (94 
controls versus 50 cases, group mean age = 66 y) originates from Tabassum et al. using Illumina Human 
HT.12.V4 arrays. (Tabassum et al. 2014). B) The vascular disease data (112 controls and 110 cases, group 
age = 53.3 y) originates from Sinnaeve et al.(Sinnaeve et al. 2009) (using Affymetrix HG-U133A arrays). 
 
3.5 Biological features of the healthy age diagnostic 
We were interested in whether the healthy-ageing diagnostic revealed any particular biological 
processes that might be open to therapeutic targeting. The bioinformatics tool, Ingenuity Pathway 
Analysis (IPA, http://www.ingenuity.com) was used to explore the biology of the age classifier 
genes. HUGO gene name identifiers were uploaded into IPA and queried against the verified IPA 
knowledge database. Out of the 150-gene list, a total of 127 genes were annotated in the database 
and revealed a few marginal functional associations (e.g. Nervous system development genes) but 
these did not remain significant following Benjamini and Hochberg correction. The top ranked 
database network (genes with published interactions) was defined as ‘cell death and survival’ and 
contained 31 molecules. 
  Then to establish the Gene ontology profile of the 150 genes (Appendix 1), we generated a 
null distribution of GO enrichment p-values by randomly sampling 10,000 lists of 150 probesets 
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from the HGU133Plus2 chip and testing each list for Molecular Function GO using the GOstats 
package in R. The entire population of probesets on the HGU133Plus2 microarray was used as the 
background population for these tests. We observed that the profile of ontological enrichment in the 
healthy-ageing diagnostic was not different from a random sample of 150 genes from the gene-chip, 
of which >99% of those 54,000 probesets had no ability to discriminate tissue age in our training 
model. In Figure 3.8 the density curves of p-values for each one of 10,000 hyper-geometric tests 
using randomly sampled gene-sets (n=150 in size) are plotted (black), along with the density curve 
of the p-values from the 150 healthy-ageing gene set (red). 
Manual searching of PubMed and OMIM yielded some plausible connections with age-
related and disease processes (Appendix 1), but such analysis is subjective. We did note that the 
150 genes included some previously identified ‘ageing’ genes; LMNA (linked with Hutchinson-
Gilford Progeria Syndrome), Unc-13 homolog (UNC13C) which is linked with beta-amyloid 
biology, as well as COL1A1 (thought to change in skin-ageing). Finally, positional gene enrichment 
analysis (PGE) was used to identify whether the classification genes (or the classifier network 
genes) were significantly enriched within given chromosomal regions (De Preter et al. 2008) as 
previously implemented (Phillips et al. 2013). When we examined if the 150 age-related genes were 
over represented at genomic loci we found no significant associations. However, on using the top 
670 genes from the first stage of the project (>70% success in training model) there were a number 
of significant findings with 3 genes originating from the top 150. In this analysis, 11q made a 
significantly greater contribution (adjusted p-value=0.005-0.007) to the enlarged prototype 
classifier than would be expected by chance (Figure 3.8 B), and there was a total of 15 genes from 
the 11q13 and 11q23 over-represented genomic locations (11q13 (ALDH3B1, CAPN1, CDC42EP2, 
CORO1B, LTBP3, NRXN2, PPP1R14B, RCE1, RCOR2, SART1, SYT12 and ZDHHC24, P=0.0005) 
and 11q23 (FXYD2, SCN2B and TMPRSS13, P=0.0009)). Interestingly, 11q23 is the location for 
age-related genetic interactions, namely the apolipoprotein A family (Garasto et al. 2003; Feitosa et 
al. 2014) as well as a region containing genetic association single nucleotide variants (SNP) which 
modify the age of onset of colorectal cancer (Talseth-Palmer et al. 2013; Lubbe et al. 2012). 
Further, 11q13 harbours SNP’s associated with age of onset of renal cell carcinoma and prostate 
cancer and modulating age-related disease emergence by 5 years (Audenet et al. 2014; Lange et al. 
2012; Jin et al. 2012). 
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Figure 3.8. GO profile and chromosomal positional enrichment analysis for the healthy ageing RNA 
signature. Pathway analysis and GO analysis indicate that the 150 healthy ageing genes are not related to a 
few specific biological processes but rather originate from across many biological processes. A) Density 
curves of raw p values for each of the 10,000 hypergeometric tests using randomly sampled probesets from 
the U133Plus2 gene-chip (n = 150 each time; black) and the density curve of the raw p values from a 
hypergeometric test using the 150 healthy ageing gene classifier probesets (red). B) Positional gene 
enrichment analysis for found over-representation at 7q22, 11q13 and 11q23. Those for 11q13 and 11q23 in 
particular were most significant, and contained genetic variants that influence the age of onset of various 
cancers. 
3.6 Discussion 
Use of fully independent training and validation data sets allows for genuine external validation to 
be demonstrated and overcomes the over-fitting/bias caveat. The ‘healthy ageing’ signature fulfilled 
the first main criteria by providing independent and accurate tissue classification despite inter-
laboratory technical variation and different gene-chip platforms. For being a novel diagnostic of  
‘healthy’ ageing it was also important to consider whether the 150 RNAs were related to any likely 
confounding factors (e.g. life-style or metabolic disease). To test this, we profiled RNA from 
healthy members of the ULSAM cohort at age 70 years and analysed follow-up data over two 
decades. In 1992, these 70y old Swedish men had normal levels of physical activity “for their age” 
and most demonstrated longevity to 90y which is not exceptional in the Swedish population 
(Danielsson & Talbäck 2012). The healthy age score demonstrated a four-fold range (Figure 3.2 A) 
while chronological age varied by no more than one year across the group. Further the score did not 
correlate with any life-style related risk factors.  We also illustrated the ageing signature’s potential 
clinical utility in three different studies including ULSAM and two AD/MCI cohorts. In ULSAM 
greater induction of the RNA signature at baseline (~70y) was associated with improved survival 
over the ensuing 20y period and better renal function at 82y. Similarly, in AD cohorts higher gene 
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score was indicative of a better cognitive function. Both, renal function and cognition are important 
determinants of all-cause mortality (Zethelius et al. 2008; Raichlen & Alexander 2014). This 
concurrent reduction in clinically observed cognitive and renal function suggests both are subject to 
a general age-related decline in organ function (Romijn et al. 2014).  
Neurological decline is predicted to contribute substantially to the economic burden of 
healthcare in the coming decades. AD is a multi-factorial disease (Hampel et al. 2014) with around 
22 genetic loci potentially associated with disease risk or progression of symptoms. The strongest 
and most reproducible genomic association, APOE-ε4, is a modifier of risk, contributing to the age 
of onset of the disease by 3.7% (Naj et al. 2014). The remaining ~9 reproducible risk loci for late-
onset AD (the most common form) contribute a further 2.2% of the variance in age of onset (Naj et 
al. 2014). In short, these DNA sequence variants will not be clinically useful for diagnosing or 
managing AD or even assessing risk, in the majority of people. Differential gene expression 
analysis and molecular classification have found disease related RNA markers of AD, using patient 
materials to build the model (Fehlbaum-Beurdeley et al. 2012). However, unknown features of the 
training dataset can bias such diagnostics. In contrast our ‘healthy age genes’ were selected via a 
hypothesis driven strategy that then relied on a validation process that included seven independent 
tissue cohorts involving multiple RNA detection technologies (so ruling out some unknown 
technical bias). Thus our healthy age gene expression signature has the key advantage of being a 
signature built using a paradigm and samples entirely distinct from Alzheimer’s case-control 
samples. The healthy age gene score allowed us to demonstrate that patients diagnosed with AD 
have an altered healthy ageing RNA expression signature in blood that demonstrates significant 
association with disease.  
Further, the muscle or blood gene score was unrelated to life-style diseases such as Type II 
diabetes and thus may be more clinically specific than earlier AD biomarkers (Laske et al. 2014; 
Lotz et al. 2013; Ray et al. 2007; Hye et al. 2014; O’Bryant et al. 2011; Hu et al. 2012; Sattlecker et 
al. 2014; Lunnon et al. 2013), most of which have already failed to replicate in independent clinical 
studies. We were able to provide independent validation for our earlier AD related ‘disease’ 
diagnostic (Lunnon et al. 2013), however, like many AD disease biomarkers (Fehlbaum-Beurdeley 
et al. 2012), it includes pro-inflammatory markers and oxidative stress, features that can be 
common to several diseases and thus it may not be specific in clinical practice. Nevertheless, when 
we combined the Lunnon et al AD biomarker (even after removing the 8 genes we found to be 
regulated in blood by diabetes or vascular disease) with the ‘healthy age genes’ we yielded an 
improved diagnostic for AD over and above either diagnostic alone (Figure 3.6). Ultimately, formal 
diagnosis of AD will continue to rely on a combination of diagnostics including invasive CSF 
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sampling, PET imaging and MRI. However, given the scale of screening required (e.g. > 1 million 
people in 2015/16) to deliver sufficient numbers of at risk subjects for AD clinical trials 
(www.iadrp.nia.nih.gov) a blood-based diagnostic will be extremely useful for pre-screening ahead 
of invasive and costly follow-up analysis. Enrichment of prevention trials with asymptomatic 
people most at risk for AD is required to ensure that event rates are sufficiently high to evaluate the 
multitude of drug-trials being considered for AD (Laske et al. 2014). Finally, while the lack of an 
apparent specific biological dialogue may be considered disappointing, the extensive independent 
clinical results strongly support that the novel 150 gene healthy ageing ‘signature’ is an important 
marker of healthy ageing in humans. Therefore regulation of this gene expression programme may 
in time reveal itself to be an important mechanism for maintaining human health and thereby a new 
opportunity for target development.  
3.7 Summary 
Our approach to develop the healthy age RNA signature was novel because we first sought to 
define a set of genes associated with ‘healthy ageing’ in ‘normal’ 65y subjects rather than with 
disease or extreme longevity. Indeed, we were able to demonstrate that the 150 ‘healthy ageing’ 
genes are consistently modulated in several tissue types, but to very differing degrees in people of 
the same chronological age. Including the ULSAM analysis (males only), we have demonstrated in 
three independent clinical cohorts that greater ‘healthy age gene score’ associates with better health 
in men and women, suggesting that promotion of this gene expression profile may be beneficial 
and/or an adaptive compensatory response. Thus, we have identified a novel and statistically robust 
multi-tissue RNA signature of human healthy ageing that can act as a diagnostic of future health, 
using only a peripheral blood sample. This RNA signature has great potential to assist research 
aimed at finding treatments for and/or management of AD and other ageing-related conditions. In 
the next chapters we will be exploring tissue ageing specifically with respect to neuro-muscular and 
vascular ageing by using our healthy ageing signature and other external models for ageing/age 
associated diseases in literature and inferring how and where they might be useful. 
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4.1 Overview of the chapter 
Approaches such as genome-wide association methods, linear models of epigenetic regulation and 
differential gene expression (transcriptomics) have identified genomic associations with ageing and 
exceptional longevity and have attempted to explain factors driving age-associated disease risk.  As 
discussed in the previous chapters, using transcriptomics and machine-learning methods we have 
developed a robust diagnostic tool that successfully discriminates between healthy young and older 
humans and effectively predicts clinical outcomes.  In this chapter, we present the first comparative 
analysis of some of the existing signatures of human ageing and longevity. We first established a 
representative RNA signature for each genomic signature and then evaluated the ability of these 
RNA signatures to classify neuro-muscular tissue age. We also examined how these multiple 
signatures relate to tissue ageing and health, clinical outcomes and each other. Together these 
assorted genomic signatures account for ~2% of the genes available on the gene-chip technology 
we used. We examined if ‘random sampling’ of the remaining ~98% of genes on the gene-chip 
could create any n=150 gene-set could replicate or exceed the performance of our RNA signature in 
age classification (Sood et al 2015). Thus, the principle goals of this chapter are: 
• To establish if existing DNA, DNAm and/or non-muscle RNA ‘age’ signatures could be 
converted to a ‘gene expression signature’ that works as a binary classifier of healthy old 
versus healthy young human muscle and human brain tissue. 
• To examine if these RNA versions of other ‘age’ signatures relate to cognitive health or age-
correlated life-style diseases (diabetes and coronary artery disease). 
• To examine whether there was any common biological context across different ‘age’ 
signatures. 
• To investigate a random sampling approach to benchmark our ageing signature. 
4.2 Different genomic signatures for ageing and longevity 
We have generated a robust binary RNA diagnostic (150 genes) of healthy older human muscle 
tissue using transcriptomics and machine-learning methods in independent studies (chapter-2 and 
3). Different studies have attempted to identify molecular associations with ageing/longevity, age-
associated disease or survival by following different approaches. Healthy ageing per se has not yet 
been investigated. After generating and validating our RNA signature we set out to establish if the 
existing DNA, DNAm and/or non-muscle RNA ‘age’ signatures could be converted to a ‘gene 
expression signature’ that worked as a binary classifier for neuro-muscular age and Alzheimer’s 
disease. Further, we were also interested in exploring a random sampling approach to examine the 
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robustness of our healthy ageing signature not only to establish the effectiveness of our machine 
learning approach but also to demonstrate that the performance of our particular set of 150 
probesets was better than that of randomly sampled sets of 150 probesets from the same platform.  
In Table 4.1 we summarize the methods used to identify the different ageing and longevity 
signatures used in our comparison study. 
Sood binary muscle Age RNA 
(Sood et al. 2015) 
Muscle from healthy but sedentary 65y+ subjects was 
used to discover potential markers of healthy ageing 
Peters linear blood Age RNA 
(Peters et al. 2015) 
Blood expression and linear modelling used to  
determine a correlative profile of ageing in human 
blood 
Wennmalm senescence RNA 
(Wennmalm et al. 2005) 
Regression based meta analysis across several 
platforms to discover consistent in vitro senescence 
genes 
Levine DNA SNP smoking-
survival (Levine & Crimmins 2016) 
Genome wide association study (GWAS) and 
network analysis used to discover DNA markers 
enriched in long-lived smokers (n=90) 
Perl DNA SNP Longevity 
(Sebastiani et al. 2012) 
Genome-wide association analysis linked with 
exceptional longevity 
Hannum DNAmethylation 
(Hannum et al. 2013) 
CpG sites correlated with age (penalized multivariate 
regression method) 
Horvath DNAmethylation 
(Horvath 2013) 
Quasilinear regression model using CpG sites across 
multiple human tissues and disease samples 
  
Table 4.1: Ageing and longevity signatures. Different Methods such as regression models and GWAS were 
used to identify the different ageing/longevity genomic signature. 
4.2.1 Producing representative RNA signature 
A representative RNA signature for each ageing signature required the genomic features of the 
signature first to be mapped to equivalent gene symbols and then to the corresponding Affymetrix 
probeset ID. We used the BioMart tool and the Ensembl database to achieve the mapping. For all of 
the six ageing signatures used in this study (Table 4.1) the gene lists were provided by the authors 
in their respective publications. The authors of the smoking resistance DNA signature (Levine & 
Crimmins 2016) used PLINK, a whole genome analysis tool to map SNPs that fell within the 
designated GRCh37/hg19 coordinates of the gene instead of assigning upstream or downstream 
SNPs to a gene. Similarly, for the Horvath DNAm signature (Horvath 2013) the CpG sites located 
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in the promoter of a gene were assigned the corresponding gene symbol. Table 4.2 shows the 
number of genomic features in each individual signature and corresponding number of genes they 
mapped to respectively. 
Existing genomic ‘age’ signature No of Genes 
Sood muscle Age RNA (150ps) 150 
Peters blood Age RNA  (1497 genes) 1497 
Larsson cell senescence RNA  (309 Genes) 309 
Levine SNP-smoking (215 SNPs) 215 
Perl Longevity DNA (281 SNPs) 130 
Hannum DNAm (71 CpG sites) 83 
Horvath DNAm (353 CpG sites) 353 
 
Table 4.2: Mapping of genomic features identified in ageing studies to gene symbols. Each of the different 
ageing and longevity signatures consisted of different genomic features which were transformed to a 
representative RNA signature for a comparative analysis. 
4.2.2 Overlap with the healthy ageing signature 
After mapping genomic features to gene symbols we noted that the overlap in gene symbols 
between the different studies was very low. We also checked the overlap of the different ageing 
signatures with our RNA signature (both n=150 and the n=670 probeset lists with success rate 
>70%) in particular and tested if the overlap was significant or not based on Fisher’s exact test. The 
only statistically significant results were for the study of DNA markers enriched in long-lived 
smokers (Levine & Crimmins 2016) and the correlative RNA signature profile of ageing in human 
blood (Peters et al. 2015). These had had overlaps of 11 and 48 genes respectively with our 670 
probeset list (p-value<0.05).  
4.3 Random sampling 
Our original study took a hypothesis driven approach to study a physiological phenomenon, namely 
healthy muscle ageing and selected a single high performing gene-set to represent the hypothesis to 
be tested in thousands of independent samples. A consistent reliable signature had never been 
achieved before for healthy ageing. Recently a pre-print study based on our microarray data that 
stated that our healthy-ageing marker genes can be replaced by essentially any random set of 150 
genes, with essentially equivalent performance (Jacob et al - 
http://biorxiv.org/content/biorxiv/early/2016/04/05/047050.full.pdf). However, the ‘random 
sampling’ strategy used had the major caveat in that it did not address our primary aim of finding a 
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single gene-set that works across all data-sets. Instead Jacob et al generated a separate gene-set each 
time and hence demonstrated low reliability. Further the idea that one can select a ‘random’ gene-
set is,  from a biological perspective, flawed as there are many genes regulated with human ageing 
(Sood et al. 2015; Peters et al. 2015; De Magalhães et al. 2009; Wennmalm et al. 2005) and none of 
these age-correlated gene-sets are random in a true sense. For a genuine test of a random sampling 
approach such age correlated genes should be excluded from the sampling. This was not done by 
Jacob et al.  
To truly demonstrate the performance of random gene-sets as tissue age classifiers we first 
removed the genes we had originally identified with classification ability in ageing (n=670) (Sood 
et al. 2015) from the starting pool of genes to be sampled. We then evaluated the ability to classify, 
with statistical significance (Fisher’s exact test), age or disease in 10,000 ‘random gene-sets’ of 
n=150 genes in multiple tissues. Importantly, unlike the Jacob et al we used the same set of 10,000 
different n=150 gene-set lists across all tissues examined. Classification performance was assessed 
using accepted methods (Speed 2003) with external validation and LOOCV so that each gene-set is 
judged in an independent data set (see section 4.5). In order to compare the performance of the 
random gene-sets across each muscle dataset we ranked the area under the curve (AUC) values 
generated from receiver-operator characteristic (ROC) curves of the random gene-sets along with 
AUC of our gene-set and six other literature derived ageing signatures (Table 4.1). We then 
calculated the cumulative median rank for each of the 10,000 random gene-sets and each of the age 
signature gene-sets (Figure 4.1). The performance of our published 150 probeset (red dot) exceeded 
the performance of all 10,000 random selections of 150 probesets (boxplot; median and quartiles) 
and previously published ageing/longevity signatures as shown (various coloured dots in Figure 
4.1).  
We then selected the top 764 performing (AUC >0.8) random gene-sets and inspected the 
genes in each of these.  From the redundant pool of ~114,600 genes we found only a subset of 131 
genes that occurred in more than one percent of the gene-sets. We created a new gene-set from 
these frequently appearing genes and tested classifier performance in muscle and brain age (Figure 
2) and in the Alzheimer cohorts(Lovestone et al. 2009; Sood et al. 2015) . We also repeated the 
same analysis by using the random n=150 genes list that had a median rank order of ~5000 
(AUC=0.73). These two random sets of n=131 genes and n=150 genes respectively were then 
compared to our RNA signature and other ageing gene-sets.  
4.4 Neuro-muscular tissue age classification 
We evaluated the ability of the different ageing signatures and each of the 10,000 probeset lists to 
distinguish neuro-muscular tissue age (young vs old) using fully independent external validation a  
Chapter-4                                                                                      Comparative analysis of different ageing signatures	
	 68	
 
Figure 4.1. The rank order for area under curve for ROC analysis on 10,000 ‘random’ samples of 150 
probesets. Following removal of our previously identified ‘healthy age’ genes (with AUC >0.7, 670 genes) 
we produced 10,000 random sets of n=150 probesets from the gene-chip (‘Stockholm’ healthy age samples). 
We assessed each set of 150 probesets for its ability to classify muscle tissue age, using gold-standard 
external validation methods and 5 independent gene-chip studies (5 nearest neighbor KNN classifier as 
implemented by Speed and Jacob). We compared the performance of these 10,000 probesets with our 
published 150 probeset and 6 additional published ‘ageing’ related gene-sets. The performance of our 
published 150 probeset (red dot) exceeded the performance of all 10,000 random selections of 150 probesets 
(boxplot; median and quartiles). Each previously published ageing/longevity is shown by a different colored 
dot. The median AUC from random sampling was 0.73 
	
process that requires both independent ‘known samples’ to define the expression space and 
independent test gene-chips (Shao et al. 2013). We used Frozen Robust Multi-array Analysis 
(fRMA) (McCall et al. 2010) for normalization and CoMBAT for batch adjustment (Johnson et al. 
2007) to account for technical variance due to different laboratories and operators. Then, kNN was 
used on 4 independent muscle data-sets (the 5th was the CAMPBELL dataset for external 
validation) and on four distinct human brain regions (120 samples) from brain-bank array source 
(Berchtold et al. 2008). We tested for statistical significance in classifier performance using 
Rank order of age/longevity signatures in muscle age classification 
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Fisher’s exact test. The resulting p values were then corrected for multiple testing using Benjamini-
Hochberg correction method(Yoav Benjamini 1995).	
The AUC for classification of muscle by these different signatures (row-wise Figure 4.2) 
was 0.92, 0.83, 0.76, 0.69, 0.85, 0.73, 0.76, 0.91 and 0.67 respectively. For brain the AUC were 
0.67,0.79,0.61,0.64,0.69,0.59,0.75,0.6 and 0.58 respectively. The absolute log10 of the adjusted p-
values are shown in the form of a heat map (Figure 4.2). Muscle tissue age was successfully 
determined with RNA signatures selected from various genomic signatures. However, in the case of 
brain tissue only our healthy ageing RNA signature, Peters RNA blood signature and Horvath 
DNAm signature performed with statistical significance (p<0.05). One of the interesting 
observation from our analysis was that relation between AUC and p-value was not necessarily 1:1 
that is a higher AUC didn’t correspond to a lower p value and vice versa. A possible explanation for 
this could be uneven class distribution (more samples in young and less samples in old or 
conversely) which could have impacted the AUC values (Daskalaki et al. 2006).  
We also studied the different gene lists ability to classify tissue age across 3 brain regions, 
hippocampus, putamen and cerebellar cortex with healthy samples from BrainEac.org gene-chip 
resource study (Ramasamy et al. 2014).  The hippocampus and putamen are both associated with 
neurodegeneration whereas cerebellar cortex is not subject to substantial age-related anatomical 
changes and thus serves as a control in this analysis (Ramasamy et al. 2014; Horvath et al. 2015). 
Using the cumulative gene score ranking approach (explained in the section 4.6) each brain region 
from each of the 134 subjects were individually ranked and the median sum of the ranked scores 
was calculated. The Wilcoxon rank sum test was used to evaluate if the expression of the different 
gene lists differed across the brain regions with age.  As already mentioned in chapter 3, across the 
3 human brain regions the RNA signature derived from healthy old muscle (Sood et al. 2015) was 
highly regulated in regions associated with neurodegeneration (hippocampus and putamen, 
Appendix 2 Figure A4.1A). The Peters blood RNA signature also tracked human brain age, albeit 
to much lesser extent (Appendix 2 Figure A4.1B). Consistent with multiple published observations 
(Ramasamy et al. 2014; Horvath et al. 2015), human cerebellar cortex did not appear to be subject 
to substantial age-related changes (Appendix 2 Figure A4.1). 
4.5 Testing prognostic abilities of signatures in clinical studies 
For clinical case-control analysis, each RNA signature was converted to a cumulative gene-ranking 
score based on individual RNA expression in the muscle classification dataset i.e. if the gene was  
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Figure 4.2: Heatmap representation of p-values for the application of each gene-set in multiple tissues 
and clinical disease samples (as per Sood et al 2015). Each row of the heat map is one gene-set 
representing one RNA signature. Columns represent the human muscle, brain, brain regions and clinical 
data-sets. The statistical analysis from Sood et al 2015 is contrasted with the adjusted p-values for the 8 
additional gene-sets (absolute log10). Grey to dark grey is non-significant, near-white being marginally 
significant (p=0.05) with red towards blue representing an increasing order of significance. Interestingly, 
when the overlapping age genes (~48) from peters signature (section 4.2.2) were excluded  it was no longer 
able to classify human brain age (second column and second row in the figure). 
	
down regulated in human muscle, from 25y to 65y, the sample with the highest expression was 
assigned a rank score of 1 and the subject with the lowest expression value was assigned the highest 
rank value. For genes up-regulated with age, the opposite ranking strategy was used. The median 
sum of these rank scores was calculated for each clinical sample (each gene provided equal 
weighting) (Sood et al. 2015). For the case-control analysis, feature selection (genes) was therefore 
independent of the clinical studies, while the direction of regulation reflected regulation of that gene 
in healthy old muscle versus healthy young muscle. To test if the cumulative gene score differed 
significantly between case and control we used Wilcoxon rank sum test. 
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Figure 2: Heatmap presentation of p-values for the application of each gene-set in multiple tissues and clinical disease
samples (as per Sood et al 2015). Each row of the heat map is one gene-set representing one RNA signature. Columns
represent the human muscle, brain, brain regions and clinical data-sets. The statistical analysis from Sood et al 2015 is
contrasted with the adjusted p-values for the 8 additional gene-sets (absolute log10). Grey to dark grey is non-significant, near-
white being marginally significant (p=0.05) with red towards blue representing an increasing order of significance. The area
under the curve for muscle classification fo these differ nt signatures (row-wise) was 0.92, 0.83, 0.76, 0.69, 0.85, 0.73, 0.76,
0.91 and 0.67 respectively. Classification of Alzheimer’s samples vs age and gender match controls was carried out as
described by Sood et al. Briefly, two cohorts of independently produced Illumina gene-chips (and different gene-chip
generations) w re analyzed by matching the 150 gene-set to the available mark rs on the Illumina gene-chips and running
classification using LOOCV in each data-set. The average p-value for these two analysis is reproduced from Sood et al and
contracted with the adjusted p values for the additional 8 gene-sets.
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As previously discussed, consistent with the substantial modulation of our RNA signature in 
human hippocampus (p=0.00005, Appendix 2 Figure A4.1A), expression of these RNA could also 
uniquely distinguish between Alzheimer’s disease cases and controls. None of the other RNA 
representative signatures including Peters RNA signature (modulated in hippocampus to some 
extent) could predict cognitive health status in either of two independent Alzheimer cohorts (Figure 
4.2) (Lovestone et al. 2009). We also used the clinical studies on blood RNA in type II diabetes 
(Tabassum et al. 2014) and blood RNA in people with and without coronary artery disease (CAD) 
(Sinnaeve et al. 2009) to test if any of the age related RNA signatures could capture some aspect of 
these age related diseases.  None of the signatures could distinguish diabetics from controls. Two 
RNA signatures (Cell senescence (Wennmalm et al. 2005)  & blood age (Peters et al. 2015)) and 
one DNA SNP (survival in smokers (Levine & Crimmins 2016)) derived RNA signature were 
diagnostic for coronary artery disease (CAD) versus control (n=222, adjusted p<0.05, Figure 4.2 
and Figure 4.3).  
 
 
Figure 4.3 Vascular disease plot. RNA rank-score in blood samples from a case-control study of middle-
aged coronary vascular disease (112 controls and 110 cases, group age=53.3y, Affymetrix HG-U133A) was 
studied in the different ageing/longevity signatures. A Wilcoxon rank-sum test tested if cumulative gene 
ranking score for controls was significantly different from patients (CAD). Peters RNA signature included 
48 of our 150 age signature genes, removing which didn’t alter its ability  to distingusih CAD from controls. 
	
Smoking is a major risk-factor for CAD and the Levine et al SNP results appear to translate 
to an RNA signature (survival to 85y despite smoking), while cellular senescence has been shown 
to play a role in vascular disease (Levine & Crimmins 2016; Wennmalm et al. 2005). The Peters 
RNA signature (Peters et al. 2015) was derived using samples with cardiovascular disease (e.g. 
hypertension) rather than age per se (Figure 4.2) and thus it comes as no surprise that it could 
discriminate CAD from controls. In all three signatures CAD had a higher gene score implying that 
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genes most regulated with age are more regulated in CAD then controls which could indicate 
response to damage. We lastly investigated if the three signatures were enriched for common 
biological process and/or molecular function gene ontologies. No overlapping ontologies were 
found across these three gene-lists.  
4.6 Discussion 
Population ageing and the shift from infectious to chronic diseases as major causes of death have 
together created an urgent need for the discovery of ageing and age related biomarkers/signatures. 
Targeting ageing is theoretically better than treating individual chronic diseases, however up to this 
point, translational routes to accomplish this objective have been purely speculative (Kaeberlein et 
al. 2015). While this subject has received considerable recent attention, there are numerous 
challenges to both the development and the implementation of diagnostics for ageing (Goldberger 
& Buxton 2013), including economic considerations.  
Given the fact that the choice of method and cohorts used for developing biomarkers has a 
great influence on the subsequent statistical analysis and biological answer, the quality and 
credibility of these methods need to be assessed fairly. There are multiple competing technological 
platforms that yield plentiful data adding to the challenge for scientists to find a way to integrate 
information across different studies. So far progress in integrating different data formats to yield 
robust and sensitive diagnostics for clinical decision making remains slow (Goldberger & Buxton 
2013). To this end, our comparison study in this chapter deals with seven representative RNA 
signatures (including our healthy ageing RNA signature) compared on healthy neuro-muscular 
ageing datasets and on clinical datasets representing various age related morbidities.  
The utility of DNA sequence variation to guide treatment of cardiovascular disease or 
neurodegeneration is just being explored (Sawhney et al. 2012). However, this approach is severely 
limited by the total contribution that DNA variants make to the heterogeneity of these types of 
diseases. A study of exceptional longevity using Genome-wide association analysis linked 281 
DNA variants with exceptional longevity (Sebastiani et al. 2012) and collectively explained only 
17% of the variance in humans with an average AUC value of 0.65.  However, long-lived humans 
appear to have a similar genetic burden for common DNA disease variants, suggesting the human 
exceptional longevity model may not be reflective of the processes that determine average 
longevity (Gierman et al. 2014).  
In their work on the transcriptional profile of ageing in peripheral blood, Peters et al found 
1497 genes to be associated with age. From this they identified only 163 genes (~11%) in cerebellar 
cortex to be significantly associated (p<0.05) with age in same direction as in whole blood.  This  
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not only highlights the caveat of correlative models being highly tissue specific but is also primarily 
at odds with studies of the human cerebellar cortex (Horvath et al. 2015; Sood et al. 2015) as this 
brain region typically does not show a genomic signature of ageing nor demonstrate typical 
morphological changes with age (Ramasamy et al. 2014). This suggest that the Peters signature is 
not age, or not only age, but may reflect a number of other biological phenomena. For example, the 
Peters et al gene set is strongly correlated with hypertension but not with neuromuscular measures 
of ageing like MMSE scores (muscle function or cognitive status). A number of other published 
datasets seem to have this characteristic. Gene-sets like Peters et al are generated from 
epidemiological cohorts, validated in a single tissue type, and this type of linear covariate analysis 
can introduce statistical artefacts and requires validation in multiple cohorts. We produced a robust 
multi-tissue binary age classifier, using a single machine learning model (Chapter 2). Nonetheless it 
is always plausible that a number of other genes, in combination, could classify muscle age and 
indeed using literature ‘age’ signatures we have shown that other combinations were significant 
classifiers of muscle age (first column in Figure 4.2). Thus we demonstrate that human muscle 
tissue age can be determined with RNA signatures selected from diverse genomic signatures (e.g. 
derived from DNA sequence or methylation).   As observed in the comparative analysis, only the 
Peters and Horvath gene-sets were able to classify both human muscle and brain but performance of 
these RNA signatures was modest.  In clinical analysis, the RNA signature derived from genes 
selected to provide protection from environmental stress (survival to 85y despite smoking) was 
diagnostic for coronary artery disease (CAD) versus control (n=215, adjusted p<0.05) (Ambrose & 
Barua 2004). Cellular senescence has been shown to play a role in vascular ageing (Erusalimsky & 
Kurz 2005; Fyhrquist et al. 2013) and the senescence RNA signature could also distinguish between 
CAD versus control (n=309, adjusted p<0.05). Similarly, the Peters RNA signature derived in 
blood could distinguish between CAD versus control (number of genes=1497, adjusted p=0.03). In 
this case the cohorts used in the study contained older participants with age-associated diseases and 
thus the ability to classify CAD was not surprising.  
Activation of different ageing signatures was studied in blood samples from two 
independent large case-control studies of Alzheimer’s disease. Except for our RNA signature none 
demonstrated significant results for cognitive health status. This could be explained by increased 
regulation of the healthy age gene score with chronological age in the hippocampus (p=0.00005), as 
well as putamen (p=0.000005) both regions associated with neurodegeneration (Laakso et al. 2000; 
Erickson et al. 2011; Taupin 2006; Sekar et al. 2014; Lunnon et al. 2013). Additionally, we noticed 
that a small subset of genes could drive the overall performance of the literature gene-sets. For 
example, the large Peters et al gene-set (n=1497) has 48 genes in common with our healthy ageing 
signature and when our 48 genes were removed, the remaining Peters et al gene-set was no longer 
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able to classify human brain age (p-value =0.08), but its relationship to CAD remained unchanged. 
This implies that the ability of the age signature of Peters et al to classify brain age is driven to 
some extent by the 48 overlapping genes from our RNA signature.  
4.7 Summary 
This chapter provides an important perspective on both the utility and limitations of different 
genomic signatures of ageing when transformed to equivalent RNA (gene expression) signatures. In 
this analysis we observed that our muscle derived gene-set was the only one related to hippocampus 
ageing and cognitive health while ‘stress’ resistant and ‘epidemiologically’ selected linear models 
related with vascular disease (CAD) Analysis of the global transcriptome (RNA), using machine 
learning methods, has produced sensitive tools for cancer diagnosis and prognosis in the past (Abd 
El-Rehim et al. 2005; Shedden et al. 2008; Patnaik et al. 2010; Menden et al. 2013). Further, it has 
been possible to select features from a tumour global RNA profile that predicts drug sensitivity 
(Knudsen et al. 2014). Given the superior technical reproducibility and throughput of the 
Affymetrix gene-expression platform over DNA-methylation assays, the study shows that RNA 
signatures may represent an ideal approach for optimizing ‘age’ diagnostics as well. Also, in this 
analysis we have shown that a hypothesis driven approach based on machine learning methods is 
more reliable than the random sampling approach detailed by Jacob et al. The latter approach fails 
to produce a single gene-set capable of acting as a multi-tissue classifier of age and with 
discriminatory power in Alzheimer’s disease. We originally identified one gene-set that works in all 
our data-sets, and in this chapter showed that after excluding our gene-set, 10,000 random samples 
cannot replicate the exceptional performance of our ‘healthy ageing gene-set. This highlights the 
limitations of ‘big data’ analysis strategies when applied in the absence of clinical or biological 
insight. 
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5.1 Overview of the chapter 
One of the earliest signs of vascular ageing is arterial stiffness, a process that is thought to be 
accelerated by arterial hypertension, resulting in an increased risk of cardiovascular morbidity and 
mortality. Arterial stiffness can be categorized by estimating vessel compliance, and decreased 
arterial compliance is one of the earliest indications of adverse structural and functional changes 
within the vessel wall. It is defined in the clinic by a parameter called pulse wave velocity (PWV), a 
measurement that is influenced by the end-user (technician) and the technology being used. In this 
chapter we investigate the possibility of developing a model for vascular ageing using gene 
expression data and clinical parameters (as dependent variables) known to co-vary with PWV 
measurements such as blood pressure and chronological age. Through this analysis we show the 
importance of understanding the difference between statistical and quantitative significance in 
diagnostics or biomarker development. Thus, the principle goals of this chapter are: 
•  To identify number of genes across the pre-existing skin tissue expression data, whose 
baseline expression correlate with PWV in vivo and transform them to a feature score 
metric. 
• To evaluate a regression model of the resulting feature score combined with BP and/or age. 
• To test the robustness of the model in validation datasets by comparing the predicted 
clinical response (PWV) with the actual observed PWV measure. 
• Lastly, to test if our healthy neuro-muscular age signature of 150 genes (derived from a non-
linear, binary approach) could be converted to a linear regression model for vascular 
stiffness (which we expected to be negative). 
5.2 Over-view of vascular ageing and arterial stiffness 
Ageing being an inevitable part of life significantly affects the heart and arterial system and is 
accompanied by decline in various physiological capacities – such as vasodilation and aerobic 
fitness. Vascular ageing is associated with changes in the structural and mechanical properties of 
the vascular wall that leads to the loss of arterial elasticity and impaired endothelial function (North 
& Sinclair 2012; Laurent 2012). Breakdown of elastic components mainly elastin and collagen in 
the aortic wall, results in its parallel stiffening and dilation (Jani & Rajkumar 2006). Thus, vascular 
changes contribute to the age dependent risk in developing vessel disease (e.g. tissue remodeling 
and atherosclerosis). In addition to non-modifiable risk factors such as chronological age and 
gender, there are other important life-style influenced risk factors such as hypertension and diabetes 
mellitus that also accelerates arterial stiffening increasing vulnerability for developing cardio 
vascular disease (Benetos et al. 2002). 
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Arterial stiffness has independent prognostic value for coronary and cardiovascular 
morbidity and mortality (Zieman et al. 2005; Nilsson et al. 2009). It  can be measured by different 
non-invasive parameters like pulse wave velocity (PWV), augmentation index, pulse contour 
analysis etc. (Kelly et al. 1989). PWV measures the velocity of the propagation of the forward and 
backward pressure waves between two points of the artery and it is a reproducible and technically 
demanding parameter for estimating blood vessel function (Yamashina et al. 2002; Hansen et al. 
2006; Laurent 2012), which is often considered as a clinical gold standard of measuring arterial 
stiffness. PWV varies greatly by blood pressure and is thus often adjusted for this variable 
(Ruitenbeek et al. 2008; Reference Values for Arterial Stiffness’ Collaboration 2010) while our 
model was adjusted for chronological age as well to establish if there was also an underlying RNA 
signature that could contribute to accurately estimating vascular ‘health’. 
In terms of genomic knowledge of vascular age, methods such as whole genome sequencing 
and genome wide association studies (GWAS) have identified different genes and chromosomal 
regions potentially involved in arterial stiffness (Medley et al. 2002; Turner et al. 2006). SNP 
association studies have recognized various population specific variant that relate to age related 
vasculature stiffness (Lajemi et al. 2001; Ye 2006). While this is a progressive step forward, it is 
important to note that arterial stiffness is a polygenic condition that occurs due to the sum of 
multiple polymorphisms, with each variant having a relatively small effect (<5%) on the phenotype 
(Lacolley et al. 2009). Moreover, GWAS studies often lack the knowledge about which gene a 
SNP/variant impacts on, as it could be a gene far removed from the SNP location. This gets more 
complicated in polygenic conditions like arterial stiffness where each SNP could potentially be 
associated with more than one gene and modelling such data is still considerable very challenging. 
Therefore, rather than individual gene variants it will be more interesting to inspect whether 
vascular ageing phenotype may relate more closely to gene expression. In the past transcriptomic 
signatures based on differential gene expression have been studied as biomarker of arterial stiffness 
in humans and have indicated that quantitative differences in gene expression have the potential to 
define a person’s phenotype (Durier et al. 2003; Heidecker et al. 2008). Thus, combining gene 
expression together with machine learning methods and clinical covariates we could yield a more 
promising approach that could also disclose the link between transcriptional regulation and vascular 
ageing.  
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5.3 Methods 
5.3.1 Dataset and participants 
Gene expression data from SKIN tissue from female Caucasian twins (~340 samples) from the 
Twins UK cohort was available on arrayExpress (Illumina Human HT-12 V3, E-TABM-1140), a 
cohort with characteristics similar to the general U.K. population (Andrew et al. 2001). The 
baseline age ranged from 39 to 85 years with a mean age of 59 years. All women underwent 
assessment of arterial stiffness by measurement of carotid-femoral pulse wave velocity (cfPWV). 
Gene expression levels were measured using Illumina Human HT-12 V3 BeadChip from skin 
tissue. From these 340 participants with gene expression data, 84 women had repeated vascular 
measures at a 4.3 ± 1.4 year follow-up.  
5.3.2 Mean Arterial Blood pressure and PWV Measurements 
Vascular measurements were performed in a temperature-controlled vascular laboratory (~ 24ºC). 
Brachial blood pressure was measured using a validated oscillometric device (Omron 705CP, 
Omron, Tokyo, Japan) after subjects had been supine for at least 10 minutes. SphygmoCor system 
(Atcor Medical, Sydney, Australia) was used to measure cfPWV by sequentially recording the 
carotid and femoral artery pulse by applanation tonometry (Nelson et al. 2010) with a high-fidelity 
transducer (Miller Instruments, Houston, Texas). Difference in time of pulse arrival from the R-
wave of the electrocardiogram between the two sites was taken as the transit and difference in 
distance was estimated from the distance between the sternal notch and femoral artery at the point 
of applanation (Cecelja et al. 2009). Measurements were made in triplicate and mean values were 
used for analysis.  
5.3.3 RNA extraction and expression profiling 
For expression analysis, punch biopsies (8mm) were taken from relatively photo-protected infra-
umbilical skin. RNA was extracted from homogenized tissue samples using Trizol Reagent 
(Invitrogen) according to manufacturer’s protocol. RNA quality was assessed with the Agilent 2100 
BioAnalyzer (Agilent technologies) and the concentrations were determined using NanoDrop ND-
1000 (NanoDrop Technologies) and samples were stored in -80°C until ready to use. Expression 
profiling was performed using the Illumina Human HT – 12 V3 BeadChips (Illumina Inc) where 
200 ng of total RNA was processed according to the protocol supplied by Illumina. For quality 
control, expression profiling was repeated two to three times on different beadchips.	The expression 
data were first transformed using variance stabilization and then quantile normalized using the 
LUMI package in R as it is neither too strict nor too negligent while normalizing the data (Du et al. 
2008; Ritchie et al. 2011). 
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Figure 5.1 Workflow for developing a linear signature of vascular ageing using machine learning 
methodology.  We developed a pipeline for selecting the features from the transcriptomic data that linearly 
correlates with the clinical endpoint, PWV in this case. The workflow gives user the flexibility to subset the 
features based on different criterions (orange boxes shows the different options). 
5.3.4 Machine learning approach for predictor development 
The aim of this analysis was to build a linear regression model that incorporates gene expression 
data along with clinical covariates such as age and blood pressure (variables that have been reported 
to relate to vascular health) to determine the PWV measure for a subject which in turn could 
provide insight into a subject’s vasculature health or age. In order to determine the set of genomic 
features for this vascular age model, we developed a pipeline (Figure 5.1) that gives a list of 
features that correlates with the clinical endpoint (PWV in this case) but is able to select the 
features based on a variety of selection criteria when applied to a second data-set. When we 
explored the development of this prototype method, we considered both the direction of association 
with the clinical phenotype and the slope 
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5.3.4.1 Data pre-processing for linear classifier pipeline 
To begin with we split the dataset into three groups, two splits/subsets were used as training 
datasets in the pipeline and one subset was used for validation (not part of the pipeline). For the 
training datasets, split 1 (~141 samples) was used for ‘feature selection’ and split 2 (~116 samples) 
was used for ‘model selection’ i.e., to combine the selected genomic features into a model that 
correlates with PWV. We ensured that distribution of the clinical variables is similar between the 
splits by plotting their distributions. While blind validation is far more robust, we did not have a 
validation set generated in a different laboratory and so relied on splitting the cohort with the third 
group being used for the statistical validation step.  
We processed the RNA expression data using a standard deviation filter to remove probes 
from the study that had both a low and invariant expression signal. To select a suitable SD filter 
value, we plotted the distribution of SD values and the peak SD in the distribution was chosen as 
the threshold for detection (in this case features with SD >8 intensity values were considered as 
detected). For the detected features (~25,107 probes) expression measurements from LUMI were 
logit normalized i.e. log transformed and scaled to mean zero and SD 1 (Chen et al. 2012; Knudsen 
et al. 2014). The expression values ranged over several orders of magnitude and transformation 
ensured that when we got to the model selection phase each gene would be equally weighted when 
considering arithmetic combinations. Further, since PWV intrinsically varies with chronological 
age and mean arterial pressure (Figure 5.2), we adjusted the transformed gene expression data, by 
the residuals extracted from the linear model fitted through the response variable (PWV) as a 
function of these two clinical covariates (age and Mean arterial pressure). These steps correspond to 
the first main block (in yellow) of Figure 5.1. 
5.3.4.2 Selection of features using feature selection dataset 
To calculate the ‘final’ correlation between PWV and RNA expression for a given probe, in the 
‘feature selection’ phase, one sample was left out of the calculation and Pearson correlation was 
calculated along with p-values, adjusted p-values and slope of the best fit line, and the median 
values for these parameters were retained. Features were taken forward if they had a median 
adjusted p-value <0.05 (option 1 in Figure 5.1) and these were ranked by the median correlation 
coefficient (CC) values. Next, from this rank ordered list the number of features to be carried 
forward downstream into the model selection run were selected (option 2 in Figure 5.1). The 
number of features selected for this prototype was arbitrary, however we tended to select a larger 
than optimal list as we wished to attempt to get a robust gene ontology profile to help interpret the 
underlying biology.  
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Figure 5.2 Relation of PWV with covariates. Pulse wave velocity, the measure of arterial stiffness is known 
to intrinsically vary with chronological age and mean arterial pressure which holds true in our data as well. 
5.3.4.3 Selecting gene sets using model selection dataset 
From the feature selection dataset, we obtained a number of interesting genes that may or may not 
combine together to produce a statistically significant linear model. Thus, the gene list obtained was 
not the end point of the analysis but the beginning of a multi-step process that includes arbitrary 
decisions according to the the pipeline shown in Figure 5.1.  Our aim was to search for genes which 
when combined together could potentially work as predictor of vascular age and inform us about 
the underlying biology. The ‘model selection’ dataset is used in a two-step selection process, where 
the first step, is an assessment of all statistically significant individual features (selected from the 
feature selection step) and all samples in model selection dataset. The impact of sequentially adding 
(i.e. 1,1+2,1+2+3, …, 1+2+…+ n) each feature at a time is calculated and the model plotted (Figure 
5.3A).  
In order to combine features together to form a model we use features scores where are 
determined by collapsing the expression values of the chosen genes into a single metric for each 
sample. Two different ways of estimating the feature score were investigated. Either as sum of the 
logit RNA expression or it could be computed as mean of logit expression values of positively 
correlated features minus the mean of logit expression values of negatively correlated features. A 
linear model of a resulting feature score versus the clinical phenotype (PWV) is created. In the 
second selection step the recorded effect (e.g. Figure 5.3B) of each feature being added to this 
model is used to decide which individual features combine together to generate the best model (in 
this case based on the final correlation coefficient). The potential effect of each feature on the 
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model are list in Table 5.1 which summarizes selection criterions used. In the pipeline this 
corresponds to option 3 of Figure 5.1. 
                                         Description 
Nosubset no refined subset selected 
Poscor selects features that are positively correlated with the clinical variable in 
the ‘feature-selection’ dataset. 
Negcor selects features are negatively correlated with the clinical variable in the 
‘feature-selection’ dataset 
UpPlus selects features that increase the correlation in an already positively 
correlated model 
Up selects features that drive either a positively or negatively correlated 
model in a positive direction. 
DownMinus selects features that drive a negative model correlation towards more 
negative values. 
Down selects features that drive either a positively or negatively correlated 
model in a negative direction. 
 
UpPlus|DownMinus 
selects features that drive the model in a negative direction if the model is 
already negative or in a positive direction if the model is already positive. 
Unlike the Up or Down options the direction and the strength of the 
association are considered. 
 
Table 5.1:  The different selection criterions for the ‘model selection’ dataset that takes into account the 
effect each feature has on the model. 
5.3.5 Final regression model for vascular ageing and validation 
The present linear classifier approach allowed us to explore the transcriptomic search space to find 
a set of features (genes) that together correlate with vascular age/stiffness. Once we have the 
knowledge about features relating with PWV, we built a final multiple regression model which was 
then used to establish if we could predict PWV values from gene expression (with or without 
covariates like chronological and blood pressure). The lm function in stats package from R(R Core 
Team 2015) was used for this purpose. The transformed feature scores (explained in section 
5.3.4.3) were combined with mean arterial pressure and chronological age to predict the PWV for 
an unknown sample.  
To validate each model 84 ‘new’ subjects from the same cohort (the third split which was not used 
in training pipeline) along with baseline clinical and PWV values measured were used. For a subset 
of the aforementioned 84 subjects (n=75), PWV value and mean arterial pressures measures from a 
4yr follow-up period (±4.3yr) were available and these were used to explore if there was a 
relationship between gene score and progression of aortic stiffness. The robustness of the model in 
these validation samples was tested by visualizing the results using Bland-Altman plots which 
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allows the comparison between the actual and predicted values. In these plots in general, if the 
plotted data clusters around the mean of the differences (called the bias), and is within ±1.95 
standard deviations of the mean known as ‘limit of agreement’ then the observed and predicted 
values are considered to be in agreement with each other.  
 
 Figure 5.3 Selection criteria in ‘model-selection’ dataset that takes into account the effect each feature 
has on the model. A) We iteratively add one feature at a time and compute the correlation coefficient of the 
gene set with PWV values. Then we record if adding the feature make the model better or worse and select 
one of the criteria from Table 5.2 B) Using the sub selection criteria we get the best model which in this case 
is a set of 124 features. 
 
5.3.6 Transforming healthy neuro-muscular age signature into a linear model  
Using KNN method of binary classification we have found a healthy neuro-muscular signature 
effective at distinguishing between young and old human muscle and brain while in human blood, it 
was related to cognitive status in two independent studies (Chapter 3). We were interested in testing 
if this multi-tissue healthy age signature of 150 genes (~128 Illumina probes) could be potentially 
converted to a linear model for vascular stiffness. Since the age signature was developed as a non-
linear model, it was necessary to find subset of genes from the 150 genes that followed a linear 
pattern of change with chronological age. Using correlative analysis and classification modeling we 
identified genes in the nonlinear model that had some linear features using a set of human muscle 
samples from the STRRIDE II cohort, a pre-clinical sedentary cohort of adults (age range of 25 to 
68 years). From these linear genes we use only those that were expressed in both blood and skin as 
if we obtained a positive outcome we would have progressed the validation using blood-based 
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gene-expression cohorts. We combined the subset of expressed linear genes following the same 
approach as for model 1 and 2 described below i.e., adjusted the gene expression values for age and 
blood pressure and collapsed it into a feature score metric and subsequently analyse its potential as 
a model of vascular ageing. 
5.4 Results and discussion 
The linear classifier pipeline provided the flexibility of choosing different selection thresholds and 
criteria first for individual features and then for model selection as explained in the methods section 
above. Based on this pipeline we selected and validated two different PWV prediction models. 
5.4.1 Predictor genes from machine learning approach  
Using the detected Illumina probes the correlation between PWV and probe RNA expression were 
calculated. The features with a median adjusted p-value <0.05 were selected (~1135 
features/probes) and ranked by the median correlation coefficient (CC). We then added each feature 
score metric (summation of logit expression values) in model selection dataset with 116 samples. In 
first instance the ‘UP’ selection criteria (Table 5.1, option 3 in Figure 5.1) gave us the best model of 
124 features (Figure 5.3B) with CC value 0.51 (Figure 5.4A) and 0.82 (Figure 5.4B) in the model 
selection and feature selection datasets respectively (p-value < 10-9). Using an alternative feature 
score calculation method (difference between the mean of logit expression values of positively 
correlated features and negatively correlated features) and UP+ criteria (Table 5.1) in ‘model-
selection’ dataset we obtained a different set of 431 features (Appendix 2 Figure A5.1) that when 
combined together gave us a prototype model with CC of 0.56 (Figure 5.4 C) and 0.66 (Figure 5.4 
D) in the model selection and feature selection datasets respectively (p-value < 10-11 ). None of the 
gene sets were enriched for any significant gene ontologies when corrected for background bias. 
5.4.2 Linear regression models for PWV prediction and validation  
Thus, the linear feature selection pipeline gave two different gene sets that correlated with PWV 
and comprised of 124 and 431 features. By collapsing the gene sets into a feature score metric 
(explained in methods section) and combining it with age and blood pressure as additional 
explanatory variables two final regression models for PWV (the dependent variable) were attained. 
Model 1 had an adjusted R2 =0.53 (p-value < 10-15) and Model 2 had adjusted R2 =0.46 (p-value < 
10-12).  
PWV= 9.532 + 0.233* feature_Score + 0.072* MeanArterialPressure + 0.104* Age    [1] 
            PWV= -5.347+ 17.459*feature_Score + 0.063* MeanArterialPressure + 0.109*Age    [2] 
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Figure 5.4 Relation between PWV values and feature score. The figure shows the correlation between the 
the PWV values and feature score calculated by summation of expression estimates from the two different 
prototype models obtained from the machine learning linear classifier comprising of gene sets of 124 
features (A and B) and 431 features (C and D) in model selection and feature selection datasets respectively. 
	
To verify that the models developed were able to predict the PWV values for vascular ageing, we 
predicted PWV measure based on the baseline gene expression and clinical data and compared it 
with the observed measures of PWV in the third data-set. Similarly, we also investigated if based 
on baseline gene expression data we could predict the PWV values ±4.3yr baseline.  
For each model, the Pearson correlation between predicted and observed values were 0.6 
and 0.65 (Figure 5.5) in the two validations datasets and with Model 2 they were 0.58 and 0.61 
respectively. However, correlation coefficient is not the only parameter to judge the value of a 
model and we used Bland Altman plots to visually check the robustness of these models. Majority 
of observations for both model 1(Figure 5.5) and model 2 values (Appendix 2 Figure A5.2) were 
within the limit of agreement (±1.95 SD), thus implying that the difference between actual and 
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predicted PWV values were trivial. These were robust if not extremely strong models, capturing 
over 50% of the variance. However, inspection of the components of model 1 and 2 indicates that 
gene expression feature score (i.e. information from gene expression) was making a very modest 
contribution to the models. To establish this, we derived another regression model (Model 3) solely 
based on mean arterial pressure and age and without the gene expression data (adjusted R2 =0.44, p-
value<10-15).  
                            PWV= -3.123+0.065*MeanArterialPressure + 0.106*Age               [3] 
On validation datasets 1 and 2, Model 3 had a CC value of 0.64 and 0.67 respectively (Appendix 2 
Figure A5.3) and Bland-Altman plots revealed that its performance on validation datasets was at 
par with models that included the gene expression data thus implying that for a reasonable model 
for vascular “stiffness” can rely on chronological age and blood pressure. 
5.4.3 Healthy neuro-muscular age signature as a model for vascular ageing 
Examination of the 150 neuro-muscular gene signature (Chapter 3) we found a subset of ~20 genes 
expressed in skin and blood and showing a linear correlation with chronological age. We then tried 
to build a linear regression model by combining these linear features with the same covariates as 
above (age and mean arterial pressure) and observed that feature score (gene expression data from 
20 linear age genes) didn’t significantly added to a linear model (p value= 0.503) while age and 
MAP did.  
Thus, a simple regression model using a subset of neuro-muscular healthy ‘age’ genes did 
not relate these features to vascular age. Indeed, we previously found neuro-muscular healthy ‘age’ 
signature did not relate to coronary vascular disease (Figure 3.7) and this additional analysis further 
ascertained the original interpretation that the ‘healthy ageing gene’ score was selectively useful in 
identifying neuro-muscular ageing and not vascular ageing (or that the vascular phenotypes are not 
directly related to biological ageing). Interestingly, in Chapter-4 of this thesis we had discussed 
Peters RNA signature and showed through our analysis that it captures the differences between 
CAD patients and controls (Figure 4.3A). Also in the original paper (Peters et al. 2015), the 
signature was strongly linked to blood pressure (p-value<10-5). Since vascular ageing is coherently 
related to both blood pressure and CAD (Lakatta & Levy 2003; Laurent 2012), therefore there is a 
strong possibility that the Peters RNA signature represents vascular ageing  instead of a general 
model of ageing as reported by the authors. 
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Figure 5.5 Validation of gene expression based vascular ageing signature. Bland Altman plots (on the 
RHS) showing robustness of Model 1 in Validation datasets 1 (A) and 2 (B) respectively. Majority of 
observations for both model 1 and model 2 values were within the limit of agreement (dashed lines), thus 
implying that the difference between actual and predicted PWV values were small.  
5.5 Summary 
We aimed to find an RNA signature for ‘vascular’ ageing (assuming ‘stiffness’ = ageing) using the 
gene expression data from skin from a TWIN cohort as skin is structurally similar to one of the 
large arteries (Nilsson et al. 2015). In order to do this, we developed a new machine learning linear 
classifier strategy which gives control over feature selection. We developed two different RNA 
models both of which statistically validated on independent set of 84 samples with baseline PWV 
measure and 75 samples with PWV measure, MAP and age measure at a different time point 
(~±4.3yr from baseline). On careful inspection we observed that feature score i.e. gene expression 
was making only a very modest contribution and it is possible to obtain a good model for vascular 
“ageing” that relies only on age and blood pressure. This is in accordance with the literature (Najjar 
et al. 2008; Kim et al. 2007) which shows that blood pressure  is one of the strongest factors 
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influencing PWV followed by age and gender (Vermeersch et al. 2008). This also shows that 
having a statistically significant model (determined by p value) does not always translate to a model 
that has clinical significance as well.   
Nonetheless, we cannot completely dismiss a genomic aspect to vascular ageing (as Peters 
RNA signature seems to grab some aspect of vascular ageing) or that changes in vascular function 
are causally related to life-style – which is also a covariate of chronological age and blood pressure 
(e.g. we become inactive and over-weight). It is also possible that our experimental design 
comprising of skin RNA does not best capture the effect of vascular age and blood RNA or vascular 
tissue might encompass more information. Another caveat of our approach could be that we built a 
linear model to explore the transcriptome search space purpose however it is possible that a non-
linear model might be more suitable, nonetheless these are unlikely to surpass BP and chronological 
age but may add further information.  
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6.1 Overview of the chapter 
This chapter aims to give a summary of the overall conclusions of this research in relation to the 
objectives set at the beginning of this thesis and how it contributes to existing knowledge. I further 
discuss potential future research directions related to this project with recommendations and 
implications. We had five key observations in our analysis which were as following: 
1. We found a signature or gene-set of 150 genes >90% accurate in classifying ‘healthy’ old muscle 
tissue samples from young muscle samples. 
2. Using hundreds of new muscle gene-chip profiles from independent human cohorts we found the 
same 150 signature was ~93% accurate in muscle. Further, this same signature could distinguish 
old from young human brain and skin tissue 
3. We produced new muscle gene-chip profiles from a 20yr longitudinal tissue cohort (ULSAM) 
and we gained access two independently produced case-control gene-chip datasets for AD. We 
found that a greater gene score in a person with given birth year (e.g. 70yrs) correlated with better 
long term renal function, mortality or better cognitive status (using the same 150 genes). 
4. In all three independent clinical cohorts there was a consistent directional pattern of gene 
expression in muscle and blood, associated with good health.  
5. The existing ‘stress’ resistant and ‘epidemiologically’ selected linear models when transformed 
to equivalent RNA signatures related with vascular disease whereas our 150 healthy age signature 
worked specifically for neuromuscular ageing. Thus, we have revealed that vascular ageing had a 
distinct profile from neuro-muscular ageing (Zahn et al. 2007). 
6.2 Discussion 
As the number of people routinely living into their eighth decade and beyond rises, the prevalence 
of age-related diseases has significantly increased and at differing rates across the various countries. 
An example of age-related disease (i.e. very low prevalence in young and middle-aged adults) 
include skeletal muscle atrophy and dysfunction (‘sarcopenia’) and neurological disorders such as 
dementia. These age-related health problems have massive economic and social consequences 
(Janssen et al. 2004; Gustavsson et al. 2011). To maintain long term effective performance in any 
job role attainment of healthy ageing would be ideal.  Furthermore, age is a routine parameter in 
most clinical decision making trees e.g. decision to screen or not for age related disease. Identifying 
the molecular processes governing healthy human ageing (and longevity) is of great medical 
importance, but there have been few human based discoveries, mainly due to the inability to 
effectively account for influential physiological and environmental factors and lack of large well-
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funded multigenerational studies.  
In the recent years, there has been a surge in the use of machine learning methods which has 
facilitated researchers to develop classifiers for identification or diagnosis of diseases. These 
computational methods accompanied by a good study design promises to aid clinicians in 
identifying patients at high-risk for poor outcomes, and in general improve patients' health while 
minimizing costs and improving overall patient management. Cancer diagnosis and treatment have 
been influenced by these machine learning approaches (Tokuda et al. 2009; Patnaik et al. 2010), 
and this arguably represents where the greatest progress has been made in terms of personalized 
medicine.  
There is a generous amount of proof that gene expression changes with ageing in different 
tissue types and in the organism as a whole (Zahn et al. 2007; Glass et al. 2013). Global RNA (W 
M Passtoors et al. 2012; Phillips et al. 2013; Glass et al. 2013; Gheorghe et al. 2014) and DNA 
methylation profiling (B. C. Christensen et al. 2009; Horvath 2013; Bell et al. 2012) has been 
utilised to search for consistent molecular events correlating with age, where samples come from 
cross-sectional studies spanning 5-8 decades. Such correlation analyses yield highly significant 
linear associations, yet by design, such models must be influenced by disease as much as the ageing 
process per se. Further, each study identified a distinct list of genes or pathways. For example, 
Hannum et al built a multi-tissue linear model of DNA methylation age-related changes that 
correlated with chronological age over seven decades (Hannum et al. 2013). However, this type 
molecular profile is not, for example, very useful for distinguishing how successful a person was 
ageing among a group with the same birth-year (Horvath 2013; Hannum et al. 2013) as 
chronological age and methylation status tends to co-vary tightly and in epidemiological cohorts, 
these DNAm models only added ~6% to models examining rates of mortality (Marioni et al. 2015).  
Further, studies exploring the genetics of human ageing most commonly consider 
exceptional longevity (e.g. 100 years or more) as phenotype of interest for human ageing. While 
longevity is driven by a strong genetic contribution (Sebastiani et al. 2012) being fit and healthy at 
age 65 year is a more common occurrence and likely to reflect complex molecular factors (Kenyon 
2010; Sabia et al. 2012). Discovery of these molecular factors could help screen for drugs that help 
people age ‘better’. In the present body of work, a novel tool has been provided that should enable 
the future translation of basic science into clinical advances, namely a robust diagnostic of healthy 
neuromuscular ageing. For our work, human skeletal muscle provided the ideal starting tissue from 
which to generate a 'clean' ageing molecular classifier, as skeletal muscle RNA is easily accessible 
(with a relatively uniform cell content e.g. >90% myocytes) and its functional status can be studied 
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in great detail prior to tissue sampling in all age groups (Gallagher et al. 2010; Timmons et al. 
2005). This lies in very distinct contrast to using post-mortem brain samples, hard to access 
myocardium tissue or any one of a number of other potential human tissue sources. In addition, it 
was possible to discover this robust set of marker genes for healthy physiological age as the 
research strategy involved tissue samples obtained from 65 year subjects who had demonstrated 
successful ageing i.e. they were selected to have good metabolic and cardiovascular health despite 
having behaviour that was sedentary (Gallagher et al. 2010; Keller et al. 2011). At this stage we do 
not know if other aspects of their life-style was unique (they were non-smokers), for example diet 
but the impact on selected nutrients on human disease and ageing has not proven to yield a 
plausible biological affect (Timmerman 2013). So the ‘healthy ageing’ component constitutes a 
novel aspect of our study that has not been used in previous studies.  
The usefulness of supervised machine learning approach in developing clinically useful 
biomarkers and diagnostic is often limited by access to multiple data-sets as the methods are 
generally prone to over-fitting (single data set bias) which do not appear evident straightaway to 
many researchers (Ambroise & McLachlan 2002; Simon et al. 2003). Without independent 
validation, these computational methods give spurious associations by developing 
classifiers/predictors that perform impressively well on the original training study but then fail 
miserably when applied to new dataset. 
In our work the discovered gene-set signature that was then extensively validated by using 
samples from different cohorts, generated in different laboratories and profiled on different gene 
detection technologies. In the absence of independent validation datasets validation methods such 
as bootstrapping and cross validation which combines training and validation of classifiers in one 
process are often used (Kohavi 1995; Steyerberg et al. 2003). Unfortunately, a large number of 
studies employing such computationally intensive approaches are not descriptive enough about 
their validation strategy which makes it difficult to assess the validity of their results. Thus, 
validating a diagnostic on subjects independent of the training set is of prime importance. However, 
researchers are often limited by the availability of publically accessible data sets that fits their study 
design and the relevant biological question. 
Hence, it is useful to have the raw data from developmental prediction/diagnostic studies in 
public domain as well as the computational methods employed (including code). This would not 
only ensure the reproducibility of the original studies but would also potentially provide a bigger 
pool of datasets to scientists for external validation and meta-analysis (Simon 2005; Kattan 2004). 
All of the datasets used in this study were made freely accessible at GEO. Our signature was 
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consistently modulated in several tissue types (muscle, brain and skin), but to very differing degrees 
in people of the same chronological age (Figure 3.2A), clearly illustrating that biological age is 
indeed different from chronological age. By this it fulfilled the first main criteria for being a novel 
diagnostic of healthy (or biological) ageing.	 Hence had more likelihood for predicting of an 
individual having an age-related clinical adverse event or developing an ageing-related disease such 
as Alzheimer’s, CAD etc. 
Neurocognitive pathology (e.g. Alzheimer’s disease) becomes more pronounced with age 
and is often apparent in individuals who are otherwise healthy. On examining the ‘healthy ageing’ 
signature in relation to identifying neurocognitive disease we found that it could distinguish AD 
samples from age-matched controls. Further the healthy ageing signature was regulated in a distinct 
manner across individual healthy brain regions with chronological age, especially in the 
hippocampus (Figure 3.4), a region associated with neurogenesis (Gould et al. 1999; Taupin 2006). 
Our analysis of the relationship between lifestyle factors and the ‘healthy age gene score’ 
(longitudinal study ULSAM) suggested that the gene score was robust to confounding effects of 
these factors. The lack of association with lifestyle modulated diseases such as diabetes, CAD 
further ascertained this. 
Therefore, our ‘healthy ageing’ signature appears ‘selectively’ useful in relation to 
identifying risk for neurocognitive disease over and above lifestyle or vascular diseases. This is not 
surprising since ageing is thought to be a continuous physiological process that could be expected 
to have a gene expression signature distinct from lifestyle related (e.g. Type II diabetes) or mutation 
driven (e.g. cancer) pathologies. Further, as discussed  before, ageing is a multifaceted process that 
has different levels of complexity and variability across cells, organs, organ systems, organism and 
species (Cevenini et al. 2008; Cevenini et al. 2010) nevertheless some aspects of ageing do appear 
consistent across tissue types based on our analysis. 
In mouse, based on the pattern of age-related transcriptional changes researchers have 
categorised tissues into three different ageing processes, that is a pattern common to neural tissues, 
a pattern for vascular tissues, and a pattern for glandular tissues (Zahn et al. 2007). Mouse studies 
are challenging to interpret because of the use of inbred strains and very controlled environments – 
a situation very different from humans. Another study replicated these findings and through tissue 
co-expression network analysis, claimed that the distinct gene expression changes with age are 
potentially synchronized at different levels with an individual (Fu et al. 2006; Huang et al. 2011). A 
similar study in humans observed tissues like heart, lung, and whole blood sharing a stronger co-
ageing pattern in comparison to tissues like muscle. This inter tissue synchronization could be a 
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reflection of their functional connectivity in the early developmental stage which probably extends 
into the late stage of their lifespan (Yang et al. 2015). In contrast, you might expect that muscle use 
and cardiac use would share a strong link to the same environmental factor like exercise while lung 
tissue remodels in the face of pollution and factors like smoking. Thus, neuromuscular ageing may 
have a distinct gene expression profile than vascular or lung ageing, with latter being more 
susceptible to lifestyle or environmental related perturbations. 
The endeavor to discover biomarkers for the ageing process has prompted the development 
of large ageing cohort studies and different ageing signatures. However, if the research question is 
ageing par se it is critical to have thoughtful use of study design, to avoid confounding the studies 
with subjects with age associated diseases and drugs. In chapter-4 we have effectively shown that 
our muscle derived gene-set was the only one related to hippocampus ageing and cognitive health 
while ‘stress’ resistant and ‘epidemiologically’ selected linear models related with vascular 
diseases. By transforming the different genomic signatures of ageing to representative RNA 
signatures we have shown that it is possible to utilize a single technology platform 
(Transcriptomic/RNA profiling) to capture sufficient clinical variance of different aspects of ageing 
such as neuromuscular, vascular etc. (Figure 4.2). We have also successfully exhibited that a 
hypothesis driven machine learning method is different and reliable then the random sampling 
approach which fails to produce a single ageing ‘gene-set’ which works as a multi-tissue age-
classifier or a discriminator for Alzheimer’s disease. This provides the first RNA risk-factor for 
Alzheimer’s disease that was not built/selected using Alzheimer’s disease clinical samples and thus 
is the most independent. However, because Alzheimer’s disease has low prevalence until the 80th 
decade and is a complex clinical diagnosis, an RNA diagnostic is going to be very challenging to 
develop.  
Vascular ageing is related to ageing of vessels or arteries that helps in circulation of blood. 
Age-related pathologies generally effect the large elastic arteries which are rich in elastin and 
collagen with latter providing the strength to vasculature at higher blood pressures (Jani & 
Rajkumar 2006). Loss of elasticity damages coronary flow and results in coronary artery disease or 
atherosclerosis (McCullagh & Balian 1975). In chapter-5, we investigated if using gene expression 
data from skin tissue, as skin structure is close to one of the large arteries (Nilsson et al. 2015), 
along with PWV measures to gauge vasculature health, we can build a model for vascular ageing. 
Since PWV is known to strongly co-vary with both blood pressure and chronological age 
(Ruitenbeek et al. 2008; Vermeersch et al. 2008; Elias et al. 2009) we decided to use a machine 
learning linear modeling/regression strategy instead of the binary approach used for our 
neuromuscular signature as in the former we could adjust for the two covariates i.e. blood pressure 
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and age. We built three distinct regression models based on different criteria from our feature 
selection pipeline. We observed that gene expression made only a very modest contribution to the 
model when compared to blood pressure and chronological age. It is crucial to understand that this 
particular analysis was based on the hypothesis that skin mRNA could capture the effect of vascular 
ageing which could have been one of the limitations of our approach and possibly blood mRNA 
encompasses more information about vascular health and age.  
6.3 Conclusion 
In conclusion, we have discovered a novel and statistically robust multi-tissue RNA signature of 
‘biological ageing’ that has potential as a health diagnostic. In particular, it was prognostic for long-
term health in older humans, remotely informing about organ function (including cognitive 
functioning) using only a peripheral blood sample. Thus, we believe that our diagnostic represents a 
reliable proxy of ‘biological’ age that could be used in clinical decision-making, currently reliant on 
calendar age. Notably, ours is the first genomic signature able to identify AD from controls based 
entirely on an independently developed research hypothesis that does not include feature selection 
using disease cohorts. We believe that when combined with clinical data, our healthy age diagnostic 
could aid identification of at-risk late middle-aged non-symptomatic people.  
6.4 Future directions 
Novel easy to administer diagnostics that accurately and sensitively predict future health risk or 
help guide preventative measures would enable the evaluation of tailored treatment strategies for 
the individual. The biomarkers discovered in this thesis provides a novel way to assess whether an 
individual has a higher or lower probability, or risk, of developing an ageing-related disease, 
depending on the expression levels of these marker genes. It is advantageous to be able to assess an 
individual’s biological age accurately, so that if an individual is identified to have a high risk of 
developing an ageing-related disease they can act accordingly to reduce their risk, such as through 
lifestyle changes or prophylactic treatment. The link between induction of the signature, renal 
decline, mortality and cognitive function suggests our signature transcends tissue specificity and 
also that it may be possible to facilitate healthier ageing e.g. to evaluate anti-ageing treatments 
using cell-based screening or to predict long-term safety in drug development. The signature could 
potentially be also used in predicting the quality of an organ based on the biological age and thus 
estimating the likelihood from a person over > 50 years of age being successfully used for 
transplantation into a donor patient by estimating the biological age of the organ. 
We also believe that it will be informative to replace age with our healthy ageing gene 
diagnostic for many conditions. For example: In diabetes patients, where age is by far the more 
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powerful predictor of future dementia rather than severity of the diabetes measured using 
glycosylated hemoglobin A1 (HbA1) (Exalto et al. 2013) and in these cases replacing chronological 
age by biological age would potentially provide a better prognosis. This highlights that, clinically, 
various decision trees exist and our healthy ageing score could be integrated to help decide which 
middle-aged subjects could be offered entry into a preventative clinical trial many years before the 
clinical expression of AD. However, like many genomic diagnostics, the full clinical utility of ours 
will only emerge when combined with additional data and clinical insight. 
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Probeset_ID Gene	Symbol Ratio	of	Y:0	muscle Gene	Title Biology	notes
236278_at HIST1H3E down Histone	cluster	1,	H3e
Replication-dependent	histone;	core	
component	of	nucleosome;	reduced	gene	
expression	in	aged	mice	in	hippocampus
204974_at RAB3A down RAB3A,	member	RAS	oncogene	family
GTPase/Ca+	signalling;	age-related	changes	
in	human	brain;	Alzheimer's	Disease	link;
205050_s_at MAPK8IP2 down mitogen-activated	protein	kinase	8	interacting	protein	2
AKA	JIP2;	scaffold	protein	that	binds	many	
JNK	isoforms;	regulates	MAPK8;	APP	and	
Glucose	-	biochem	of	'ageing	diseases'
206416_at ZNF205 down zinc	finger	protein	205 DNA	binding	protein;	regulates	human	M-LPH	-	potentially	oxidative	stress	related
229730_at SMTNL2 down smoothelin-like	2 JNK	substrate
226674_at SHISA4 down shisa	homolog	4	(Xenopus	laevis)
Secreted	and	transmembrane	protein;	in	
Xenopus	Shisa	proteins	may	inhibit	Wnt	and	
FGF	signaling
234495_at KLK15 down kallikrein-related	peptidase	15
Serine	protease;	upregulated	in	advanced	
tumours;	snp	associated	with	cancer	risk;	
androgen	regulated
240686_x_at TFRC down transferrin	receptor	(p90,	CD71)
Iron	delivery	to	cells;	previously	identified	as	
underexpressed	with	age	(in	meta-analysis)
234536_at SARDH down sarcosine	dehydrogenase Mitochondrial	matrix	protein,	catalyses	oxidative	demethylation	of	sarcosine
239446_x_at DCBLD2 down discoidin,	CUB	and	LCCL	domain	containing	2 Cancer-linked
222197_s_at LOC100128008 down Similar	to	RIKEN	4933439F11 ---
227738_s_at ARMC5 down armadillo	repeat	containing	5
Armadillo/beta-catenin-like	repeats.	A	
tandemly	repeated	sequence	motif	first	
identified	in	the	Drosophila	segment	polarity	
gene	armadillo;	repeats	also	found	in	the	
mammalian	armadillo	homolog	beta-catenin,	
the	junctional	plaque	protein	plakoglobin,	
the	adenomatous	polyposis	coli	(APC)	tumor	
suppressor	protein,	and	a	number	of	other	
proteins
228876_at BAIAP2L2 down BAI1-associated	protein	2-like	2 Binds	phosphoinositides
234694_at CNTROB down centrobin,	centrosomal	BRCA2	interacting	protein
Cell	division	-	centriole	associated;	cancer-
related
203842_s_at MAPRE3 down
microtubule-associated	
protein,	RP/EB	family,	
member	3
Microtubule-associated
217079_at 217079_at down q12.13	Homo	sapiens	unknown	protein	mRNA ---
217696_at FUT7 down fucosyltransferase	7	(alpha	(1,3)	fucosyltransferase) Involved	in	creation	of	sialyl-Lewis	X	antigen
217700_at CNPY4 down Canopy	4	homolog	(zebrafish)
AKA	Prat4b;	secreted;	negative	regulator	of	
Toll-like	receptor	trafficking/cell	surface	
expression
221309_at RBM17 down RNA	binding	motif	protein	17 Part	of	spliceosome	complex
230044_at PCYT2 down phosphate	cytidylyltransferase	2,	ethanolamine
Enzyme	involved	in	phospholipid	
biosynthesis;	mice	with	PCYT2	accumulate	
more	DAG	and	TG	with	age
236091_at HMGB2 down high-mobility	group	box	2 Chromatin-associated;	linked	to	osteoarthritis
212512_s_at CARM1 down coactivator-associated	arginine	methyltransferase	1
Transcription;	methylates	proteins	including	
histones	&	chromatin-associated	proteins;	in	
skeletal	muscle,	linked	to	glycogen	gene	
expression	and		differentiation
244707_at HCN4 down
hyperpolarization	activated	
cyclic	nucleotide-gated	
potassium	channel	4	(HCN4)
Potassium	channel
215488_at 215488_at down Vitelliform	macular	dystrophy	2	(Best	disease,	bestrophin)
Bestrophins	may	form	chloride	channels	or	
regulate	voltage-gated	L-type	calcium	
channels;	linked	to	Vitelliform	macular	
dystrophy
202588_at AK1 down adenylate	kinase	1 Cytosolic;	energy	metabolism
215844_at TNPO2 down transportin	2 RanGTP-binding	nuclear	transport	receptors;	HuR	is	TRN2	export	substrate;	RNA	binding
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Probeset_ID Gene	Symbol Ratio	of	Y:0	muscle Gene	Title Biology	notes
228279_s_at TNK2 down Homo	sapiens	tyrosine	kinase,	non-receptor,	2 RAC	related;	tumour	motility;	cdc42hs?
238006_at SIN3A down SIN3	transcription	regulator	homolog	A	(yeast)
Transcriptional	corepressor	activity;	HDAC	
regulation/chromatin	remodelling
240147_at C7orf50 down chromosome	7	open	reading	frame	50 Includes	a	pro-survival	human	ageing	SNP
243906_at 243906_at down Organic	solute	transporter	alpha ---
244504_x_at ARF1 down ADP-ribosylation	factor	1	(microRNA	3620	within?)
Modulates	cell	surface	Cdc42	dynamics;	GTP-
binding	protein	involved	in	protein	
trafficking;	modulates	vesicle	
budding/uncoating	within	Golgi	complex
210483_at TNFRSF10C down
tumor	necrosis	factor	receptor	
superfamily,	member	10c,	
decoy	without	an	intracellular	
domain
AKA	DCR1/TRAILR3;	cytokine	related,	
tumour	related;	receptor	has	extracellular	
TRAIL-binding	domain	+	TM	domain	but	no	
cytoplasmic	death	domain	-	not	able	to	
induce	apoptosis	but	thought	to	be	
antagonistic	receptor	that	protects	cells	from	
TRAIL-induced	apoptosis
216327_s_at SIGLEC8 down sialic	acid	binding	Ig-like	lectin	8
Adhesion	molecule	that	mediates	sialic-acid	
dependent	binding	to	cells;	mostly	expressed	
in	eosinophils	and	mast	cells
217046_s_at AGER down advanced	glycosylation	end	product-specific	receptor
AKA	RAGE;	transmembrane	receptor	of	Ig	
superfamily;	binds	advanced	glycation	
endproducts;	linked	to	pro-inflammatory	
gene	activation;	alternatively	spliced	with	6	
isoforms	-	some	lack	TM	domain	and	thought	
to	be	secreted;	linked	to	impaired	skeletal	
muscle	insulin	action	via	AGEs;	increased	in	
Alzheimer's	Disease;	Diabetes	linked
222080_s_at SIRT5 down Sirtuin	5
NAD-dependent	protein	acetylase	associated	
with	the	mitochondria;	involved	in	ammonia	
detoxification;	deactivated	by	suramin;	
sirtuins	linked	to	lifespan	extension	in	
rodents	-	resveratrol	(possible	SIRT	activator)	
inhibits	gene	exp	profile	associated	with	
muscle	ageing;	linked	to	brain	ageing
227456_s_at C6orf136 down chromosome	6	open	reading	frame	136 ---
227781_x_at FAM57B down family	with	sequence	similarity	57,	member	B
Transmembrane	protein;	PPARg	responsive	
and	linked	to	ceramides/adipogenesis	
regulation
229508_at U2AF2 down U2	(RNU2)	small	nuclear	RNA	auxiliary	factor	2 Pre-mRNA	splicing	factor
211180_x_at RUNX1 down runt-related	transcription	factor	1
AKA	AML1;	transcription	factor	that	binds	to	
core	elements	of	enhancers	&	promoters;	
regulates	differentiation	of	hemopoietic	
stem	cells	into	mature	blood	cells;	leukemia	
link
213690_s_at 213690_s_at down ---
213987_s_at CDK13 down cyclin-dependent	kinase	13
Family	members	have	roles	as	master	
switches	in	cell	cycle	control;	impact	on	RNA	
processing/splicing
218063_s_at CDC42EP4 down CDC42	effector	protein	(Rho	GTPase	binding)	4
May	be	GTPase	related;	GTP	Rho	binding;	
organisation	of	actin	cytoskeleton
219150_s_at ADAP1 down centaurin,	alpha	1 Phospholipid	binding	protein;	linked	to	Alzheimer's	Disease
229607_at LOC100652912 down uncharacterized	LOC100652912 ---
236269_at ZNF628 down zinc	finger	protein	628 ---
239125_at SLC25A5-AS1 down SLC25A5	antisense	RNA	1	(non-protein	coding)
Antisense	RNA	to	mitochondrial	ANT2;	
SLC25A5	is	an	inner	mitochondrial	
membrane	transport	protein	that	
translocates	ADP
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Probeset_ID Gene	Symbol Ratio	of	Y:0	muscle Gene	Title Biology	notes
239422_at GPC2 down glypican	2	(cerebroglycan)
Cell	surface	proteoglycan;	found	in	
developing	nervous	system;	role	in	cell	
adhesion
239837_at ADAM11 down ADAM	metallopeptidase	domain	11 Metalloprotease-like	protein
240098_at RIF1 down RAP1	interacting	factor	homolog	(yeast)
Maybe	involved	in	DNA	repair;	telomere-
associated	(may	regulate	telomere	length)
244182_at 244182_at down Homo	sapiens,	clone	IMAGE:5756056,	mRNA ---
89476_r_at NPEPL1 down aminopeptidase-like	1 May	catalyze	removal	of	unsusbstituted	N-terminal	AA	from	various	peptides
202312_s_at COL1A1 down collagen,	type	I,	alpha	1 Reduced	in	aging	skin	and	bone;	osteoporosis	linked
208232_x_at NRG1 down neuregulin	1 Repairs	nerve	damage	in	the	adult;	high	levels	linked	to	longevity	in	rodents
209280_at MRC2 down mannose	receptor,	C	type	2 Role	in	ECM	remodelling;	linked	to	tumourigenesis	and	metastasis
220482_s_at SERGEF down secretion	regulating	guanine	nucleotide	exchange	factor
Guanyl-nucleotide	exchange	factor	activity	-	
may	be	involved	in	secretion	process;	
deafness-related
226871_s_at ATG4D down autophagy	related	4D,	cysteine	peptidase
Cysteine-type	endopeptidase	involved	in	
autophagy	
244164_at FAM223B down
Homo	sapiens	family	with	
sequence	similarity	223,	
member	B	(non-protein	
coding)	(FAM223B),	non-
coding	RNA
Non-protein	coding
244591_x_at RNF207 down Ring	finger	protein	207 Variation	in	QT	interval	SNPS
211837_s_at PTCRA down pre	T-cell	antigen	receptor	alpha T	cell	development
214213_x_at LMNA down lamin	A/C
Linked	to	Hutchinson-Gilford	Progeria	
Syndrome	(HGPS),	caused	by	a	spontaneous	
mutation	(truncated	version),	and	
characterized	by	premature	aging.	Nuclear	
membrane	structural	component-	roles	in	
cell	cycle	control,	DNA	Replication	&	
chromatin	organisation;	cleaved	during	
apoptosis;	mice	deficient	have	enhanced	
mTORC1	signaling	linked	to	dystrophic	
pathology
214316_x_at CALR down Calreticulin
Calcium	binding/regulation;	protein	folding	
in	ER;	possible	nuclear	receptor	modulation;	
reduced	protein	expression	during	aging	in	
mouse	skeletal	muscle
223415_at RPP25 down ribonuclease	P	25kDa	subunit
Component	of	ribonuclease	P,	a	protein	
complex	that	generates	mature	tRNA	by	
cleaving	their	5'	ends;	linked	to	
developmental	brain	disorders
228677_s_at RASAL3 down RAS	protein	activator	like	3 Ras	GTPase	activator	activity
228684_at ZNF503 down zinc	finger	protein	503 AKA	Nolz1;	RAR	signalling
236845_at TRIM62 down tripartite	motif	containing	62 E3	ubiquitin	ligase;	potential	immune	role
238046_x_at PWWP2B down PWWP	domain	containing	2B Histone	modification	biochemistry
207883_s_at TFR2 down transferrin	receptor	2 iron	homeostasis
209983_s_at NRXN2 down neurexin	2
Neurological	role;	loss	of	function	disorders	-	
neuronal	cell	surface	protein	with	role	in	cell	
recognition	and	adhesion	molecule	binding
210364_at SCN2B down sodium	channel,	voltage-gated,	type	II,	beta	subunit
Subunit	of	voltage-gated	sodium	channel;	
may	be	regulated	by	BACE1
219967_at MRM1 down
mitochondrial	rRNA	
methyltransferase	1	homolog	
(S.	cerevisiae)
Mitochondrial	ribosome	complex;	RNA	
methylation
220989_s_at AMN down amnion	associated	transmembrane	protein
Developmental		gene;	transmembrane	
protein	thought	to	regulate	bone	
morphogenetic	protein	(BMP)	receptor	
function
231764_at CHRAC1 down chromatin	accessibility	complex	1 Histone-fold	protein	that	binds	DNA
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233894_x_at EMID2 down EMI	domain	containing	2 AKA	COL26A1
234003_at ENOX2 down ecto-NOX	disulfide-thiol	exchanger	2
Cell	surface	protein;	two	enzyme	activities	-	
catalysis	of	hydroquinone	or	NADH	oxidation	
and	protein	disulfide	interchange	-	may	
control	physical	membrane	displacement	for	
vesicle	budding	or	cell	enlargement;	pro-
growth	in	tumour	cells
235671_at 235671_at down Homo	sapiens	BAC	clone	RP11-489G24 ---
236746_at GALNT1 down
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide	N-
acetylgalactosaminyltransferas
e	1	(GalNAc-T1)
O-linked	oligosaccharide	biosynthesis;	
reduced	with	age	of	bone	cell	donor
206080_at PLCH2 down phospholipase	C,	eta	2 G-coupled	protein	receptor	modulation;	lipid	catabolic	processes
213433_at ARL3 down ADP-ribosylation	factor-like	3
Member	of	ribosylation	factor	family	of	GTP-
binding	proteins;	RP2	is	a	GTPase-activating	
protein	(GAP)	for	ARL3
214209_s_at ABCB9 down
ATP-binding	cassette,	sub-
family	B	(MDR/TAP),	member	
9
Membrane-associated	ATP-binding	cassette	
transporter;	may	transport	peptides	from	
cytosol	into	lysosomal	lumen;	associated	
with	antigen	processing
215649_s_at MVK down mevalonate	kinase
Mevanolate	kinase	activity	-	key	enzyme	in	
isoprenoid	and	sterol	biosynthesis;	substrate	
for	Geranylgeranylpyrophosphate	leads	to	
aberrant	activation	of	the	small	GTPase	Rac1
230693_at ATP2A1 down ATPase,	Ca++	transporting,	cardiac	muscle,	fast	twitch	1
Catalyzes	ATP	hydrolysis	coupled	with	Ca++	
translocation,	&	is	involved	in	muscle	
excitation	and	contraction
231520_at SLC35F3 down Solute	carrier	family	35,	member	F3 ---
239523_at TUSC5 down tumor	suppressor	candidate	5
Expressed	abundantly	in	WAT,	BAT	and	
peripheral	afferent	neurons;	may	be	
involved	in	fat	metabolism	-	increased	
expression	in	response	to	PPARgamma	
agonist	in	3T3-L1	cells
240116_at 240116_at down AT	rich	interactive	domain	1B	(SWI1-like) ---
241427_x_at FBXW7 down
Homo	sapiens	F-box	and	WD	
repeat	domain	containing	7,	
E3	ubiquitin	protein	ligase	
(FBXW7)
Substrate	recognition	component	of	SCF	
(SKP1-CUL1-F-box	protein)	E3	ubiquitin-
protein	ligase	complex	-	mediates		
ubiquitination	of	cyclin	E;	mutations	linked	
to	cancer
208129_x_at RUNX1 down
runt-related	transcription	
factor	1	(acute	myeloid	
leukemia	1;	aml1	oncogene)
AKA	AML1;	transcription	factor	that	binds	to	
core	elements	of	enhancers	&	promoters;	
regulates	differentiation	of	hemopoietic	
stem	cells	into	mature	blood	cells;	leukemia	
link
216980_s_at SPN down sialophorin	(gpL115,	leukosialin,	CD43)
Transmembrane	protein	found	on	surface	of	
immune	cells;	Wiskott-Aldrich	syndrome
218762_at ZNF574 down zinc	finger	protein	574 ---
219756_s_at POF1B down premature	ovarian	failure,	1B Associated	with	premature	ovarian	failure
226141_at CCDC149 down coiled-coil	domain	containing	149 ---
229047_at PLEKHB1 down
Pleckstrin	homology	domain	
containing,	family	B	(evectins)	
member	1
developmental;	membrane-associated	signal	
transduction	activity
229343_at GTSE1 down G-2	and	S-phase	expressed	1
Expressed	in	S	&	G2	phase	of	cell	cycle;	
microtubule-associated	protein	important	in	
cell	migration
237046_x_at IL34 down interleukin	34
Alternative	ligand	for	Csf-1	receptor;	vitD	
regulated	in	skeletal	cells;	increased	in	serum	
and	synovial	fluid	from	rheumatoid	arthritis	
patients
239060_at 239060_at down Homo	sapiens	Chromosome	11q13	BAC	Clone	b79g17 ---
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240241_at 240241_at down RP11-269P11	on	chromosome	9 ---
207914_x_at EVX1 down even-skipped	homeobox	1 Developmental;	altered	methylation	in	cancers
213052_at PRKAR2A down
protein	kinase,	cAMP-
dependent,	regulatory,	type	II,	
alpha
Subunit	of	cAMP-dependent	protein	kinase;	
age-dependent	changes	reported	in	rats
217410_at AGRN down agrin
Large	proteoglycan;	Induces	aggregation	of	
signaling	proteins	in	immune	and	nervous	
systems	through	a	common	lipid	raft	
pathway;	role	in	development	of	NMJ	during	
embryogenesis;	binds	several	proteins	on	
skeletal	muscle	surface	like	MuSK	receptor,	
laminin	&	dystroglycan	-	stabilise	NMJ
225072_at ZCCHC3 down zinc	finger,	CCHC	domain	containing	3 ---
234400_at 234400_at down ---
203055_s_at ARHGEF1 down Rho	guanine	nucleotide	exchange	factor	(GEF)	1 Rho	guanine	nucleotide	exchange	factor
206906_at ICAM5 down intercellular	adhesion	molecule	5,	telencephalin
Transmembrane	glycoprotein	involved	in	
adhesion
220529_at FLJ11710 down uncharacterized	protein	FLJ11710 ---
231242_at BHLHE41 down basic	helix-loop-helix	family,	member	e41
AKA	DEC2	or	Sharp-1;	regulator	of	aggressive	
breast	cancer;	antitumour	promotes	HIF1	
deg.;	negative	regulator	of	transcription	
from	RNA	Pol	II	promoter;	regulator	of	
molecular	clock
234342_at FAM20C down family	with	sequence	similarity	20,	member	C
Calcium-binding	kinase	that	phosphorylates	
the	caseins	and	several	secreted	proteins	
implicated	in	biomineralization;	loss	relates	
to	bone	disorders
234748_x_at KIF20B down kinesin	family	member	20B Plus-end-directed	motor	enzyme	that	is	required	for	completion	of	cytokinesis
240325_x_at SOX30P1 down
Homo	sapiens	SRY	(sex	
determining	region	Y)-box	30	
pseudogene	1	(SOX30P1)	
Transcriptional	activator;	developmental
201592_at EIF3H down
eukaryotic	translation	
initiation	factor	3,	subunit	3	
gamma,	40kDa
Important	in	initiation	of	protein	translation;	
cancer-linked
203876_s_at MMP11 down matrix	metallopeptidase	11	(stromelysin	3)
AKA	stromelysin	3;		overexpressed	in	human	
tumours
223137_at ZDHHC4 down zinc	finger,	DHHC-type	containing	4 ---
223426_s_at EPB41L4B down erythrocyte	membrane	protein	band	4.1	like	4B
Cytoskeletal	binding	protein;	highly	
expressed	in	melanoma	cells;	progression	in	
breast	cancer
227563_at FAM27E3 down family	with	sequence	similarity	27,	member	E3 ---
231402_at 231402_at down Homo	sapiens	BAC	clone	RP11-563K23	from	7 ---
238125_at ADAMTS16 down
ADAM	metallopeptidase	with	
thrombospondin	type	1	motif,	
16
Expressed	in	human	cartilage	and	synovium;	
increased	expression	in	tissues	from	
osteoarthritis	patients;	increased	by	TGFbeta	
in	chondrocytes;	linked	to	hypertension
209097_s_at JAG1 down jagged	1
rs2273061	of	JAG1	gene		associated	with	
high	BMD;	lower	fracture	risk;	G	allele	
rs2273061	higher	JAG1	mRNA;	ligand	for	
Notch	receptors;	reduced	expression	in	
skeletal	muscle	from	older	men	compared	to	
young
214125_s_at NENF down Neuron	derived	neurotrophic	factor Neuron	differentiation	and	development
215026_x_at SCNN1A down sodium	channel,	non-voltage-gated	1	alpha	subunit
Subunit	of	non-voltage-gated,	amiloride-
sensitive,	sodium	channel;	lung	fluid	
homeostasis	role
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217074_at SMOX down spermine	oxidase 	Polyamine	oxidase;	some	link	to	SMAD	signalling
220096_at RNASET2 down Homo	sapiens	ribonuclease	T2	(RNASET2)
Ribonuclease;	appears	to	suppress	
tumorigenicity
222323_at CRYGEP down crystallin,	gamma	E,	pseudogene ---
227211_at PHF19 down PHD	finger	protein	19
Polycomb	repressive	complex	2;	Phf19	binds	
with	H3K36me2	and	H3K36me3;	zinc	bindng;	
transcriptional	repressor;	overexpressed	in	
many	types	of	cancer
227720_at ANKRD13B down ankyrin	repeat	domain	13B Related	to	EGF	signalling
230345_at SEMA7A down
semaphorin	7A,	GPI	
membrane	anchor	(John	
Milton	Hagen	blood	group)
Axonal	growth;	t-cell	function;	binds	to	cell	
surfaces	via	GPI	linkage;	role	in	integrin-
mediated	signaling	-	promotes	formation	of	
focal	adhesion	complexes;	promotes	pro-
inflammatory	cytokine	production	by	
monocytes	&	macrophages
205224_at SURF2 down surfeit	2 ---
212114_at ATXN7L3B down hypothetical	LOC552889 Linked	to	neurological	disease
220849_at LOC79999 down uncharacterized	LOC79999 ---
223153_x_at TMUB1 down transmembrane	and	ubiquitin-like	domain	containing	1
Cell	cycle	progression,	DNA	repair,	apoptosis;	
mouse	wakefulness
230576_at BLOC1S3 down
Biogenesis	of	lysosome-
related	organelles	complex-1,	
subunit	3
Biogenesis	of	organelles	of	the	endosomal-
lysosomal	system
238406_x_at SEZ6L2 down seizure	related	6	homolog	(mouse)-like	2
Cell	surface	protein;	link	to	autism	spectrum	
disorders	&	increased	in	lung	cancers
224886_at JMJD8 down jumonji	domain	containing	8 Possibly	epigenetic-related
225693_s_at CAMTA1 down calmodulin	binding	transcription	activator	1
Tumour	suppressor;	transcriptional	
activator;	cancer-related
226706_at FAM20C down ---
227287_at CITED2 down
Cbp/p300-interacting	
transactivator,	with	Glu/Asp-
rich	carboxy-terminal	domain,	
2
Regulates	PPARg/PGC1a,	HIF1;	increased	by	
fasting;	downregulated	in	ageing	rat	tendon;	
transcriptional	coactivator	of	p300/CBP-
mediated	transcriptional	coactivator	
complex;	positive	regulator	of	TGFbeta	
signaling
239522_at IL12RB1 down interleukin	12	receptor,	beta	1 Innate	immunity;	forms	part	of	the	IL-12R	complex	for	high	affinity	binding	of	IL-12
244193_at DNAJC22 down DnaJ	(Hsp40)	homolog,	subfamily	C,	member	22
Heat-shock	family	member;	protein	folding;	
wurst	protein;	endocytosis
220024_s_at PRX down periaxin
Nerve	development;	interacts	with	
dystroglycan	complex;	early	onset	Charcot-
Marie-Tooth	neuropathy	
241563_at 241563_at down Homo	sapiens	chromosome	3	clone	RP11-384L8 ---
240550_at OTUB2 down OTU	domain,	ubiquitin	aldehyde	binding	2 De-ubiquitinating	enzyme
235879_at MBNL1 up muscle	blind	like	1
RNA	binding;	regulates	splicing;	regulates	
insulin	receptor	splicing	-	affecting	binding	
kinetics
239629_at CFLAR up CASP8	and	FADD-like	apoptosis	regulator
anti-apoptotic;	inhibits	TNFRSF6-mediated	
apoptosis;	lacks	caspase	acivity;	c-FLIP	may	
be	related	to	muscle	ageing	in	mouse	model	-	
overexpression	in	TG	mice	affected	satellite	
cell	prolif	&	promoted	SM	ageing
241789_at RBMS3 up RNA	binding	motif,	single	stranded	interacting	protein	3
TGFbeta-related;	links	to	bone	mineral	
density	and	tumours
212649_at DHX29 up DEAH	(Asp-Glu-Ala-His)	box	polypeptide	29
RNA	helicase	involved	in	translation	
initiation
219737_s_at PCDH9 up protocadherin	9 Calcium-dependent	cell-cell	adhesion	and	recognition	protein;	neural
230375_at PNISR up PNN-interacting	serine/arginine-rich	protein
AKA	splicing	factor,	arginine/serine-rich	18;	
regulated	by	ageing	in	mouse	(PMID:	
19968875)
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204362_at SKAP2 up src	kinase	associated	phosphoprotein	2
Adapter	protein;	linked	to	actin	assembly	&	
stress	fibre	formation	-	regulates	HSF4b	
(linked	to	cataracts);		increased	with	age	in	
mice	hearts	-	reversed	by	caloric	restriction	
231199_at RP11-271C24.3 up Mak3	homolog	(S.	cerevisiae) ---
221589_s_at ALDH6A1 up aldehyde	dehydrogenase	6	family,	member	A1
AKA	MMSDH;	targeted	in	ageing	rat	heart;	
mitochondrial	tetramer	expressed	at	high	
levels	in	the	liver,	kidney	and	heart	and	at	
lower	levels	in	muscle	and	brain;	
mitochondrial	enzyme	with	role	in	valine	and	
pyrimidine	catabolic	pathways
204731_at TGFBR3 up
transforming	growth	factor,	
beta	receptor	III	(betaglycan,	
300kDa)
AKA	betaglycan;	cell	surface	proteoglycan	
that	acts	as	co-receptor	with	other	TGFB	
receptor	superfamily	members;	reduced	
expression	in	various	cancers
1556095_at UNC13C up unc-13	homolog	C	(C.	elegans)
Link	to	processing	of	phorbol	esters	
processing:	APP,	receptor	activation	may	
reduce	Beta-A:	Learning?;	unc13	genes	in	
c.elegans	linked	to	aging	and	longevity
242197_x_at CD36 up CD36	molecule	(thrombospondin	receptor)
Receptor	for	oxidised	lipids;	increases	with	
age;	contributes	to	obesity-related	cardiac	
hypertrophy	in	mice
121
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Samples	 Gender Description Included	in
Stockholm Skeletal	Muscle GSE59880 HGU133Plus2 30 30M;0F
Training	dataset	for	our		healthy	ageing	
prototype	classifier.		All	the	samples	are	
disease	free	and	matched	for	aerobic	
fitness.
Chapter-2
Campbell Skeletal	Muscle GSE9419 HGU133Plus2 66 66M;0F Dataset	used	as	training	for	Independent	Validation
Chapter-3	and	
Chapter-4
Trappe Skeletal	Muscle GSE28422 HGU133Plus2 48 24M;24F Test	dataset	used	for	Independent	Validation
Chapter-3	and	
Chapter-4
Kraus Skeletal	Muscle GSE47969 HGU133Plus2 33 16M;17F Test	dataset	used	for	Independent	Validation
Chapter-3	and	
Chapter-4
Hoffman Skeletal	Muscle GSE38718 HGU133Plus2 22 11M;11F Test	dataset	used	for	Independent	Validation
Chapter-3	and	
Chapter-4
Derby Skeletal	Muscle GSE47881 HGU133Plus2 26 15M;11F Test	dataset	used	for	Independent	Validation
Chapter-3	and	
Chapter-4
Berchtold Brain GSE11882 HGU133Plus2 120 97M;23F Test	dataset	used	for	Independent	Validation	(tests	robustness	across	tissue)
Chapter-3	and	
Chapter-4
Muther Skin E-TABM-1140* Illumina	HT-12	V3	Beadchip 279 0M;279F
Test	dataset	used	for	Independent	
Validation	(tests	robustness	across	tissue	
and	platform)
Chapter-3	and	
Chapter-5
Ulsam Skeletal	Muscle GSE48264 HuExonST 108 108M;0F Longitudinal	study		of	~70y	old	swedish	men	with	20	year	follow	up	period Chapter-3
BrainEac Brain GSE60862 HuExonST 1231 905F;326F
Dataset	used	to	study	the	'healthy	ageing	
gene	score'		in	ten	post-mortem	brain	
regions	from	134	subjects	representing	1231	
samples	(free	from	neurological	diseases)
Chapter-3	and	
Chapter-4
AddNeuromed	Cohort	
1	(AD	vs	CTL) Blood GSE63060
Illumina	HT-12	V3	
Beadchip 113 48M:75F
Dataset	used	to		study	the	'healthy	ageing	
gene	score'	in	AD	patients		vs	controls.
Chapter-3	and	
Chapter-4
AddNeuromed	Cohort	
1	(MCI	vs	CTL) Blood GSE63060
Illumina	HT-12	V3	
Beadchip 106 41M;65F
Dataset	used	to		study	the	'healthy	ageing	
gene	score'	in	MCI	patients		vs	controls.
Chapter-3	and	
Chapter-4
AddNeuromed	Cohort	
2	(AD	vs	CTL) Blood GSE63061
Illumina	HT-12	V4	
Beadchip 111 44M;67F
Dataset	used	to		study	the	'healthy	ageing	
gene	score'	in	AD	patients		vs	controls.
Chapter-3	and	
Chapter-4
AddNeuromed	Cohort	
2	(MCI	vs	CTL) Blood GSE63061
Illumina	HT-12	V4	
Beadchip 102 35M;67F
Dataset	used	to		study	the	'healthy	ageing	
gene	score'	in	MCI	patients		vs	controls.
Chapter-3	and	
Chapter-4
CAD	study Blood GSE12288 HG-U133A 222 172M;50F
Gene-chip	clinical	study	used	for		comparing	
blood	RNA	in	people	with	and	without	
coronary	artery	disease	
Chapter-3	and	
Chapter-4
Diabetes	Study Blood GSE49925 Illumina	HT-12	V4	Beadchip 144 93M:51F
Gene-chip	clinical	study	used	to	compare	
blood	RNA	in	type	II	diabetes	with	control	
Chapter-3	and	
Chapter-4
*	Dataset		available	in	arrayExpress
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Table A3.1: Univariate linear regression on baseline characteristics in ULSAM at 70 years of 
age versus healthy age gene score. Number of obs. denotes the number of complete observations 
available for each variable. Mean and SD denote mean and standard deviation respectively, 
variables marked with * are categorical and hence reported using median. R denotes the 
regression-coefficient of the variable. R2 and P-value denote r-squared and p-value of the 
univariate analysis. 
Variable Number of obs. Mean@70y SD R R2 P-value 
Cystatin C calculated GFR (ml/min) 123 64 12 0.48 0.110 0.0006 
BMI (kg/m2) 128 25.8 2.8 -1.43 0.052 0.0172 
s-Albumin (g/l) 126 59.9 32.1 -0.12 0.045 0.0221 
Weight (kg) 128 78.9 9.9 -0.37 0.042 0.0338 
OGTT p-gluc 60 min (mmol/l) 128 9.6 2.6 -1.14 0.028 0.0834 
s-Phosphate (mmol/l) 127 43.0 2.3 1.26 0.025 0.1036 
OGTT p-insulin AUC 128 1.4 0.8 -3.38 0.023 0.1195 
OGTT p-gluc 120 min (mmol/l) 128 7.2 2.7 -0.78 0.015 0.2164 
Free fatty acids (mmol/l) 128 4,0 1,0 2.14 0.014 0.2270 
OGTT p-gluc 30 min (mmol/l) 128 9.1 1.6 -1.26 0.013 0.2400 
Interleukin-6 (ng/l) 122 3.9 4.9 0.40 0.014 0.2432 
HDL cholesterol (mmol/l) 125 0.5 0.2 -8.25 0.015 0.2558 
s-Cholesterol (mmol/l) 128 1.3 0.3 6.07 0.012 0.2577 
Systolic blood pressure supine (mmHg) 128 145 19 -0.10 0.010 0.2969 
Leisure time physical activity 125 3*  2.99 0.010 0.3221 
u-Albumin excretion rate (µg/min) 122 11.8 37.1 -0.05 0.009 0.3393 
s-Triglycerides (mmol/l) 128 6.0 1.1 1.43 0.008 0.3648 
s-Insulin (pmol/l) 124 45.3 20.7 -0.08 0.008 0.3673 
OGTT p-gluc 0 min (mmol/l) 128 5.5 1.0 1.20 0.004 0.5099 
Diastolic blood pressure supine (mmHg) 128 84 9 -0.13 0.004 0.5143 
Pulse rate (beats/min) 128 65 9 -0.13 0.004 0.5149 
Mini Mental State examination 121 28*  0.07 0.002 0.6276 
s-Creatinine (mol/l) 127 340 64 0.01 0.002 0.6474 
s-Uric acid (mol/l) 125 1.0 0.3 2.04 0.001 0.7157 
C-reactive protein (mg/l) 124 2.6 2.7 0.16 0.001 0.7972 
LDL cholesterol (mmol/l) 126 80.2 30.8 0.01 0.0005 0.8272 
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Figure A3.1 Logistic regression using genes involved in inflammatory response and 
mitochondrial ontologies respectively for ULSAM study with a 20 y follow-up period. One-
hundred and eight subjects provide a healthy tissue biopsy in 1992 that was suitable for RNA 
profiling and the fully annotated mortality-data, covering 2009-2011, was retrieved from the 
Swedish national health registry. Based on the literature premise that increased inflammation was 
bad for health and decreased mitochondrial gene expression was also bad for long term health, 
members of the Inflammatory response (GO:0006954) and Mitochondrion (GO:0005739) gene 
ontology families were selected from ENSEMBL (BioMart) and used to rank baseline samples by 
calculating gene expression score for these samples. A) A Logistic regression analysis performed 
using the genes involved in inflammation response showed no significant relationship between the 
median gene score and probability of death in the 20 y follow-up period (p=0.173). Here a high 
gene score implies higher value of expression for the members of inflammation response and vice-
versa.  B) Logistic regression analysis performed using the genes involved in mitochondrial biology 
showed no significant relationship between the median gene score and probability of death in the 
20 y follow-up period (p=0.337). Here a high gene score implies higher value of expression for the 
members of mitochondrion ontology and vice-versa.  However, using the cumulative ranking metric 
of top 150 genes from our original prototype was a good prognostic for mortality (Figure 3.3A).  
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Figure A4.1 RNA signatures were studied across three anatomical human brain regions using 
BrainEac.org resource. One hundred and thirty-four subjects were ranked for each brain region 
using the gene score method as discussed in section 4.5 and the median sum of the rank score was 
calculated for young and old brain regions. A) The RNA signature derived from healthy old muscle 
was highly regulated in regions associated with neurodegeneration. B) The Peters blood RNA 
signature also tracked human brain age, albeit to much lesser extent. Consistent with multiple 
published observations, human cerebellar cortex does not appear to be subject to substantial age-
related changes. 
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Figure A5.1 Selection criteria in ‘model-selection’ dataset that takes into account the effect each 
feature has on the model. A) We iteratively add one feature at a time and compute the correlation 
coefficient of the gene set with PWV values. Then we record if adding the feature make the model 
better or worse and select one of the criteria from Table 5.2 B) Using the sub selection criteria we 
get the best model which in this case is a set of 431 features. 
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Figure A5.2 Validation of model 2 for vascular ageing. Bland Altman plots (on the RHS) showing 
robustness of Model 2 in Validation datasets 1 (A) and 2 (B) respectively. Majority of observations 
for the model 2 were within the limit of agreement (dashed lines), thus implying that the difference 
between actual and predicted PWV values were marginal.  
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Figure A5.3 Validation of model 3 for vascular ageing. Bland Altman plots (on the RHS) showing 
robustness of Model 3 in Validation datasets 1 (A) and 2 (B) respectively. Majority of observations 
for the model 3, like the previous two models, were within the limit of agreement (dashed lines), 
thus implying that the difference between actual and predicted PWV values were trivial. Model 3 
was a regression model based solely on clinical data i.e. blood pressure and age and didn’t take 
into consideration the gene expression data. 
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 3.1 Binary classifier reverse entry prototype 
 
 
   We first clear the workspace and  load required libraries. 
 
rm(list=ls()) 
 
library(affy) 
library(class) 
library(limma) 
 
 
The  data is loaded  into R and  the .CEL  su   x stripped from each of the cel file names. 
 
dataIn <- ReadAffy(celfile.path= CEL_files_path  ) 
# remove .CEL from file names 
sampleNames(dataIn) <- sub( \\.CEL$ ,   , sampleNames(dataIn)) 
 
 
The phenotype data  is loaded from an external file. This file contains the array  identifiers as well as phenotype 
information such  as group  membership. We use the array name  to ensure  that the rows of the phenotype 
data match the order  of the arrays. 
 
phenoTable <- read.table( Phenodata/dataset.csv , sep= , , header=T) 
rownames(phenoTable) <- phenoTable$array 
 
#make a vector that matches the cel names of the arrays to the row names of the pheno data 
mt<-match(sampleNames(dataIn), rownames(phenoTable)) 
 
# attach the pheno data 
phenoData(dataIn)  = new( AnnotatedDataFrame , data = phenoTable[mt,]) 
 
# create the exp.group vector in the correct order. 
exp.group <- factor(as.numeric(phenoData(dataIn)$group)) 
 
 
We  next set up  parameters for the Leave  One  Out Cross  Validation (LOOCV) procedure. These  are  the 
smallest and  greatest number of genes  to use  in the K-nearest neighbour (KNN) classifier  as well as the 
number of neighbours used. 
 
# largest number of genes used to classify 
max.gene <- 200 
# lower bound of genes used to classify 
min.gene <- 2 
# number of KNN neighbours to consider 
knn.k <- 3 
 
 
The  gene expression  is normalised using the RMA algorithm and  then centered and  scaled  prior  to KNN. 
 
eset.data <- rma(dataIn) 
expr.data <- scale(exprs(eset.data), center=TRUE) 
 
 
We’ll be collecting data as a result of the classification. In this code below we set up the data structures we 
will use to collect this data. 
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#Initialise results vector 
summary.vector  <- vector(length=max.gene-min.gene+1) 
names(summary.vector) <- min.gene:max.gene 
 
# Initialise the scorematrix 
scorematrix <- matrix(rep(0,nrow(expr.data)*2), nrow=nrow(expr.data), ncol=2) 
rownames(scorematrix) <- rownames(expr.data) 
 
# Score for each gene list (of n=200-2+1=199) 
list.score <- vector(length=max.gene-min.gene + 1) 
list.score[] <- 0 
 
# Score for each PS used in list.opt(initilaised in the loop) classification  list.scorePS 
<-  matrix(rep(0,nrow(expr.data)*2), nrow=nrow(expr.data), ncol=3) colnames(list.scorePS) 
<- c("Appearance Count","Successful Predictions", "Success Ratio" ) rownames(list.scorePS) 
<- rownames(expr.data) 
 
 
We now begin the selection of probesets for classification.  This is a nested loop procedure. In the outer loop 
we hold out each array in turn. The middle loop uses KNN  to examine  the ability of selected probesets to 
classify the array. The innermost loop is used to select the probesets used in the middle loop. 
 
The inner loop is used to select potentially useful probesets. Within the innermost loop an array is held out 
and limma is used  to rank  probesets in the remaining arrays by t-value. The top 200 probesets are taken 
forward in reverse  order  so that probesets with lower t-values are used for classification first.  The ability of 
the selected probesets to classify the held out array is then tested using KNN.  The results of the prediction 
and whether an individual probeset was used in that prediction are  recorded. Each probeset is positively 
scored  if it contributes to a correct classification. 
 
This information is then used to select the top 150 performing probesets and these in turn go forward into a 
second KNN classification  step on a second held out sample  in the middle  loop.  Once again the classification 
performance of each probeset is recorded. 
 
for (test.array in 1:ncol(expr.data)){ 
#Loop 2 
for (list.opt in c(1:ncol(expr.data))[-test.array]){ 
 
#Loop 3. Testing predictive power of 2-200 genes 
for (ngenes in min.gene:max.gene){ 
 
#If first time through loop for any holdout array get sig genes first 
if (ngenes == min.gene){ 
 
# set design matrix 
design <- cbind(1,exp.group[-c(test.array,list.opt)]) 
 
# fit models 
fit <- lmFit(exprs(eset.data)[,-c(test.array, list.opt)], design = design) 
 
# do empirical Bayes 
fit2 <- eBayes(fit) 
 
# get t stats, abs value 
sig.genes <- abs(fit2$t[,2]) 
# sorted in order of abs t-value, decreasing
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sig.genes <- sort(sig.genes,  d=TRUE) 
} # end eBayes here 
 
# get top 200 sig probesets 
top.200 <- sig.genes[c(1:max.gene)] 
 
# REVERSE this list so lowest probesets go in first 
top.200 <- rev(top.200) 
 
# get the probesets to test this will vary with ngenes. 
test.probes <- top.200[1:ngenes] 
 
# get scaled expression data for ngenes (2 to 200), transpose for knn 
candidate.genes  <- expr.data[rownames(expr.data) %in% names(test.probes), ] 
 
# transpose for knn (row-wise) 
candidate.genes  <- t(candidate.genes) 
 
# take out the test.array and list.opt for training 
training.data <- candidate.genes[-c(test.array, list.opt),] 
 
# select test list.opt for testing 
test.sample <- candidate.genes[list.opt, ] 
 
# Prepare training, test and class data for knn 
training.groups  <- exp.group[-c(test.array, list.opt)] 
 
# predict list.opt 
predict  <- knn(train=training.data, test=test.sample,  cl=training.groups, k=knn.k) 
# which probesets were used in this prediction 
list.score.index  <- which(rownames(list.scorePS) %in% names(test.probes)) 
# record the use (appearance) of that probeset 
list.scorePS[list.score.index , 1] <- list.scorePS[list.score.index , 1] + 1 
 
# print some details on classification 
cat(paste("Predicting sample ", list.opt, "which is ", exp.group[list.opt], 
" and leaving out sample", test.array,"\tusing", 
ngenes, "genes \t"), sep="") 
 
# so now we check result for list.opt for each ngenes 
# if the prediction is right then add +1 to list.score position for ngenes 
# this gives the list.size for a positive prediction 
# if the prediction is right 
# add +1 to the probe.performance  position for included probes 
if (predict==exp.group[list.opt]){ 
cat ("CORRECT\n") 
list.score[ngenes-min.gene+1] <- list.score[ngenes-min.gene+1] + 1 
list.scorePS[list.score.index,2] <- list.scorePS[list.score.index,2]+1 
} 
 
else { 
cat ("Incorrect\n") 
}
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} 
# END LOOP 3 - INNER LIST OPTIMISATION PREDICTIONS 
 
# Select the first 150 genes from sig.genes for kNN prediction 
test.length <- 150 
# get the scaled expression data for the genes that correctly predicted 
# test.array in loop 3 
candidate.genes.testing <- expr.data[rownames(expr.data) %in% 
names(sig.genes[1:test.length]),] 
# transpose for knn 
candidate.genes.testing <- t(candidate.genes.testing) 
# take out the test.array for training data 
training.data <- candidate.genes.testing[c(1:nrow(candidate.genes.testing)) 
[-c(test.array)],] 
# get data for test.array only 
test.sample <- candidate.genes.testing[test.array,] 
# the true classes for training data only 
training.groups  <- as.factor(exp.group[-c(test.array)]) 
# do the prediction for the test.array 
predict.testing  <- knn(train=training.data, test=test.sample, 
cl=training.groups, k=knn.k) 
#print progress 
cat ("Predicting TEST ARRAY with ", test.length," genes\t") 
# if the prediction for test.array is right with ngenes 
if (predict.testing==exp.group[test.array]){ 
cat ("CORRECT\n") 
# and add +1 to those contributing genes in 1st column of the scorematrix 
scorematrix[colnames(candidate.genes.testing),1] <- 
scorematrix[colnames(candidate.genes.testing),1] + 1 
} 
else { 
cat ("Incorrect\n") 
} 
 
# add +1 to the second column of score matrix for each candidate gene tested 
# to count the number of times that gene is used in a prediction attempt 
scorematrix[colnames(candidate.genes.testing),2] <- 
scorematrix[colnames(candidate.genes.testing), 2] + 1 
} 
# END LOOP 2 (predicting test.array 1 with all poss list.opt) 
} 
# END LOOP 1 
 
 
We record  the probesets used  in classification and  the number of appearances each  probeset makes  in the 
classification  step above.  For each probeset the ratio  of correct predictions to total appearances is calculated 
and  finally the data is written out. 
 
# keep only probesets used in predictions 
# i.e. column 2 on scorematrix does not equal 0 
scorematrix <- scorematrix[which(scorematrix[,2]!=0),] 
colnames(scorematrix) <- c("Correct Preds", "Appearances") 
 
# Sort according to scoring first column (correct classifications);  best predictors first
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scorematrix_App_Sorted <- scorematrix[order(scorematrix[,2], decreasing=TRUE),] 
scorematrix_Appearance_data <- scorematrix_App_Sorted[,2] 
 
# keep only probesets which appeared in top.200 lists 
# i.e. column 1 on list.scorePS does not equal 0 
list.scorePS  <- list.scorePS[which(list.scorePS[,1]!=0),] 
 
#calculates success ratio i.e correct predictions/ total appearance, for list.scorePS 
list.scorePS[,3]  <- list.scorePS[,2]/list.scorePS[,1] 
 
#Sort list.scorePS according to first column (appearance count); 
list.scorePS_Sorted <- list.scorePS[order(list.scorePS[,1], decreasing=TRUE),] 
 
# write out data 
write.table(scorematrix, "scorematrix_appearances_reverse_entry_prototype.txt", 
sep="\t", quote=FALSE) 
 
write.table(list.scorePS_Sorted, 
"FinallistofclassifiyingPS_individualPS_appearances_successrate_ 
REVERSE_ENTRY_PROTOTYPE.txt", 
sep="\t", quote=FALSE
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  3.2 Independent Validation 
 
 
Having previously identified a set of genes able to classify tissues as having a young or old profile we now 
examine the ability of this ‘geneset’ to classify independent datasets of young vs old tissue samples (samples 
not  used  in generating the classification model). The original data used to select the genes is not used at ANY 
stage of this subsequent process 
 
We first clear the workspace, load required  libraries  and  set some pointers to directories containing the data 
required. 
 
rm(list=ls()) 
 
library(inSilicoDb) 
library(inSilicoMerging) 
library(affy) 
library(class) 
library(limma) 
library(frma) 
library(ROCR) 
#Set pathway to CEL files 
pathC =  Path/training_set 
pathM =  Path/test_set 
#Set names 
Training_data<-  training_set_name 
Test_data<- test_set_name 
 
 
The  data to be classified is loaded.  These  are microarray cel files. 
 
dataC <- ReadAffy(celfile.path=pathC) 
dataM <- ReadAffy(celfile.path=pathM) 
 
 
The phenotype data  is loaded from an external file. This file contains the array  identifiers as well as phenotype 
information such  as group  membership. We use the array name  to ensure  that the rows of the phenotype 
data match the order  of the arrays. 
 
sampleNames(dataM)  <- sub( \\.CEL$ ,   , sampleNames(dataM)) 
phenoTableM <- read.table( Phenodata/training_set.csv , sep= , , header=T) 
rownames(phenoTableM) <- phenoTableM$array 
mtM <- match(sampleNames(dataM), rownames(phenoTableM)) 
 
sampleNames(dataC)  <- sub( \\.CEL$ ,   , sampleNames(dataC)) 
phenoTableC <- read.table( Phenodata/test_set.csv , sep= , , header=T) 
rownames(phenoTableC)<-phenoTableC$array 
mtC<-match(sampleNames(dataC), rownames(phenoTableC)) 
 
# attach the pheno data 
phenoData(dataM)  = new( AnnotatedDataFrame , data = phenoTableM[mtM,]) 
phenoData(dataC)  = new( AnnotatedDataFrame , data = phenoTableC[mtC,]) 
 
 
The  microarray data  we will use to validate our classifier were generated in di  erent laboratories at  di  erent 
times and  are independent biologically  and  from a technical perspective (including gene-chip  format). The 
di  erent sources of data  can introduce technical variance  that does not reflect the biological experiment.  Below
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we use the fRMA algorithm to limit the influence  of technical variance e.g. di  erent batches of microarrays. 
The  technical manual for fRMA is here. 
 
esetC <- frma(dataC) 
esetM <- frma(dataM) 
 
 
The  fRMA datasets are adjusted using the COMBAT method which also corrects for batch  e  ects across the the 
separate microarray datasets. After this treatment the adjusted datasets are prepared for the assessment of 
classification performance. 
 
esets <- list(esetC, esetM) 
esetMerge1 <- merge(esets, method = "COMBAT") 
mtC <- which(esetMerge1$dataset=="training_set") 
mtM <- which(esetMerge1$dataset=="test_set") 
 
 
We  use  the knn  classifier  with a constant k=5 to examine the performance of our  classifying  geneset on 
independent microarray datasets. The  strategy here is to use a NEW  microarray dataset as the ‘expression 
space’ (named  ‘train’ in the code) for predicting one sample at a time from the new ‘test’ batch  of microarray 
data. 
 
In this section we also create  the data  structures required  for later  receiver operator curve (ROC)  analysis  of 
the results.  Specifically  we set up a two column  matrix with columns for the actual class (label) of each 
case and  the prediction made  by the knn  classifier  (predict). Label  ‘1’ is assigned  to a case if it is ‘young’ 
and  ‘-1’ if it is ‘old’. 
 
Using  the training  and  testing  data we first  extract only  expression data for the previously selected  age 
classifier geneset (which  remains  a fixed variable). 
 
knn.k <- 5 
 
#Load previously identified classification  genes 
scoreMatrix<-read.table("genes.txt",sep= \t , header=T) 
rownames(scoreMatrix) <- scoreMatrix[,1] 
 
#train data 
expr.train <- exprs(esetMerge1[,mtC]) 
train.genes <- expr.train[rownames(expr.train) %in% rownames(scoreMatrix), ] 
training.groups  <- factor(as.numeric(pData(esetMerge1[,mtC])$group)) 
 
#test data 
expr.test<- exprs(esetMerge1[,mtM]) 
test.genes <- expr.test[rownames(expr.test) %in% rownames(scoreMatrix), ] 
testing.groups  <-factor(as.numeric(pData(esetMerge1[,mtM])$group)) 
 
validation.score  <- matrix(ncol=2,nrow=ncol(expr.test)) # create object to collect results 
 
#Transpose for knn 
training.data <- t(train.genes) 
 
## set up matrix for ROC analysis 
rocScore <- matrix(ncol=2,nrow=ncol(expr.test)) 
colnames(rocScore)  <- c("label","predict") 
 
labels <- testing.groups
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for(i in 1:ncol(expr.test)){ 
if(labels[i] == 1) 
rocScore[i,1] <- -1 
else if(labels[i] == 2) 
rocScore[i,1] <- 1 
} 
 
 
Predictions rely on one ‘test’ sample  at a time and  in this scenario  the ‘training data’ to examine which  5 
members of the data are  closest to a given member of the test data. The  predictions made  in this process 
are  recorded in the predict column  of the rocScore matrix we set up  above.   In addition we record  the 
specific array  tested and  whether the prediction was correct or not  for each that array  (these are recorded  in 
columns1  & 2 of the validation.score matrix respectively). If the prediction is correct we increment the 
record variable by 1 and  use this to calculate the percentage of correct classifications. 
 
record <- 0 
 
for (validation.array  in 1:ncol(expr.test)){ 
test.data <-t(test.genes[,validation.array]) 
predict  <- knn(train=training.data, test=test.data,cl=training.groups, k=knn.k) 
 
if(predict==1){ 
rocScore[validation.array,2] <- -1 
} 
else if(predict==2){ 
rocScore[validation.array,2] <- 1 
} 
 
if (predict==testing.groups[validation.array]){ 
validation.score[validation.array,1] <- colnames(expr.test)[validation.array] 
validation.score[validation.array,2] <- "Correct Prediction" 
record <- record+1 
} 
else  { 
validation.score[validation.array,1] <- colnames(expr.test)[validation.array] 
validation.score[validation.array,2] <- "Incorrect Prediction" 
} 
} 
 
percentage <- 0 
percentage <- ceiling((record/validation.array)*100) 
 
 
We  assess  the results  of the classification by  ROC  analysis in the code  below.   We  classify  the young  as 
‘positive’ and  the old as ‘negative’  (these are arbitrary). To calculate the true positive rate  (young  classified 
as young)  we first create a binary vector of true young.  We then sum the predict values  after filtering the 
rocScore dataframe by the binary vector. 
 
Sensitivity  is then calculated as the true positives  divided by  the actual  number of young  in the sample 
(i.e. the sum of the binary.values vector. 
 
We  calculate the false positives and  false positive rate in a similar  way  to above,  by inverting the binary 
labels.  Finally  we calculate the specificity.
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threshold <- 0 
# boolean vector of classes (young=TRUE; old=FALSE) 
binary.labels <- rocScore[,1] == 1 
# calculates total number of True Positives, i.e young classified as young 
tp <- sum((rocScore[,2]  > threshold) & binary.labels) 
# calculates sensitivity i.e TP/total Positives from class labels 
sensitivity <- tp/sum(binary.labels) 
 
# calculates false positives  for FPR/ 1-specificity 
fp <- sum((rocScore[,2]   > threshold ) & (!binary.labels)) 
# 1-specificity 
fpRate <- fp/sum(!binary.labels) 
 
sens <- round(sensitivity, digits = 3) 
FPR <- round(fpRate, digits = 3) 
spec <- 1-FPR 
 
# Calculate area under the curve by using ROCR package 
pred<-prediction(rocScore[,2], rocScore[,1]) 
auc<-attributes(performance(pred,  auc ))$y.values[[1]] 
 
 
Finally  we write out a text file containing data on sensitivity and  specificity. 
 
write.table(validation.score,paste(Test_data,"_test_",Training_data, 
"_Train   BatchAdj_150PS_",percentage,"SR_Sens=",sens, 
"_Spec=",spec,".csv",sep=""),sep= , ,quote=
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 3.3 Gene ranking score calculation 
 
 
This  code calculates the tissue ageing  Gene Score for each sample,  as an median  of all of the selected genes 
(the classification  gene-set).  It is applied  in one of two scenarios.  1) to samples  where all individuals  have the 
same  chronological age (birth year)  or 2) to contrast cases versus  controls where  the chronological age and 
gender  is equal in both  groups.  The  ranking  score can be standardised to the total number  of samples  being 
ranked to compare  across  studies. 
 
Thus, if a gene  was  downregulated with  age  in  the discovery data set,  then the sample  with  the lowest 
expression  in this new data  set will be marked  youngest and if upregulated the sample with highest score will 
be the youngest 
 
Setting up preliminaries like clearing  workspace  and  setting study names 
 
rm(list=ls()) 
name_of_study<-"Study" 
signature<-"study_signature" 
 
 
Loading  data - normalised intensities matrix 
 
expr.data <- read.table("Expression_matrix.txt",sep="\t",header=TRUE,row.names=1) 
 
 
Loading the list of genes with annoteted directionality calculated in training dataset: downregulated with 
‘down’ sign and  upregulated genes with ‘up’ values 
 
genesUD <- read.delim("list_of_genes.txt",sep= \t , header=T) 
 
 
Select only the geneID  and  directionality column  from the file 
 
genesUD<- subset(genesUD,select=c("geneID","Directionality")) 
 
 
Select genes that are present on a paltform 
 
genesUD<-genesUD[genesUD$geneID %in% rownames(expr.data),] 
 
 
Seperate up and  down regulated genes 
 
down <- subset(genesUD,genesUD$Directionality=="down") 
dReg<-down$geneID 
 
up <- subset(genesUD,genesUD$Directionality=="up") 
uReg<-up$geneID 
 
 
Calculates score of each gene for all samples 
 
geneRank <- matrix(nrow=ncol(expr.data), ncol=length(genesUD[,1]) ) 
rownames(geneRank)  <- colnames(expr.data) 
colnames(geneRank)  <- c(as.character(dReg), as.character(uReg)) 
 
 
DownRegulated genes with aging:  Scores the sample  with highest expression  value as youngest and  values it 
1, then the next sample  maximum/higher value  as 2 and  so on
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for(i in 1: length(dReg)){ 
record <- 0 
PS <-  as.matrix(expr.data[which(rownames(expr.data)==dReg[i]),]) 
PS <- t(PS) 
for(j in 1: ncol(expr.data))  { 
maxIn <-which.max(PS) 
maxIndex <- rownames(PS)[maxIn] 
PS   <- as.matrix(PS[-maxIn,]) 
sample <- which(maxIndex==rownames(geneRank)) 
geneRank[sample,which(colnames(geneRank)==dReg[i])] <- record 
} 
} 
 
 
Upregulated genes with aging:  Scores the sample  with lowest expression value  as youngest and  values  it 1, 
then the next sample  minimum/lower value  as 2 and  so on. 
 
for(i in 1: length(uReg)){ 
record <- 0 
PS <-  as.matrix(expr.data[which(rownames(expr.data)==uReg[i]),]) 
PS <- t(PS) 
for(j in 1: ncol(expr.data))  { 
minIn <-which.min(PS) 
minIndex <- rownames(PS)[minIn] 
PS  <- as.matrix(PS[-minIn,]) 
sample <- which(minIndex==rownames(geneRank)) record <- 
record + 1 
geneRank[sample,which(colnames(geneRank)==uReg[i])] <- record 
} 
} 
 
 
Calculate median  value  for each sample  based  on their individual genes score 
 
cumulative_geneRank<- apply(geneRank,1,median) 
geneRank <- cbind(geneRank,cumulative_geneRank) 
 
 
Write out the ranking matrix 
 
write.table(geneRank, paste(name_of_study,"_genescore_ranking_basedon_",signature, 
".csv",sep=""),sep= , ,quote=F) 
